
<html lang="en"     class="pb-page"  data-request-id="8c17f97d-cd7e-4a2a-95fa-666c8caea295"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm101177s;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2010.53.issue-24"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor" /></meta><meta name="dc.Creator" content="David  Moffat" /></meta><meta name="dc.Creator" content="Sanjay  Patel" /></meta><meta name="dc.Creator" content="Francesca  Day" /></meta><meta name="dc.Creator" content="Andrew  Belfield" /></meta><meta name="dc.Creator" content="Alastair  Donald" /></meta><meta name="dc.Creator" content="Martin  Rowlands" /></meta><meta name="dc.Creator" content="Judata  Wibawa" /></meta><meta name="dc.Creator" content="Deborah  Brotherton" /></meta><meta name="dc.Creator" content="Lindsay  Stimson" /></meta><meta name="dc.Creator" content="Vanessa  Clark" /></meta><meta name="dc.Creator" content="Jo  Owen" /></meta><meta name="dc.Creator" content="Lindsay  Bawden" /></meta><meta name="dc.Creator" content="Gary  Box" /></meta><meta name="dc.Creator" content="Elisabeth  Bone" /></meta><meta name="dc.Creator" content="Paul  Mortenson" /></meta><meta name="dc.Creator" content="Anthea  Hardcastle" /></meta><meta name="dc.Creator" content="Sandra  van Meurs" /></meta><meta name="dc.Creator" content="Suzanne  Eccles" /></meta><meta name="dc.Creator" content="Florence  Raynaud" /></meta><meta name="dc.Creator" content="Wynne  Aherne" /></meta><meta name="dc.Description" content="A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described. The compounds are potent enzyme inhibitors (IC50 values less than 100 nM), an..." /></meta><meta name="Description" content="A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described. The compounds are potent enzyme inhibitors (IC50 values less than 100 nM), an..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 16, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm101177s" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm101177s" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm101177s" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm101177s" /></link>
        
    
    

<title>Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm101177s" /></meta><meta property="og:title" content="Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0016.jpeg" /></meta><meta property="og:description" content="A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described. The compounds are potent enzyme inhibitors (IC50 values less than 100 nM), and improved activity in cell proliferation assays was achieved by modulation of polar surface area (PSA) through the introduction of novel linking groups. Employing oral pharmacokinetic studies in mice, comparing drug levels in spleen to plasma, we selected compounds that were tested for efficacy in human tumor xenograft studies based on their potential to distribute into tumor. One compound, 21r (CHR-3996), showed good oral activity in these models, including dose-related activity in a LoVo xenograft. In addition 21r showed good activity in combination with other anticancer agents in in vitro studies. On the basis of these results, 21r was nominated for clinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm101177s"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm101177s">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm101177s&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm101177s&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm101177s&amp;href=/doi/10.1021/jm101177s" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 8663-8678</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm101183p" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm101179e" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-<i>N</i>-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Moffat">David Moffat</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sanjay++Patel">Sanjay Patel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Day">Francesca Day</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Belfield">Andrew Belfield</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alastair++Donald">Alastair Donald</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Rowlands">Martin Rowlands</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Judata++Wibawa">Judata Wibawa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deborah++Brotherton">Deborah Brotherton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lindsay++Stimson">Lindsay Stimson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vanessa++Clark">Vanessa Clark</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jo++Owen">Jo Owen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lindsay++Bawden">Lindsay Bawden</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gary++Box">Gary Box</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elisabeth++Bone">Elisabeth Bone</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Mortenson">Paul Mortenson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthea++Hardcastle">Anthea Hardcastle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++van+Meurs">Sandra van Meurs</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suzanne++Eccles">Suzanne Eccles</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Florence++Raynaud">Florence Raynaud</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wynne++Aherne">Wynne Aherne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Haddow Laboratories, Cancer Research UK, Centre for Cancer Therapeutics, The Institute for Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, U.K.</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Evotec (UK) Ltd., 114 Milton Park, Abingdon, OX14 4SA, U.K.</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: +44(0)1235 829120. Fax: +44(0)1235 828125. E-mail: <a href="/cdn-cgi/l/email-protection#afcbced9c6cb81c2c0c9c9cedbefccc7ddc0c2cedbc7caddcedfcadadbc6ccdc81ccc0c2"><span class="__cf_email__" data-cfemail="fe9a9f88979ad0939198989f8abe9d968c91939f8a969b8c9f8e9b8b8a979d8dd09d9193">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm101177s&amp;href=/doi/10.1021%2Fjm101177s" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 8663–8678</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 16, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 September 2010</li><li><span class="item_label"><b>Published</b> online</span>16 November 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 December 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm101177s" title="DOI URL">https://doi.org/10.1021/jm101177s</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8663%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDavid%2BMoffat%252C%2BSanjay%2BPatel%252C%2BFrancesca%2BDay%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D24%26contentID%3Djm101177s%26title%3DDiscovery%2Bof%2B2-%25286-%257B%255B%25286-Fluoroquinolin-2-yl%2529methyl%255Damino%257Dbicyclo%255B3.1.0%255Dhex-3-yl%2529-N-hydroxypyrimidine-5-carboxamide%2B%2528CHR-3996%2529%252C%2Ba%2BClass%2BI%2BSelective%2BOrally%2BActive%2BHistone%2BDeacetylase%2BInhibitor%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8678%26publicationDate%3DDecember%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm101177s"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3153</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">58</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm101177s" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Moffat&quot;},{&quot;first_name&quot;:&quot;Sanjay&quot;,&quot;last_name&quot;:&quot;Patel&quot;},{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Day&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Belfield&quot;},{&quot;first_name&quot;:&quot;Alastair&quot;,&quot;last_name&quot;:&quot;Donald&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Rowlands&quot;},{&quot;first_name&quot;:&quot;Judata&quot;,&quot;last_name&quot;:&quot;Wibawa&quot;},{&quot;first_name&quot;:&quot;Deborah&quot;,&quot;last_name&quot;:&quot;Brotherton&quot;},{&quot;first_name&quot;:&quot;Lindsay&quot;,&quot;last_name&quot;:&quot;Stimson&quot;},{&quot;first_name&quot;:&quot;Vanessa&quot;,&quot;last_name&quot;:&quot;Clark&quot;},{&quot;first_name&quot;:&quot;Jo&quot;,&quot;last_name&quot;:&quot;Owen&quot;},{&quot;first_name&quot;:&quot;Lindsay&quot;,&quot;last_name&quot;:&quot;Bawden&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;Box&quot;},{&quot;first_name&quot;:&quot;Elisabeth&quot;,&quot;last_name&quot;:&quot;Bone&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Mortenson&quot;},{&quot;first_name&quot;:&quot;Anthea&quot;,&quot;last_name&quot;:&quot;Hardcastle&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;van Meurs&quot;},{&quot;first_name&quot;:&quot;Suzanne&quot;,&quot;last_name&quot;:&quot;Eccles&quot;},{&quot;first_name&quot;:&quot;Florence&quot;,&quot;last_name&quot;:&quot;Raynaud&quot;},{&quot;first_name&quot;:&quot;Wynne&quot;,&quot;last_name&quot;:&quot;Aherne&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;8663-8678&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm101177s&quot;},&quot;abstract&quot;:&quot;A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described. The compounds are potent enzyme inhibitors (IC50 values less than 100 nM), and improved activity in cell proliferation assays was achieved by modulation of polar surface area (PSA) through the introduction of novel linking groups. Employing oral pharmacokinetic studies in mice, comparing drug levels in spleen to plasma, we selected compounds that were tested for efficacy in human tumor xenograft studies based on their potential to distribute into tumor. One compound, 21r (CHR-3996), showed good oral activity in these models, including dose-related activity in a LoVo xenograft. In addition 21r showed good activity in combination with other anticancer agents in in vitro studies. On the basis of these results, 21r was nominated for clinical development.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm101177s&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm101177s" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm101177s&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm101177s" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm101177s&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm101177s" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm101177s&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm101177s&amp;href=/doi/10.1021/jm101177s" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm101177s" /></input><a href="/doi/pdf/10.1021/jm101177s" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm101177s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm101177s%26sid%3Dliteratum%253Aachs%26pmid%3D21080647%26genre%3Darticle%26aulast%3DMoffat%26date%3D2010%26atitle%3DDiscovery%2Bof%2B2-%25286-%257B%255B%25286-Fluoroquinolin-2-yl%2529methyl%255Damino%257Dbicyclo%255B3.1.0%255Dhex-3-yl%2529-N-hydroxypyrimidine-5-carboxamide%2B%2528CHR-3996%2529%252C%2Ba%2BClass%2BI%2BSelective%2BOrally%2BActive%2BHistone%2BDeacetylase%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D24%26spage%3D8663%26epage%3D8678%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jmcmar.2010.53.issue-24/production/jmcmar.2010.53.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described. The compounds are potent enzyme inhibitors (IC<sub>50</sub> values less than 100 nM), and improved activity in cell proliferation assays was achieved by modulation of polar surface area (PSA) through the introduction of novel linking groups. Employing oral pharmacokinetic studies in mice, comparing drug levels in spleen to plasma, we selected compounds that were tested for efficacy in human tumor xenograft studies based on their potential to distribute into tumor. One compound, <b>21r</b> (CHR-3996), showed good oral activity in these models, including dose-related activity in a LoVo xenograft. In addition <b>21r</b> showed good activity in combination with other anticancer agents in in vitro studies. On the basis of these results, <b>21r</b> was nominated for clinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31472" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31472" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Histone deacetylases (HDACs<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>) <div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: HDAC, histone deacetylase; PSA, polar surface area; SAHA, suberoylanilide hydroxamic acid; HDACi, histone deacetylase inhibitor; TBME, <i>tert</i>-butyl methyl ether; TFA, trifluoroacetic acid; DMAP, 4-dimethylaminopyridine; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; HOBt, hydroxybenzotriazole; mCPBA, <i>m</i>-chloroperoxybenzoic acid; ZBG, zinc binding group; AUC, area under curve; Cl, clearance; <i>F</i>, oral bioavailability; HLM, human liver microsomes; MLM, mouse liver microsomes; BOC, <i>tert</i>-butoxycarbonyl; Boc<sub>2</sub>O, di-<i>tert</i>-butyl dicarbonate; EtOAc, ethyl acetate; THF, tetrahydrofuran; DMF, dimethylformamide; DMSO, dimethylsulfoxide; EGF, epidermal growth factor; PBS, phosphate buffered saline; FACS, fluorescence-activated cell sorting; ND, not determined; ELISA, enzyme-linked immunosorbent assay; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PARP, poly ADP-ribose polymerase.</p></div> are a family of epigenetic regulator enzymes, the inhibition of which leads to a reversal of tumor suppressor silencing, cell cycle arrest, differentiation, and/or apoptosis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Because of these effects, which manifest themselves most strikingly in transformed cells, HDAC inhibition has emerged as a strategy to reverse aberrant epigenetic changes associated with cancer.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> A number of HDAC inhibitors have shown antitumor activity in animal models of human cancer and are now in clinical trials (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The first such agent to reach pivotal clinical trials was the hydroxamate, SAHA<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5-7)</a> (vorinostat); this drug has been approved for use in the treatment of cutaneous T-cell lymphoma. The cyclic depsipeptide romidepsin has been registered for the treatment of the same disease. A wealth of preclinical data suggest that HDAC inhibitors have potential against a wide range of tumor types either alone or in combination with other therapies.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. HDAC inhibitors under clinical investigation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The HDACs comprise three separate classes of enzyme.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Both class I and class II enzymes are metalloenzymes containing a catalytic zinc atom. There are thought to be at least 11 isoforms of the metalloenzyme HDAC proteins: class I HDACs (HDACs 1, 2, 3, and 8) are ubiquitously expressed and generally detected in the nucleus, while class II HDACs (HDACs 4, 5, 6, 7, 9, and 10) can shuttle between the cytoplasm and nucleus. HDAC11 has a related catalytic domain but has only weak homology with the others. The class III enzymes are not metalloenzymes and, while relevant to certain human diseases, are not yet strongly implicated in cancer.</div><div class="NLM_p last">The major objectives of our discovery efforts toward therapeutically useful HDAC inhibitors were to achieve good intratumoral distribution of drug via oral administration and class I isoform selectivity. The latter goal was driven by the hypothesis that these isoforms are those most predominantly involved in cellular proliferation.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> It has been suggested from extensive analysis of published protein and mRNA expression of HDAC isoforms that class I HDACs are often overexpressed in tumors compared to corresponding normal tissue, and this overexpression generally correlates with poor prognosis. In contrast, expression of class II HDACs may be associated with better prognosis, suggesting that their inhibition may not be useful in cancer therapy.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We designed a series of <i>N</i>-hydroxypyrimidine-5-carboxamides as potential HDAC inhibitors based on an analysis of all previously described families that assessed their ability to meet our goal of robust physicochemical properties to facilitate improved cell permeability and oral dosing as well as to provide novelty. We decided to utilize the pyrimidine hydroxamate moiety as the zinc-binding group (ZBG) in our approach, as this seemed likely to be the most metabolically stable functionality that would be compatible with good HDAC inhibitory activity. The Johnson & Johnson group has previously reported on HDAC inhibitors from this chemical class.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> In parallel to our work,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> this group has pursued a strategy aimed at improving the pharmacodynamic properties of their initial lead series through introduction of an ionizable group to improve solubility.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Work on the project was initiated with docking studies using an available structure of the class I isoform HDAC8<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> based on coordination of the pyrimidine hydroxamate unit to the zinc ion at the base of the catalytic site. We believed that this would permit the identification of novel linker groups that would appropriately position the inhibitor headgroup in the hydrophobic region at the entrance of the active site. These studies indicated that the hexahydropyrrolo[3,4-<i>c</i>]pyrrole and azabicyclo[3,1,0]hexane linkers (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) were of a requisite length to provide good interaction between aryl- or heteroaryl substituents and this hydrophobic surface. We have previously described the optimization of the hexahydropyrrolo[3,4-<i>c</i>]pyrrole linked compounds.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In this article we detail the development of the azabicyclo[3,1,0]hexane series toward a compound that has progressed to clinical study.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural components of pyrimidine hydroxamate HDAC inhibitors containing hexahydropyrrolo[3,4-<i>c</i>]pyrrole (A) and azabicyclo[3,1,0]hexane (B) linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our approach to the synthesis of the pyrimidine hydroxamate target molecules was dependent on the availability of several key intermediates (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Intermediate <b>2</b> was prepared from commercially available ethyl 4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxylate in a two step procedure involving zinc mediated removal of the 4-chloro substituent followed by subsequent oxidation of the 2-methanesulfanyl group. The route to our linker unit required the synthesis of the Boc-protected 6-amino-3-aza-bicyclo[3.1.0]hexane <b>8</b> following a multistep procedure starting from <i>N</i>-benzylmaleimide via the known intermediate <b>6</b>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Selenium dioxide mediated oxidation of 6-fluoro-2-methylquinoline gave the aldehyde intermediate <b>10</b> in excellent yield. The differentially Boc-protected methylaminoazabicyclohexane derivative <b>12</b> was available from a previously described method,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> as was <i>O</i>-(1-isobutoxyethyl)hydroxylamine <b>11</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This was employed to introduce the hydroxamate functionality in the final steps of our analogue preparation.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Zn powder, H<sub>2</sub>O, <i>t</i>-BuOH, THF, 85 °C, 57%. (b) <i>m</i>CPBA, THF, 0 °C, 77%. (c) BrCH<sub>2</sub>NO<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temp, 42%. (d) NaBH<sub>4</sub>, BF<sub>3</sub>·THF, 45−50 °C, 42%. (e) CH<sub>3</sub>CHClOCOCl, ClCH<sub>2</sub>CH<sub>2</sub>Cl, 55−65 °C, 25%. (f) Boc<sub>2</sub>O, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 92%. (g) 10% Pd−C, H<sub>2</sub>, EtOH, room temp, 95%. (h) SeO<sub>2</sub>, dioxane, 100 °C, 87%.</p></p></figure><div class="NLM_p">Sulfonation of the amino group of compound <b>8</b> with aryl- or heteroarylsulfonyl chlorides followed by removal of the Boc group gave suitable intermediates <b>13a</b>,<b>b</b> for condensation with the pyrimidine intermediate <b>2</b> through displacement of the 2-methanesulfonyl substituent (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Base hydrolysis of the intermediate ester gave carboxylic acids <b>14a</b>,<b>b</b> which were coupled with the protected hydroxylamine <b>11</b> to give intermediates that could be purified via flash chromatography on silica. Subsequent deprotection of the hydroxamate was facile under acidic conditions, giving target molecules <b>15a</b> and <b>15b</b>. The corresponding amide analogues <b>18a</b>−<b>c</b> were prepared by similar methodology beginning with amidation of <b>8</b> with readily available acid chlorides. In the case of the alkylamine analogues <b>21a</b>−<b>r</b> the six-step sequence from <b>8</b> proved to be a robust and efficient process in which the intermediates <b>19</b> and <b>20</b> could generally be reached without the need for a purification step. The conformation of the azabicyclo[3,1,0]hexane linker unit was determined by X-ray diffraction studies on compound <b>21r</b>. The constrained three-membered ring was observed in the <i>exo</i>-conformation, consistent with previous reports.<a onclick="showRef(event, 'ref19 ref22'); return false;" href="javascript:void(0);" class="ref ref19 ref22">(19, 22)</a></div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Pyrimidine Hydroxamate Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) RSO<sub>2</sub>Cl, triethylamine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp. (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, room temp. (c) Ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temp. (d) NaOH, MeOH, THF, room temp. (e) <i>O</i>-(1-Isobutoxyethyl)hydroxylamine, EDC hydrochoride, HOBt, triethylamine, room temp. (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, room temp or 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp. (g) ROCl, pyridine, 0 °C. (h) 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp. (i) RCHO, NaBH<sub>4</sub>, MeOH, NaOH, room temp, 58%. (j) 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp.</p></p></figure><div class="NLM_p">Methylation of the intermediate sulfonamide, formed by the reaction of amine <b>8</b> and 2-naphthylenesulfonyl chloride provided <b>22</b>, facilitating the synthesis of final hydroxamate <b>23</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). The condensation of <b>8</b> with 1-chloroisoquinoline furnished the desired aminoisoquinoline intermediate <b>24</b>, allowing access to final compound <b>25</b>. The extended methylamino analogue <b>27</b> was obtained by the reaction of Boc-protected azabicyclo[3,1,0]hexane <b>12</b> with the 2-methanesulfonyl intermediate <b>2</b> followed by subsequent ester hydrolysis to give intermediate <b>26</b>. The hydroxamate functionality of <b>27</b> was introduced as for previous analogues.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0013.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Further Pyrimidine Hydroxamate Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, EDC hydrochloride, HOBt, DMF, room temp, 90%. (b) NaH, (MeO)<sub>2</sub>SO<sub>2</sub>, THF, room temp. (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, MeOH, room temp, 3% over two steps. (d) 1-Chloroisoquinoline, 100 °C. (e) Ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, DMF, room temp. (f) NaOH, THF, H<sub>2</sub>O, room temp, 30% over three steps. (g) <i>O</i>-(1-Isobutoxyethyl)hydroxylamine, EDC hydrochloride, HOBt, triethylamine, room temp, 36%. (h) 4 M HCl in dioxane, room temp, 58%. (i) Ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, DMF, room temp, 90%. (j) 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 97%. (k) 2-Naphthaldehyde, NaBH<sub>4</sub>, MeOH, room temp. (l) NaOH, THF, H<sub>2</sub>O, room temp. (m) <i>O</i>-(1-Isobutoxyethyl)hydroxylamine, EDC hydrochloride, HOBt, triethylamine, room temp, 46% over two steps. (n) 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 50%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86052" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86052" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The intrinsic HDAC potency of test compounds was established through IC<sub>50</sub> determination (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) in an assay utilizing nuclear extract from HeLa cells. Similar levels of inhibition were observed for the sulfonamide <b>15a</b>, amide <b>18a</b>, and alkylamino <b>21a</b> compounds, confirming a hypothesis from our modeling studies that all these linkers from the azabicyclohexane spacer would place the 2-naphthyl headgroup in a similar position at the surface of the protein (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). However, we did observe that the cell-to-enzyme potency ratio (GI<sub>50</sub>(HCT116)/IC<sub>50</sub>(HDAC)) was reduced for the naphthylmethylene analogue <b>21a</b> when growth inhibition of the HCT116 human colon carcinoma cell line was examined. The cell-to-enzyme ratios for <b>15a</b>, <b>18a</b>, and <b>21a</b> were 73, 32, and 13, respectively. We attributed this observation to the lower calculated PSA of <b>21a</b> in comparison to <b>15a</b> and <b>18a</b>. This hypothesis appears to be supported by an analysis of an expanded panel of 84 pyrimidine hydroxamates made in this project. Although the absolute correlation between PSA and cell-to-enzyme ratio is relatively weak, the trends for low cell-to-enzyme ratios, arbitrarily set at <20, were made evident by binning PSA data (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). For 53 compounds that had cell-to-enzyme ratio of less than 20 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>a), 58% had a PSA value of less than 100 Å<sup>2</sup>. In comparison, for the 31 compounds with a ratio greater than 20, 81% of compounds had a PSA of >100 Å<sup>2</sup> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b), suggesting that targeting a lower PSA value was important for good cell activity. Since these lower PSA values are achieved by the introduction of the alkylamino linkage, we decided to focus our optimization on these derivatives. We also believed that the more lipophilic nature of these analogues resulting from reduced PSA in conjunction with the introduction of the ionizable aminoalkyl linker would perhaps lead to improved distribution of drug to the tumor.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Expansion of the SAR of compound <b>21a</b> indicated that many aryl and heteroaryl groups are tolerated as the aminoalkyl substituent and that good cell-to-enzyme ratios are maintained.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Proposed binding mode of <b>15a</b> with HDAC8 (cross section). The Zn<sup>2+</sup> ion is shown as a sphere and the protein as a surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pie charts showing the percentage distribution of pyrimidine hydroxamate compounds in PSA bins. Compounds are divided between those with cell-to-enzyme ratio of <20 (a) and those with cell-to-enzyme ratio of >20 (b). Compounds with PSA of 70−100 Å<sup>2</sup> are represented in bright green, 100−130 Å<sup>2</sup> in light green, 130−160 Å<sup>2</sup> in amber, and 160−190 Å<sup>2</sup> in red. Pie charts were generated with Vortex (Dotmatics Ltd., U.K.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibition of HDAC Activity IC<sub>50</sub>, Growth Inhibition GI<sub>50</sub> Values in Human Colorectal Cancer Cell Line HCT116, and PSA Values for Compounds <b>15a</b>,<b>b</b>, <b>18a</b>−<b>c</b>, and <b>21a</b>−<b>r</b></div><p class="last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0014.gif" alt="" id="fx1" /></img></p></div></div><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col align="center" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0015.gif" alt="" id="fx2" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Values are the mean of two independent determinations or mean ± SD of three or more experiments. The <i>K</i><sub>i</sub> for <b>21r</b> was 4.8 nM. SAHA was used as a positive control: IC<sub>50</sub> = 87 ± 13 nM.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last"><i>n</i> = 6. SAHA gave a GI<sub>50</sub> (mean of three experiments) in these assays of 920 ± 120 nM.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Cell/enzyme ratio = (HCT116 GI<sub>50</sub>)/(HDAC IC<sub>50</sub>).</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Not determined.</p></div></div></div><div class="NLM_p">An additional factor limiting cell penetration of <b>15a</b> may have been the ionization of the sulfonamide linker. The calculated p<i>K</i><sub>a</sub> for this group is 3.4, suggesting that it will be negatively charged at physiological pH. We therefore decided to investigate whether methylation of the sulfonamide nitrogen would mitigate this effect. The HDAC IC<sub>50</sub> value of 23 nM for <b>23</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) indicated that while the introduction of the methyl substituent was not detrimental to potency, activity in the cell growth inhibition assay was still moderate at 1 μM. This result enhanced our belief that high PSA limits cell penetration of these compounds.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition of HDAC Activity (IC<sub>50</sub>), Growth Inhibition (GI<sub>50</sub>) in Human Colorectal Tumour Cell Line HCT116, and PSA Values for Compounds <b>23</b>, <b>25</b>, and <b>27</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">HDAC IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">HCT116 GI<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">cell/enzyme ratio<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">PSA (Å<sup>2</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">1000</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">124</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">130</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">103</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">370</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">90</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Values are the mean of two independent determinations. SAHA was used as a positive control: IC<sub>50</sub> = 87 ± 13 nM.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last"><i>n</i> = 6. SAHA gave a GI<sub>50</sub> (mean of three experiments) in these assays of 920 ± 120 nM.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Cell/enzyme ratio = (HCT116 GI<sub>50</sub>)/(HDAC IC<sub>50</sub>).</p></div></div></div><div class="NLM_p">We next decided to examine the effect of linker length on potency through the synthesis of compounds <b>25</b> and <b>27</b>. The truncated aminoisoquinoline compound <b>25</b> maintained good potency against the target, in relation to the aminoalkyl analogues <b>21a</b>−<b>r</b>. The introduction of an additional methylene unit in compound <b>27</b> led to an HDAC IC<sub>50</sub> value of 32 nM which compared favorably to the potency of <b>21a</b> which inhibits the enzyme with a potency of 14 nM. Thus, it would appear that HDAC activity is relatively insensitive to linker length in this series. It has been reported that, at least for HDAC8, the protein surface at the opening to the active site is malleable allowing it to accommodate binding of a variety of ligands.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Thus, the narrow range of inhibition within our series is unsurprising.</div><div id="sec4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Pharmacokinetic Data</h3><div class="NLM_p">With good enzyme and cell potency demonstrated, we decided to investigate the exposure of this series of compounds by the oral route of administration to ascertain which compounds to progress to efficacy studies. With many compounds of similar potency available, we pursued a triaging strategy based on comparison of the AUCs of these analogues following oral cassette dosing at 3 mg/kg in mice, the best compounds being shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Interestingly <b>21r</b> had significantly higher exposure in the spleen in comparison to the 2-naphthyl analogue <b>21a</b>. This presumably reflects the ability of the fluoroisoquinoline group in <b>21r</b> to prevent the rapid oxidative metabolism of the naphthyl headgroup observed for <b>21a</b> in microsomal studies (data not shown). From this work <b>21f</b> and <b>21r</b> were identified as lead compounds for progression.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. AUC Values from Mouse po Cassette Studies<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center" char=".">AUC<sub>0−<i>t</i></sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">plasma</th><th class="colsep0 rowsep0" align="center" char=".">spleen</th><th class="colsep0 rowsep0" align="center" char=".">spleen/plasma ratio</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">145</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21f</b></td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">436</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21k</b></td><td class="colsep0 rowsep0" align="char" char=".">83</td><td class="colsep0 rowsep0" align="char" char=".">251</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21o</b></td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">219</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21q</b></td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">294</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21r</b></td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">775</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Cassettes comprised four compounds dosed at 3 mg/kg po to CD1 mice.</p></div></div></div><div class="NLM_p">Further in vitro profiling of <b>21f</b> and <b>21r</b> indicated that both compounds demonstrated moderate to good permeability in a Caco-2 monolayer assay, particularly in comparison to the prototypical sulfonamide inhibitor <b>15a</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Good metabolic stability in mouse and human liver microsomes was also observed, particularly for <b>21r</b>, with a significant amount of parent drug remaining after 30 min of incubation in both preparations. The glucoronide was the major metabolite identified in mouse liver microsomes with smaller amounts of the amide and carboxylic acid being observed (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). No detectable metabolites were identified from human microsomes. Compounds <b>21f</b> and <b>21r</b> also displayed favorable drug−drug interaction profiles, with no significant inhibitory activity being observed against CYP2C19, CYP2D6, and CYP3A4 at concentrations below 10 μM. The equilibrium solubility<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> of <b>21a</b> and <b>21r</b> was measured in phosphate buffer at pH 5.5 and 7.4. The solubility of <b>21a</b> was pH dependent as expected, but the solubility of <b>21r</b> was surprisingly poor, especially at the lower pH. Despite this, we were encouraged to profile the in vivo PK of <b>21f</b> and <b>21r</b> in other species to further assess their suitability as potential drug candidates. We were pleased to find that the oral exposure demonstrated in the mouse oral PK studies translated into good bioavailability for both compounds in the dog, with <i>F</i> values of 56% and 40% for <b>21f</b> and <b>21r</b>, respectively. In the rat, <b>21r</b> also demonstrated good bioavailability (<i>F</i> = 27%); <b>21f</b> was not tested (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolism of <b>21f</b> and <b>21r</b> in the mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro ADME Properties of HDAC Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center">Caco-2 <i>P</i><sub>app</sub> (cm/s)</th><th class="colsep0 rowsep0" colspan="2" align="center">in vitro Cl (% remaining 30 min)</th><th class="colsep0 rowsep0" colspan="3" align="center">CYP IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" colspan="2" align="center">solubility (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">A2B</th><th class="colsep0 rowsep0" align="center">B2A</th><th class="colsep0 rowsep0" align="center">MLM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">HLM<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">2C19</th><th class="colsep0 rowsep0" align="center">2D6</th><th class="colsep0 rowsep0" align="center">3A4</th><th class="colsep0 rowsep0" align="center">pH 5.5</th><th class="colsep0 rowsep0" align="center">pH 7.4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="left"><0.5</td><td class="colsep0 rowsep0" align="left">8.9</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">10−50</td><td class="colsep0 rowsep0" align="left">10−50</td><td class="colsep0 rowsep0" align="left">10−50</td><td class="colsep0 rowsep0" align="left">74</td><td class="colsep0 rowsep0" align="left">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">208</td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21f</b></td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">10−50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21r</b></td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">10−50</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">MLM = mouse liver microsome.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">HLM = human liver microsome.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Not determined.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters of Compounds <b>21f</b> and <b>21r</b> in Rat<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> and Dog<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center" char=".">iv (1 mg/kg)</th><th class="colsep0 rowsep0" colspan="3" align="center" char=".">po (10 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0−<i>t</i></sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">Cl ((mL/min)/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0−<i>t</i></sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog <b>21f</b></td><td class="colsep0 rowsep0" align="char" char=".">265</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">1475</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog <b>21r</b></td><td class="colsep0 rowsep0" align="char" char=".">241</td><td class="colsep0 rowsep0" align="char" char=".">70</td><td class="colsep0 rowsep0" align="char" char=".">950</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat <b>21r</b></td><td class="colsep0 rowsep0" align="char" char=".">124</td><td class="colsep0 rowsep0" align="char" char=".">134</td><td class="colsep0 rowsep0" align="char" char=".">102</td><td class="colsep0 rowsep0" align="left">5.2</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">The vehicle for rat iv and po dosing was 1% DMSO-HPβC (11.25% w/v).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">The vehicle for dog iv dosing was 5% DMSO-HPβC (11.25% w/v) and 5% DMSO-saline for the po arm.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Not determined.</p></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Pharmacology</h3><div class="NLM_p">We were keen to determine the HDAC isoform selectivity of <b>21f</b> and <b>21r</b>, and so their IC<sub>50</sub> values against a panel of HDAC isoforms were determined (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). We were pleased to observe that <b>21f</b> and <b>21r</b> showed excellent potency against the class I isoforms, HDACs 1, 2, and 3, and good selectivity over HDACs 5 and 6, members of the class II family. These two compounds were ∼700-fold selective for HDAC1 compared to HDAC6, whereas SAHA showed equipotent activity. To further investigate this subtype selectivity at the cellular level, we used the HCT116 cell line to evaluate the acetylation status of histone H3 in comparison to that of the HDAC6-specific substrate α-tubulin. We found that <b>21f</b>, <b>21r</b>, and SAHA have almost equivalent effects on histone acetylation at equitoxic doses whereas SAHA has a greater effect on tubulin acetylation (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). The inability of <b>21f</b> and <b>21r</b> to induce significant acetylation of α-tubulin confirmed that they are not effective inhibitors of HDAC6. The cleavage of PARP was also observed in HCT116 cells (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), this being indicative of apoptosis.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Substrate selectivity of <b>21f</b> and <b>21r</b> in HCT116 cells. Human HCT116 colon carcinoma cells were incubated with the indicated concentrations of <b>21f</b>, <b>21r</b>, and SAHA for 30 h. Total cell lysates were prepared and analyzed by SDS−PAGE and Western blotting using antibodies to acetylated H3K9 (Abcam 1:5000 dilution) and acetylated α-tubulin (Abcam, 1:500 dilution). GAPDH was used as a loading control. Similar results were obtained using a fixed cell ELISA (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Induction of PARP cleavage by <b>21f</b> and <b>21r</b> in comparison to SAHA. Human HCT-116 colon carcinoma cells were incubated with the indicated concentrations of <b>21f</b>, <b>21r</b>, and SAHA for 30 h. Total cell lysates were prepared and analyzed by SDS−PAGE and Western blotting using antibodies to PARP and cleaved PARP (both Cell Signaling, 1:1000 dilution). GAPDH was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibition of HDAC Isoforms (IC<sub>50</sub> in nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">HDAC</th><th class="colsep0 rowsep0" align="center" char="."><b>21f</b></th><th class="colsep0 rowsep0" align="center" char="."><b>21r</b></th><th class="colsep0 rowsep0" align="center" char=".">SAHA</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">500</td><td class="colsep0 rowsep0" align="char" char=".">200</td><td class="colsep0 rowsep0" align="char" char=".">3000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">3300</td><td class="colsep0 rowsep0" align="char" char=".">2100</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Assays were performed by BPS Biosciences (San Diego, CA) using human recombinant enzyme.</p></div></div></div><div class="NLM_p">Given the important role of HDACs in tumor cell proliferation, we measured the antiproliferative effects of <b>21f</b> and <b>21r</b>, again in comparison to SAHA, against an expanded panel of transformed human cell lines originating from both solid and hematological cancers (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). As shown, <b>21r</b> exhibits growth inhibition in the range 31−750 nM and was generally 2−3 times more potent than <b>21f</b> across the cell panel. In comparison to SAHA, <b>21r</b> was 5−20 times more potent.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antiproliferative Activity of <b>21f</b> and <b>21r</b> in a Panel of Human Tumour and Leukemic Cell Lines (GI<sub>50</sub> in nM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">origin</th><th class="colsep0 rowsep0" align="center"><b>21f</b></th><th class="colsep0 rowsep0" align="center"><b>21r</b></th><th class="colsep0 rowsep0" align="center">SAHA</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCT116</td><td class="colsep0 rowsep0" align="left">colon carcinoma</td><td class="colsep0 rowsep0" align="left">210</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="left">740</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LoVo</td><td class="colsep0 rowsep0" align="left">colon carcinoma</td><td class="colsep0 rowsep0" align="left">310</td><td class="colsep0 rowsep0" align="left">140</td><td class="colsep0 rowsep0" align="left">1700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A2780</td><td class="colsep0 rowsep0" align="left">ovarian adenocarcinoma</td><td class="colsep0 rowsep0" align="left">410</td><td class="colsep0 rowsep0" align="left">210</td><td class="colsep0 rowsep0" align="left">3150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Du145</td><td class="colsep0 rowsep0" align="left">prostate adenocarcinoma</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">1050</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC3</td><td class="colsep0 rowsep0" align="left">prostate adenocarcinoma</td><td class="colsep0 rowsep0" align="left">260</td><td class="colsep0 rowsep0" align="left">160</td><td class="colsep0 rowsep0" align="left">2000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2</td><td class="colsep0 rowsep0" align="left">hepatocellular adenocarcinoma</td><td class="colsep0 rowsep0" align="left">470</td><td class="colsep0 rowsep0" align="left">230</td><td class="colsep0 rowsep0" align="left">4600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MG63</td><td class="colsep0 rowsep0" align="left">osteocarcinoma</td><td class="colsep0 rowsep0" align="left">1600</td><td class="colsep0 rowsep0" align="left">750</td><td class="colsep0 rowsep0" align="left">>10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MiaPaca-2</td><td class="colsep0 rowsep0" align="left">pancreatic carcinoma</td><td class="colsep0 rowsep0" align="left">620</td><td class="colsep0 rowsep0" align="left">280</td><td class="colsep0 rowsep0" align="left">3500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="left">lung adenocarcinoma</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left">250</td><td class="colsep0 rowsep0" align="left">5700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">COR-L23</td><td class="colsep0 rowsep0" align="left">large cell lung carcinoma</td><td class="colsep0 rowsep0" align="left">210</td><td class="colsep0 rowsep0" align="left">105</td><td class="colsep0 rowsep0" align="left">1100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">COR-L23 “R”</td><td class="colsep0 rowsep0" align="left">doxorubicin resistant variant</td><td class="colsep0 rowsep0" align="left">1100</td><td class="colsep0 rowsep0" align="left">560</td><td class="colsep0 rowsep0" align="left">3300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Molt-4</td><td class="colsep0 rowsep0" align="left">acute lymphoblastic leukemia</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">670</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hut78</td><td class="colsep0 rowsep0" align="left">T-cell lymphoma</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">295</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U937</td><td class="colsep0 rowsep0" align="left">histiocytic lymphoma</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">450</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRC5- SV 2</td><td class="colsep0 rowsep0" align="left">transformed lung fibroblast</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">2100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last"><i>n</i> = 6 replicates measured by WST-1 assay.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Not determined.</p></div></div></div><div class="NLM_p">With attention turning increasingly toward combination trials of HDAC inhibitors<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> we decided to investigate the synergy between our lead compounds with other anticancer agents. HDAC inhibitors have been reported to act in a synergistic manner with other antitumor agents in a number of in vitro studies.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Therefore, conventional Chou and Talalay median effect analysis<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> was conducted following the generation of appropriate cell proliferation data using <b>21f</b> and <b>21r</b> in combination with erlotinib<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (EGF receptor kinase inhibitor), decitabine<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> (DNA methyltransferase inhibitor), and tosedostat<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (aminopeptidase inhibitor). As indicated by the combination index (CI),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> good additivity and synergy were seen across a panel of human cancer cell lines (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). The most striking synergy was observed with a combination of <b>21r</b> and tosedostat against cells originating from pancreatic carcinoma and malignant melanoma.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vitro Synergy Studies between HDAC Inhibitors and Anticancer Agents</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">combination</th><th class="colsep0 rowsep0" align="center">schedule</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">type of cancer</th><th class="colsep0 rowsep0" align="center">CI<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a><b>21f</b> (mean)</th><th class="colsep0 rowsep0" align="center">CI <b>21r</b> (mean)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDACi plus erlotinib</td><td class="colsep0 rowsep0" align="left">HDACi (24 h), washout then erlotinib (6 days)</td><td class="colsep0 rowsep0" align="left">H358</td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">0.32</td><td class="colsep0 rowsep0" align="left">0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">H520</td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">0.54</td><td class="colsep0 rowsep0" align="left">0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">DU-145<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">prostate carcinoma</td><td class="colsep0 rowsep0" align="left">0.63</td><td class="colsep0 rowsep0" align="left">0.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDACi plus decitabine</td><td class="colsep0 rowsep0" align="left">decitabine (48 h) then decitabine plus HDACi (72 h)</td><td class="colsep0 rowsep0" align="left">MDA-MB-231</td><td class="colsep0 rowsep0" align="left">breast carcinoma</td><td class="colsep0 rowsep0" align="left">0.94</td><td class="colsep0 rowsep0" align="left">0.773</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MDA-MB-435</td><td class="colsep0 rowsep0" align="left">breast ductal carcinoma</td><td class="colsep0 rowsep0" align="left">0.74</td><td class="colsep0 rowsep0" align="left">1.097</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDACi plus tosedostat</td><td class="colsep0 rowsep0" align="left">HDACi (24 h), washout then CHR-2797 (72 h)</td><td class="colsep0 rowsep0" align="left">BxPC-3</td><td class="colsep0 rowsep0" align="left">pancreatic carcinoma</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.262</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">RPMI-7951</td><td class="colsep0 rowsep0" align="left">malignant melanoma</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.288</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">H23</td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.780</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">5 day erlotinib for DU-145.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">CI values indicate the degree of synergy according to the following system. CI: >1.1, antagonism; 0.90−1.10, nearly additive; 0.70−0.90, slight to moderate synergism; 0.30−0.70, synergism; 0.10−0.30, strong synergism; <0.10, very strong synergism.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Not determined.</p></div></div></div><div class="NLM_p">Flow cytometric analysis was employed to determine the relative abilities of <b>21f</b>, <b>21r</b>, and SAHA to induce cell cycle arrest (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>), following the treatment of HCT116 cells with 300 nM inhibitor for 15 h. An increase in cells in the sub-G1 phase was observed for all three compounds, but only <b>21r</b> showed accumulation at G2/M compared to nontreated cells at this concentration and time-point.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Cell Cycle Effects of <b>21f</b> and <b>21r</b><a class="ref internalNav" href="#tbl9-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="4" align="center" char=".">HCT116 cells after 15 h of drug treatment (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">sub-G1</th><th class="colsep0 rowsep0" align="center" char=".">G1</th><th class="colsep0 rowsep0" align="center" char=".">S</th><th class="colsep0 rowsep0" align="center" char=".">G2/M</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vehicle treated</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21f</b></td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21r</b></td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">32</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl9-fn1"><div class="footnote" id="tbl9-fn1"><sup>a</sup><p class="last">Human HCT116 colon carcinoma cells were incubated with 300 nM inhibitor. DNA content of nuclei was evaluated using propidium iodide staining followed by flow cytometry analysis, and the number of cells in sub-G1, G1, S, and G2/M phases was calculated as a percentage of control. Results are expressed as percent of total cells, and a representative experiment out of three is shown.</p></div></div></div><div class="NLM_p">The promising pharmacological and PK profiles of <b>21f</b> and <b>21r</b> prompted an in vivo efficacy study of these compounds against some of the human cancer cell lines employed in our in vitro cell growth inhibition studies. Initially we wanted to ensure that pharmacodynamic effects observed in tumor growth models were consistent with HDAC inhibition. Female CrTac:NCr-<i>Fox1(nu)</i> mice with established HCT116 tumor xenografts were dosed orally on a daily schedule for 16 days with 50 mg/kg <b>21f</b>. Although the efficacy of <b>21f</b> in this study was disappointing (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>a), the compound was well tolerated and an increase in histone acetylation was observed in the tumors of <b>21f</b>-treated animals relative to vehicle animals for at least 4 h (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>b). As expected from in vitro studies, α-tubulin acetylation was unchanged in the tumors from <b>21f</b>-treated mice compared with controls. Concentrations of <b>21f</b> in the spleen were 4−14 times higher than those in plasma, consistent with our earlier cassette PK study (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). The measured tumor concentration of <b>21f</b> was sustained for at least 4 h at levels more than 4 times greater than its IC<sub>50</sub>, consistent with the observed duration of increased histone acetylation.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Efficacy of <b>21f</b> 50 mg/kg po daily and (b) histone acetylation in HCT116 tumor tissue from mice treated with <b>21f</b>. (a) Relative tumor volumes in HCT116 human tumor mouse xenograft study. Compound <b>21f</b> (50 mg/kg po in 10% DMSO-saline) was administered for 16 days to female CrTac:NCr-<i>Fox1(nu)</i> mice bearing established HCT116 colon carcinoma xenografts. (b) Histone acetylation in HCT116 tumor tissue treated with <b>21f</b> as in (a). Tumour tissue was obtained, and lysates were prepared 0.5, 1.0, and 4 h following the last dose of <b>21f</b>. The samples were analyzed using a quantitative sandwich ELISA with electrochemiluminescent end point (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Histone acetylation was also measured by Western blot using an antibody to acetylated histone H3 (Abcam) and GAPDH as loading control (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Gray bars are <b>21f</b>-treated samples. Black bars show densitometry results from the Western blot normalized to GAPDH, and white bars represent the samples from vehicle control animals. C = samples from vehicle treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a second HCT-116 mouse xenograft study (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>a) we compared the efficacy of <b>21f</b> (75 mg/kg po q.d.) with <b>21r</b> (50 mg/kg po q.d.). We found that <b>21r</b>, even at a lower dose than <b>21f</b>, resulted in almost complete suppression of tumor growth. Examination of tumor concentrations revealed that <b>21r</b> (133 ng/mL) achieved levels almost 5 times higher in comparison to the higher dose of <b>21f</b> (28 ng/mL). The ratio of tumor to plasma concentrations for <b>21r</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>b) also reflected our earlier studies of distribution to spleen (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Given that <b>21r</b> in general showed greater in vitro potency and enhanced distribution to tumor compared to <b>21f</b>, this result was perhaps unsurprising. We therefore decided to examine the efficacy of <b>21r</b> in a second human tumor xenograft model. A study was performed to evaluate the effect of a lower dose level of <b>21r</b> on subcutaneous growth of a LoVo human colorectal xenograft in female BALB/c nude mice (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). The compound was administered orally at 50 and 25 mg/kg daily, with <b>21r</b> again substantially reducing tumor volume and demonstrating an apparent dose dependency. As a result of these observations <b>21r</b> (CHR-3996)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> was selected as our clinical candidate.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (a) Relative tumor volumes in HCT116 tumor xenografts after treatment with <b>21f</b> and <b>21r</b>. Compound <b>21f</b> (75 mg/kg po) and <b>21r</b> (50 mg/kg po) were administered for 14 days to female nude BALB/c mice in 5% DMSO-saline bearing the HCT116 colon carcinoma xenograft (EpiStem Ltd.). (b) Plasma and tumor concentrations of <b>21f</b> and <b>21r</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Growth curves of LoVo human colon xenografts after treatment with <b>21r</b>. Relative tumor volumes in LoVo tumor xenograft study. Compound <b>21r</b> (25 and 50 mg/kg po) was administered for 19 days to female nude BALB/c mice in 5% DMSO-saline bearing the LoVo colon carcinoma xenograft (EpiStem Ltd.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15154" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15154" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Through an optimization process we have identified <b>21r</b> as a 7 nM inhibitor of HDAC with a class I isotype selectivity that shows good potency for the inhibition of tumor cell growth. We have demonstrated that the compound can be delivered via oral administration with good distribution to tissue as measured by drug level in the mouse spleen and xenograft tissue and that the compound shows complete inhibition of growth in two human tumor xenograft models. <b>21r</b> has been selected for a phase 1 clinical trial and represents a highly promising new agent with the potential to be applied to a broad range of human cancers.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Biological Methods. Measurement of HDAC Activity</h3><div class="NLM_p last">The HeLa cell nuclear extract (catalog no. CC-01−20-50) was obtained from Cilbiotech S.A., Mons, Belgium. Histone deacetylase (HDAC) activity was determined using the Fluor De Lys system with the substrate (catalog no. KI-104) and the developer concentrate (catalog no. KI-105) purchased from Biomol International, Palatine House, Matford Court, Exeter, U.K. All assays were run in polystyrene, flat-bottomed Immulon 2HB 96-well plates purchased from Thermo Life Sciences, Milford, MA, U.S. The fluorimetric assay of HDAC activity was carried out as described in the Biomol technical manual. The Fluor De Lys substrate, developer concentrate, and HeLa cell nuclear extract were all diluted with the assay buffer (25 mM Tris-HCl, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl<sub>2</sub>, pH 8.0). Compounds (30 μM in 0.3% DMSO) were preincubated for 5 min with the diluted enzyme (10 μg of HeLa cell nuclear extract protein) at room temperature in a 15 μL volume. The reaction was initiated by the addition of the substrate (15 μL, 0.125 mM). After 15 min of incubation at room temperature the developer concentrate (25 μL), which contained 2 μM trichostatin A to stop the reaction, was added and the plate shaken. After the mixture was left to stand for 10 min, the fluorescence signal was read on a Victor II plate reader with excitation at 355 nm and emission at 455 nm. On each assay plate, column 1 contained DMSO alone for the totals and column 12 had buffer added rather than enzyme to generate the blank values. For the IC<sub>50</sub> determinations, each compound was assayed at eight concentrations in duplicate and the data were analyzed in Graph Pad Prism. Preliminary kinetic assays with the Fluor de Lys substrate produced a <i>K</i><sub>m</sub> of 60 ± 10 μM (Biomol <i>K</i><sub>m</sub> = 54 μM), so all assays were run at a substrate concentration of 62.5 μM. Under these conditions, enzyme activity was linear up to 15 min of incubation and 40 μg of protein. Measurement of inhibitor activity for HDAC isoforms was performed by BPS Biosciences (San Diego, CA) using human recombinant enzymes in a fluorogenic assay kit. Protocols are available at <a href="http://www.bpsbioscience.com" class="extLink">http://www.bpsbioscience.com</a>.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Cellular Proliferation Assays</h3><div class="NLM_p last">Cells were seeded in 96-well BD-Falcon plates (Becton Dickinson) at a density of (1−5) × 10<sup>3</sup> cells per well in the appropriate serum-containing culture medium and cultured at 37 °C in a humidified 5% (v/v) CO<sub>2</sub> incubator for 24 h. Samples (50 μL) of different HDAC inhibitor concentrations (0.6−10000 nM), diluted in the relevant culture medium, were transferred to the wells containing the cells for a further 72 h. During the final 4 h of the incubation, cells were pulsed with 10 μL of the tetrazolium salt Cell Proliferation Reagent, WST-1 (Roche). In the presence of viable cells WST-1 is metabolized to formazan product which is measured spectrophotometrically at 450 nm against a background media control (reference wavelength of 650 nm). Antiproliferative effects of HDAC inhibitors on the cells were expressed as percentage inhibition of the vehicle response and were the plotted as the mean ± SD, <i>n</i> = 6 replicates. Results are summarized as GI<sub>50</sub> values, i.e., the concentration of inhibitor that inhibits 50% of the vehicle response.</div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Western Blotting and Flow Cytometry</h3><div class="NLM_p last">HCT116 cells were seeded at 2 × 10<sup>4</sup> cells/mL and 24 h later treated with the stated doses of compound or vehicle for 6, 15, or 30 h. Samples were harvested on ice and washed twice with ice cold PBS before (a) lysing the pellet in RIPA buffer to prepare SDS−PAGE samples or (b) fixing pellet overnight at 1 × 10<sup>6</sup> cells/mL in 70% ethanol/30% PBS (ice cold) before preparing samples for FACS. Gel samples were loaded at 10 μg/lane on 4−12% acrylamide gels, transferred to nitrocellulose, and stained with primary antibodies to acetylated α-tubulin, acetylated H3 lysine 9 (K9), GAPDH, and PARP. Signal was visualized using ECL and film. FACS samples were prepared by washing twice with PBS before resuspending cells gently in propidium iodide/RNase solution for 30 min before reading the output using a FACScanto. Cells were gated to give populations of sub-G1, G1, S, and G2/M phases. Numbers shown represent the percent of each population from the total number of single cells counted (10 000 per sample).</div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Thymidine Incorporation Proliferation Assays for Synergy Studies</h3><div class="NLM_p last">Cells were seeded in 96-well BD-Falcon plates (Becton Dickinson, Oxford, U.K.) at a density of (1−5) × 10<sup>3</sup> cells per well in the appropriate serum containing culture medium and cultured at 37 °C in a humidified 5% CO<sub>2</sub> incubator for 24 h. Compounds to be tested were serially diluted in the relevant culture medium and then added to the wells for a further 72 h before pulsing the cells for 4 h with 0.4 μCi per well of <sup>3</sup>H-methylthymidine (specific activity 1 mCi/mL Amersham Biosciences, U.K.). For synergy experiments, minor dosing modifications were carried out to take account of the necessary scheduling differences required when studying more than one drug combination. Cells were then harvested onto glass fiber filter mats (GF/C Perkin-Elmer LAS, U.K.) using a Tomtec harvester and then counted on a 1450 MicroBeta scintillation counter to determine the amount of radioactive thymidine incorporated into cellular DNA. Data were expressed as a mean percentage ± SD, relative to vehicle response, which measures the amount of <sup>3</sup>H-thymidine incorporation into cells in the presence of medium containing 0.1% DMSO and no test compound. Results are calculated as the GI<sub>50</sub> or concentration of compound that inhibited the vehicle response by 50%.</div></div><div id="sec7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> In Vitro ADME Studies</h3><div class="NLM_p last">Microsomal stability studies were performed using published methods.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Inhibition studies for CYP2D6 and 3A4 were performed using previously described methods.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> IC<sub>50</sub> values for CYP2C19 were determined by Cyprotex (U.K.).</div></div><div id="sec7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Human Tumour Xenograft Studies</h3><div class="NLM_p last">Female CrTac:NCr-<i>Fox1(nu)</i> athymic mice 6−8 weeks of age bred in-house at ICR were inoculated bilaterally sc with 2 million human HCT116 colon carcinoma cells. Daily treatment with <b>21f</b> (50 mg/kg po) commenced on day 6, when tumors were established (approximately 5 mm mean diameter). Controls received an equal volume of vehicle alone, 10% DMSO in saline). Tumor measurements and body weights were recorded three times weekly. The study was terminated on day 16, and plasma, spleen, and tumor samples were obtained and stored frozen for later PK and biomarker assays. Additional efficacy studies in HCT116 and LoVo human tumor xenograft bearing mice using <b>21r</b> were carried out at Epistem Ltd. (U.K.).</div></div><div id="sec7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Chemistry General Methods</h3><div class="NLM_p last">All nonaqueous reactions were carried out under a nitrogen atmosphere unless otherwise noted. All solvents employed were commercially available HPLC grade. <sup>1</sup>H NMR spectra were determined with a Bruker AV spectrometer at 300 MHz. Chemical shifts are reported in parts per million (δ) relative to residual chloroform (7.26 ppm) or dimethylsulfoxide (2.54 ppm) as internal reference with coupling constants (<i>J</i>) reported in hertz (Hz). The peak shapes are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. Analytical HPLC/MS was performed on an Agilent HP1100 LC system using reverse phase Luna C18 columns (3 μm, 50 mm × 4.6 mm), gradient 5−95% B (A = water/0.1% formic acid, B = acetonitrile/0.1% formic acid) over 2.25 min, flow rate of 2.25 mL/min. UV spectra were recorded at 220 and 254 nm using a G1315B DAD detector. Mass spectra were obtained over the range <i>m</i>/<i>z</i> 150−800 on a LC/MSD SL G1956B detector. Data were integrated and reported using ChemStation and ChemStation Data Browser software. The purity of all the above-mentioned compounds was found to be above 95%. Reverse phase HPLC purifications were performed on Gilson preparative systems using reverse phase Axia prep Luna C18 columns (10 μm, 100 mm × 21.2 mm), gradient 0−100% B (A = water/0.05% TFA, B = acetonitrile/0.05% TFA) over 10 min, flow rate of 25 mL/min, monitored by UV detection at 220 or 254 nm. Thin-layer chromatography (TLC) analysis was performed with Kieselgel 60 F<sub>254</sub> (Merck) plates and visualized using UV light. The terms “concentrated” and “evaporated” refer to removal of solvents using a rotary evaporator at water aspirator pressure with a bath temperature equal to or less than 40 °C. Unless otherwise noted, reagents were obtained from commercial sources and were used without further purification.</div></div><div id="sec7_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Modeling and Calculated Properties</h3><div class="NLM_p">Compounds were docked with Glide, version 55211 (Schrodinger Inc., Portland, OR, U.S.) using the SP settings. The protein structure used was PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T67">1T67</a>, which was prepared in MOE, version 2008.1001 (Chemical Computing Group, Montreal, Canada). Initially the software perceived the ligand as having a double bond between the N and O atoms of the hydroxamic acid. This was manually adjusted to a single bond, and the oxygen was assigned a formal negative charge. The Protonate 3D tool was then used to assign the remaining ionization states, add hydrogen atoms, and adjust tautomers and conformers of His, Asn, and Gln residues. This structure was then transferred to Maestro (Schrodinger Inc., Portland, OR, U.S.) where all waters were removed except Wat392 (the 11th one as read from the PDB file). This water appears to play an important role in the ligand binding by bridging between its amide oxygen and His180. The positions of the hydrogen atoms were then refined using the OPLS2005 force field in Maestro’s protein preparation wizard before generating a Glide grid for docking purposes. This included a constraint to ensure that the ligands bind to the zinc ion of the active site.</div><div class="NLM_p last">PSA values (Å<sup>2</sup>) were calculated using Pipeline Pilot, version 7.01.100 (Accelrys, Cambridge, U.K.). p<i>K</i><sub>a</sub> values were calculated using Structure Designer (ACD Labs, Toronto, Canada).</div></div><div id="sec7_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Method A. Reductive Amination Reactions of Compound (<b>8</b>)</h3><div class="NLM_p last">Compound <b>8</b> (1.2 equiv) was stirred in MeOH at room temperature under N<sub>2</sub>, and aldehyde (1 equiv) was added. The resultant solution was stirred for 3 h. After this time, NaBH<sub>4</sub> (1.7 equiv) was added and the solution stirred for 10 min. Then 1 M NaOH (3−4 equiv) was added, forming an opaque white solution that was stirred for 20 min. Water was then added and the solution extracted with Et<sub>2</sub>O. The combined organic extracts were dried (MgSO<sub>4</sub>) and solvent was removed in vacuo to give the product which was either used without purification or purified by flash column chromatography.</div></div><div id="sec7_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Method B. Boc Deprotection of N-Substituted <i>tert</i>-Butyl 6-Amino-3-azabicyclo[3,1,0]hexane-3-carboxylates</h3><div class="NLM_p last">A solution of the Boc-protected 6-aminoazabicyclo[3,1,0]hexane (1 equiv) was stirred in 4 M HCl in dioxane (8 equiv) under N<sub>2</sub> at room temperature for 0.5 h. The solvent was removed under reduced pressure to give the product amine hydrochloride salt which was used without purification.</div></div><div id="sec7_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Method C. Reaction of N-Substituted 6-Amino-3-azabicyclo[3,1,0]hexanes with Ethyl 2-(Methylthio)pyrimidine-5-carboxylate and Hydrolysis of the Resulting Ethyl 2-{6-Amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylates</h3><div class="NLM_p last">K<sub>2</sub>CO<sub>3</sub> (3 equiv) was added to a stirred suspension of the N-substituted 6-amino-3-azabicyclo[3.1.0]hexane trifluoroacetate (1 equiv) in CH<sub>3</sub>CN at room temperature under N<sub>2</sub>. A solution of compound <b>2</b> (1 equiv) in CH<sub>3</sub>CN was added dropwise over 5 min, leading to the formation of a precipitate which was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc, giving a suspension that was washed with water. The precipitate in the organic phase was isolated by filtration, washed with TBME, and air-dried to give the product. The product may be used without purification or purified by flash column chromatography. Aqueous 1 M NaOH (10 equiv) was added to a solution of the resulting product (1 equiv) in THF and MeOH at room temperature. The reaction mixture was stirred at room temperature for 18 h. The organic solvents were removed in vacuo, and the resultant aqueous solution was acidified to pH ∼5 with 1 M aq HCl. The precipitate was isolated by filtration, washed with H<sub>2</sub>O, and dried by azeotroping with toluene, giving the product which was used without purification or purified by trituration.</div></div><div id="sec7_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Method D. Hydroxamate Formation Using <i>O</i>-(1-Isobutoxyethyl)hydroxylamine (<b>7</b>) Followed by Deprotection</h3><div class="NLM_p last">The pyrimidine-5-carboxylate (1 equiv) was stirred with EDC hydrochloride (1.2 equiv) and HOBt (1.2 equiv) in DMF at room temperature under a nitrogen atmosphere. <i>O</i>-(1-Isobutoxyethyl)hydroxylamine <b>7</b> (5 equiv) was then added followed by triethylamine (5 equiv) and the mixture left to stir for 16 h. The mixture was then diluted with H<sub>2</sub>O and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over MgSO<sub>4</sub>, and solvent was removed in vacuo. The residue was purified by column chromatography using an eluent of 0−10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to give the product. The protected hydroxamate product (1 equiv) was stirred in CH<sub>2</sub>Cl<sub>2</sub> at room temperature and 4 M HCl in dioxane (2 equiv) added. The mixture was stirred for 10 min and then the solvent removed in vacuo. The residue was purified by preparative HPLC to give the product as a TFA salt.</div></div><div id="sec7_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Ethyl 2-(Methylsulfonyl)pyrimidine-5-carboxylate <b>2</b>: Step 1</h3><div class="NLM_p">To a suspension of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate <b>1</b> (5.0 g, 21.5 mmol) in THF (25 mL) at 85 °C was added slowly dropwise powdered zinc (7.0 g, 107.7 mmol) in water (25 mL). Following complete dissolution of the zinc powder, <i>tert-</i>BuOH (1 mL) was added and heating was continued at 90 °C with vigorous stirring for 18 h. The mixture was cooled to room temperature and filtered through a Celite pad which was washed with further EtOAc (20 mL). The combined filtrates were concentrated, redissolved in EtOAc (30 mL), and washed with water. The EtOAc layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to dryness and the residue purified by flash column chromatography [eluting with 0−100% EtOAc in hexane] to give ethyl 2-(methylthio)pyrimidine-5-carboxylate as a colorless oil (2.45 g, 57%). <i>m</i>/<i>z</i> 199 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.0 (2H, s), 4.35 (2H, q, <i>J</i> = 7.2 Hz), 2.60 (3H, s), 1.30 (3H, t, <i>J</i> = 7.2 Hz).</div><div id="secaa" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Step 2</h4><div class="NLM_p last">To a stirred solution of ethyl 2-(methylthio)pyrimidine-5-carboxylate (2.9 g, 14.64 mmol) in dry THF (76 mL) was added 77% mCPBA (11.0 g, 64.4 mmol) at 0 °C under N<sub>2</sub>. The reaction mixture was allowed to warm to room temperature, stirred for 2 h before evaporating to dryness. The residue was purified by flash column chromatography [eluting with, 100% hexane followed by 1:5:3 CH<sub>2</sub>Cl<sub>2</sub>/heptane/Et<sub>2</sub>O, followed by 1:1:1 CH<sub>2</sub>Cl<sub>2</sub>/heptane/Et<sub>2</sub>O] to give compound <b>2</b> as a white solid (10.0 g, 66%). <i>m</i>/<i>z</i> 231 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.50 (2H, s), 4.40 (2H, q, <i>J</i> = 7.2 Hz), 3.50 (3H, s), 1.40 (3H, t, <i>J</i> = 7.2 Hz).</div></div></div><div id="sec7_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>tert</i>-Butyl 6-Aminoazabicyclo[3.1.0]hexane-3-carboxylate <b>8</b>. Step 1. Preparation of 3-Benzyl-6-nitro-3-azabicyclo[3.1.0]hexane-2,4-dione <b>4</b></h3><div class="NLM_p">To a solution of N-benzylmaleimide (5.0 g, 26.7 mmol) in CH<sub>3</sub>CN (334 mL) was added bromonitromethane (1.87 mL, 26.7 mmol). K<sub>2</sub>CO<sub>3</sub> (3.69 g, 26.7 mmol) was added and the reaction mixture was vigorously stirred at room temperature. After 4 h an additional portion of bromonitromethane (0.2 mL, 2.8 mmol) was added. Further bromonitromethane portions (0.2 mL, 2.8 mmol) were added at further 4 h intervals (x4). After 48 h the reaction mixture was evaporated to dryness and the residue was purified by column chromatography [eluting with, 100% CH<sub>2</sub>Cl<sub>2</sub>], giving <b>4</b> as a white solid (3.0 g, 42%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.35−7.24 (5H, m), 4.52 (2H, s), 4.41 (1H, s,), 3.33 (2H, s).</div><div id="secd" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 2. Preparation of 3-Benzyl-6-nitro-3-azabicyclo[3.1.0]hexane <b>5</b></h4><div class="NLM_p last">To a solution of 3-benzyl-6-nitro-3-azabicyclo[3.1.0]hexane-2,4-dione <b>4</b> (3.0 g, 12.2 mmol) in dry THF (30 mL) was added NaBH<sub>4</sub> (1.15 g, 30.48 mmol). The mixture was stirred for 15 min at room temperature under N<sub>2</sub>. BF<sub>3</sub>·THF complex (3.15 mL, 13.4 mmol) was added dropwise and the mixture heated at 40 °C for 4 h. Further NaBH<sub>4</sub> (0.15 g, 3.96 mmol) was added followed by BF<sub>3</sub>·THF complex (0.32 mL, 1.4 mmol). Heating was continued at 45 °C for 30 min. A mixture of THF/H<sub>2</sub>O (1:1 v/v, 60 mL) was added dropwise with stirring. The resulting mixture was heated at 50 °C for 1 h before standing at room temperature for 16 h. The THF was removed under reduced pressure and the resulting aqueous mixture was extracted with EtOAc (3 × 50 mL), dried (MgSO<sub>4</sub>) and evaporated to dryness to give <b>5</b> as a yellow oil (2.47 g, 93%). <i>m</i>/<i>z</i> 219 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.63 (2H, br m), 7.44−7.42 (3H, m), 5.38 (1H, br s), 4.33 (2H, br s), 3.57 (4H, br s), 2.91 (24H, s).</div></div><div id="secc" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 3. Preparation of 6-Nitro-3-azabicyclo[3.1.0]hexane Hydrochloride <b>6</b></h4><div class="NLM_p last">To a solution of 3-benzyl-6-nitro-3-azabicyclo[3.1.0]hexane <b>5</b> (2.47 g, 11.3 mmol) in 1,2-dichloroethane (5 mL) was added 1-chloroethylchloroformate (1.83 mL, 16.9 mmol) at 0 °C. The reaction mixture was heated to 55 °C for 4 h. Further 1-chloroethylchloroformate (0.5 mL) was added, and heating continued for 2 h. The reaction mixture was then evaporated to dryness. MeOH (15 mL) was added, and the reaction mixture was heated at 65 °C for 3 h. Concentrated HCl (1 mL) was added and the mixture stirred at room temperature for 2 h. A precipitate formed which was isolated by filtration and washed with Et<sub>2</sub>O to give <b>6</b> as a gray powder (464 mg, 25%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.50 (2H, br s), 4.75 (1H, s), 3.60−3.31 (4H, m), 2.90 (2H, s).</div></div><div id="secb" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step 4. Preparation of <i>tert</i>-Butyl 6-Nitro-3-azabicyclo[3.1.0]hexane-3-carboxylate <b>7</b></h4><div class="NLM_p last">6-Nitro-3-azabicyclo[3.1.0]hexane hydrochloride <b>6</b> (464 mg, 2.82 mmol) was suspended in dry CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and cooled to 0 °C. Di-<i>tert</i>-butyl dicarbonate (677 mg, 3.10 mmol) was added followed by DMAP (1 crystal) and triethylamine (0.43 mL, 3.10 mmol). The reaction mixture was stirred at room temperature for 5 h. The solvent was removed under reduced pressure to give a white solid. Purification by flash column chromatography [eluting with 25% EtOAc in heptane) gave <b>7</b> as a white solid (592 mg, 92%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 4.10 (1H, t), 3.77 (2H, br m), 3.51 (2H, br d), 2.67 (2H, s), 1.46 (9H, s).</div></div><div id="seca" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Step 5. <i>tert</i>-Butyl 6-Aminoazabicyclo[3.1.0]hexane-3-carboxylate <b>8</b></h4><div class="NLM_p last"><i>tert</i>-Butyl 6-nitro-3-azabicyclo[3.1.0]hexane-3-carboxylate <b>7</b> (592 mg, 2.59 mmol) was reduced in the presence of 10% Pd/C (20 mg) in EtOH (5 mL) under H<sub>2</sub> (balloon pressure) for 18 h at room temperature. The catalyst was removed by filtration through Celite washing with EtOH and the filtrate concentrated to give <b>8</b> as a pale yellow oil (487 mg, 95%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 3.54 (1H, d, <i>J</i> = 10.6 Hz), 3.51 (1H, d, <i>J</i> = 10.7 Hz), 3.38−3.32 (2H, br m), 2.12 (1H, t, <i>J</i> = 0.8 Hz), 2.01−1.93 (2H,br m), 1.49 (2H, t, <i>J</i> = 10.5 Hz), 1.44 (9H, s).</div></div></div><div id="sec7_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 6-Fluoroquinoline-2-carbaldehyde <b>10</b></h3><div class="NLM_p last">6-Fluoro-2-methylquinoline (1.0 g, 6.2 mmol) was stirred in dioxane (50 mL) at room temperature under a nitrogen atmosphere. SeO<sub>2</sub> (0.86 g, 7.4 mmol) was added and the mixture heated to 100 °C for 1 h, during which time the mixture changed from an opaque brown color to a clear dark red solution. The mixture was cooled to room temperature, filtered and the filtrate concentrated in vacuo. The residue was purified by column chromatography [eluting with 0−3% MeOH in CH<sub>2</sub>Cl<sub>2</sub>] to give the product as an off-white solid (944 mg, 87%). <i>m</i>/<i>z</i> 239 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.11 (1H, s), 8.60 (1H, d, <i>J</i> = 11.0 Hz), 8.32 (1H, dd, <i>J</i> = 7.6, 11.0 Hz), 8.04 (1H, d, <i>J</i> = 11.0 Hz), 7.96 (1H, dd, <i>J</i> = 4.4, 11.0 Hz), 7.85 (1H, td, <i>J</i> = 4.4, 11.0 Hz).</div></div><div id="sec7_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-Hydroxy-2-{6-[(2-naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide Trifluoroacetate <b>15a</b>: Step 1. 6-[(2-Naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hexane Trifluoroacetate <b>13a</b></h3><div class="NLM_p">2-Naphthalenesulfonyl chloride (20.07 g, 97.39 mmol) was added to a solution of <i>tert</i>-butyl 6-aminoazabicyclo[3.1.0]hexane-3-carboxylate <b>5</b> (1.69 g, 8.54 mmol) and triethylamine (24.7 mL, 177.07 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (270 mL) at 0 °C under N<sub>2</sub>, giving a light brown solution which was allowed to warm to room temperature overnight. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (200 mL) and saturated NaHCO<sub>3</sub> (200 mL). The organic phase was separated and washed with H<sub>2</sub>O (2 × 200 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to give a pale yellow oil. Trituration with 5% TBME in heptane (50 mL) gave a solid which was isolated by filtration and washed with heptane to afford <b>13a</b> as a white solid (27.99 g, 82%). <i>m</i>/<i>z</i> 389 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.47 (1H, m), 8.02−7.99 (2H, m), 7.93 (1H, d, <i>J</i> = 7.9 Hz), 7.85 (1H, m), 7.68−7.62 (2H, m), 5.12 (1H, br s), 3.56−3.41 (2H, m), 3.34−3.29 (2H, m), 1.96 (1H, m), 1.82 (2H, m), 1.35 (9H, s). A solution of <i>tert</i>-butyl 6-[(2-naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hexane-3-carboxylate (27.50 g, 68.43 mmol) in 20% TFA in CH<sub>2</sub>Cl<sub>2</sub> (300 mL) was stirred at room temperature for 2 h. The reaction mixture was concentrated in vacuo and then CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added and re-evaporated in vacuo three times to remove excess TFA, giving <b>13a</b> as the trifluoroacetate salt (crude yield 34.0 g). This product was used in the next step without purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.20 (1H, br s), 8.48 (1H, s), 8.33 (1H, br s), 8.23−8.18 (3H, m), 8.08 (1H, d, <i>J</i> = 8.7 Hz), 7.83 (1H, d, <i>J</i> = 7.9 Hz), 7.75−7.70 (2H, m), 3.22 (4H, m), 2.20 (1H, m), 1.86 (2H, s).</div><div id="secf" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step 2. Preparation of 2-{6-[(2-Naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylic Acid <b>14a</b></h4><div class="NLM_p last">Following method C, K<sub>2</sub>CO<sub>3</sub> (28.33 g, 205.29 mmol) was added to a stirred suspension of 6-[(2-naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hexane trifluoroacetate <b>13a</b> (27.50 g, 68.43 mmol) in CH<sub>3</sub>CN (300 mL) at room temperature under N<sub>2</sub>. A solution of compound <b>2</b> (15.74 g, 68.43 mmol) in CH<sub>3</sub>CN (50 mL) was added dropwise over 5 min, leading to the formation of a precipitate which was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc (250 mL), giving a suspension which was washed with water (2 × 250 mL). The precipitate in the organic phase was isolated by filtration, washed with TBME, and air-dried to give ethyl 2-{6-[(2-naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylate as a white solid (25.40 g, 85%). <i>m</i>/<i>z</i> 439 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.70 (2H, s), 8.50 (1H, m), 8.22−8.15 (3H, m), 8.04 (1H, d, <i>J</i> = 8.3 Hz), 7.84 (1H, m), 7.67−7.71 (2H, m), 4.23 (2H, q, <i>J</i> = 7.3 Hz)), 3.70−3.67 (2H, m), 3.53−3.50 (2H, m), 1.90 (1H, m), 1.82 (2H, s), 1.26 (3H, t, <i>J</i> = 7.3 Hz). Aqueous 1 M NaOH (500 mL) was added to a solution of ethyl 2-{6-[(2-naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylate (25.40 g, 58.00 mmol) in THF (500 mL) and MeOH (100 mL) at room temperature, and the reaction mixture was stirred for 18 h. The organic solvents were removed in vacuo, and the resultant aqueous solution was acidified to pH 5 with 1 M aqueous HCl. A heavy white precipitate was formed which was isolated by filtration, washed with H<sub>2</sub>O, and dried by azeotroping with toluene to give 2-{6-[(2-naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylic acid <b>14a</b> as a white solid (22.19 g, 93%). <i>m</i>/<i>z</i> 411 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.83 (2H, s), 8.66 (1H, s), 8.36−8.31 (3H, m), 8.21 (1H, d, <i>J</i> = 8.7 Hz), 8.01 (1H, m), 7.88−7.84 (2H, m), 3.89−3.82 (2H, m), 3.67−3.64 (2H, m), 2.05 (1H, s), 1.97 (2H, s).</div></div><div id="sece" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Step 3. Preparation of <i>N</i>-Hydroxy-2-[6-(naphthalene-2-sulfonylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxamide <b>15a</b></h4><div class="NLM_p last">Following method D, EDC hydrochloride (7.27 g, 37.9 mmol) was added to a suspension of 2-{6-[(2-naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylic acid <b>14a</b> (22.19 g, 54.12 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and anhydrous THF (500 mL) at room temperature under N<sub>2</sub>. Triethylamine (22.6 mL, 162.14 mmol) was added followed by HOBt (8.78 g, 64.97 mmol) and <i>O</i>-(1-isobutoxyethyl)hydroxylamine <b>7</b> (8.9 mL, 64.89 mmol). After being stirred at room temperature for 6 days, the reaction mixture was re-treated with EDC hydrochloride (10.25 g, 53.47 mmol), HOBt (7.22 g, 53.43 mmol), and triethylamine (19.4 mL, 139.0 mmol). After being stirred for another 3 days at room temperature, the reaction mixture was evaporated to dryness and suspended in EtOAc (100 mL) and water (100 mL). A white solid was collected by filtration, washed with EtOAc (50 mL), water (50 mL), MeOH (50 mL), and dried in vacuo to give a white solid. This was stirred in EtOH (1500 mL) at 60 °C for 1 h, giving a white suspension which was cooled to room temperature, filtered, and air-dried to give <i>N</i>-(1-isobutoxyethoxy)-2-[6-(naphthalene-2-sulfonylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxamide <b>15a</b> as a white solid (24.0 g, 87%). <i>m</i>/<i>z</i> 511 [M + H]<sup>+</sup>. A solution of 4 M HCl in dioxane (350 mL, 1.4 mol) was added in portions over 5 min to <i>N</i>-(1-isobutoxyethoxy)-2-[6-(naphthalene-2-sulfonylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxamide (10.0 g, 19.65 mmol) at room temperature with vigorous stirring under N<sub>2</sub>. After 2 h CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added followed by another portion of 4 M HCl in dioxane (20 mL) and stirring was continued for a further 2.5 h. The reaction mixture was evaporated in vacuo to ∼200 mL volume, and CH<sub>2</sub>Cl<sub>2</sub> (200 mL) was added in portions effecting precipitation. The resultant white precipitate was isolated by filtration and washed with CH<sub>2</sub>Cl<sub>2</sub> (5 mL), giving <b>15a</b> as a white powder (6.25 g, 75%). <i>m</i>/<i>z</i> 426 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.02 (1H, br s), 8.97 (1H, br s), 8.58 (2H, s), 8.50 (1H, s), 8.24−8.10 (3H, m), 8.05 (1H, d, <i>J</i> = 8.8 Hz), 7.83 (1H, dd, <i>J</i> = 1.8, 8.8 Hz), 7.80−7.65 (2H, m), 3.65 (2H, d, <i>J</i> = 12.0 Hz), 3.45 (2H, d, <i>J</i> = 12.0 Hz), 3.20 (1H, s), 1.80 (1H, s). Anal. Calcd for C<sub>21</sub>H<sub>26</sub>ClN<sub>5</sub>O<sub>6</sub>S: C, 49.27; H, 5.12; Cl, 6.92; N, 13.68. Found: C, 49.70; H, 5.09; Cl, 7.10; N, 13.55.</div></div></div><div id="sec7_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-Hydroxy-2-{6-[(naphthalene-2-carbonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}-pyrimidine-5-carboxamide <b>18a</b></h3><div class="NLM_p last">To a stirred solution of <i>tert</i>-butyl 6-aminoazabicyclo[3.1.0]hexane-3-carboxylate <b>8</b> (300 mg, 1.51 mmol) in pyridine (1 mL) at 0 °C was added 2-naphthoyl chloride (316 mg, 1.66 mmol). The mixture was stirred for 1 h, and water (8 mL) was then added. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>tert</i>-butyl 6-(2-naphthoylamino)-3-azabicyclo[3.1.0]hexane-3-carboxylate (406 mg, 76%). <sup>1</sup>H NMR (300 MHz, C<i>D</i>Cl<sub>3</sub>) δ: 8.26 (1H, s), 7.88−7.95 (3H, m), 7.81 (1H, d, <i>J</i> = 1.8, 8.8 <i>Hz</i>), 7.60−7.54 (2H, m), 6.37 (1H, br s), 3.82 (2H, d, <i>J</i> = 11.4 Hz), 3.50−3.40 (2H, m), 2.71 (1H, d), 1.85 (2H, s), 1.47 (9H, s). Following method B, <i>tert</i>-butyl 6-(2-naphthoylamino)-3-azabicyclo[3.1.0]hexane-3-carboxylate (406 mg, 1.15 mmol) was stirred in 4 M HCl in dioxane (10 mL) to give <i>N</i>-(3-azabicyclo[3.1.0]hex-6-yl)naphthalene-2-carboxamide hydrochloride <b>16a</b> as a pink solid which was carried forward without purification. <i>m</i>/<i>z</i> 353 [M + H]<sup>+</sup>. Following method C, compound <b>16a</b> (1.15 mmol), compound <b>2</b> (350 mg, 1.15 mmol), and K<sub>2</sub>CO<sub>3</sub> (3.9 g, 28.75 mmol) gave ethyl 2-[6-(2-naphthoylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylate (343 mg, 74% over two steps). <i>m</i>/<i>z</i> 403 [M + H]<sup>+</sup>. Ethyl 2-[6-(2-naphthoylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylate (343 mg, 0.85 mmol) was hydrolyzed with 6 M NaOH (5 mL, 30 mmol) to give 2-[6-(2-naphthoylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylic acid <b>17a</b> (167 mg, 52%) which was carried forward without purification. <i>m</i>/<i>z</i> 375 [M + H]<sup>+</sup>. Following method D, 2-[6-(2-naphthoylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylic acid <b>17a</b> (167 mg, 0.45 mmol), HOBt (83 mg, 0.54 mmol), EDC hydrochloride (103 mg, 0.54 mmol), triethylamine (314 μL, 2.25 mmol), and <i>O</i>-(1-isobutoxyethyl)hydroxylamine (309 μL, 2.25 mmol) gave <i>N</i>-(1-isobutoxyethoxy)-2-[6-(2-naphthoylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxamide (58 mg, 26%). <i>m</i>/<i>z</i> 490 [M + H]<sup>+</sup>. <i>N</i>-(1-Isobutoxyethoxy)-2-[6-(2-naphthoylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxamide (58 mg, 0.12 mmol) was stirred in 4 M HCl in dioxane (60 mL, 0.29 mmol) at room temperature for 5 min. The solvent was removed in vacuo and the residue dried under reduced pressure to give <i>N</i>-hydroxy-2-{6-[(naphthalene-2-carbonyl)amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide <b>18a</b> (27 mg, 59%). <i>m</i>/<i>z</i> 390 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.05 (1H, br s), 9.01 (1H, br s), 8.74 (1H, d, <i>J =</i> 3.9 Hz), 8.69 (2H, s), 8.43 (1H, br s), 8.05−7.55 (4H, m), 7.55−7.66 (2H, m), 3.95 (2H, d, <i>J =</i> 11.6 Hz), 3.70−3.60 (2H, m), 2.70−2.64 (1H, m), 2.04 (2H, br s).</div></div><div id="sec7_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-Hydroxy-2-{6-[(2-naphthylmethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide <b>21a</b></h3><div class="NLM_p last">Following method A, <i>tert</i>-butyl 6-aminoazabicyclo[3.1.0]hexane-3-carboxylate <b>8</b> (200 mg, 1.01 mmol), 2-naphthaldehyde (148 mg, 0.96 mmol), and sodium borohydride (61 mg, 1.62 mmol) gave <i>tert</i>-butyl 6-(naphth-2-ylmethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate as a colorless oil which was used in the subsequent step without purification. <i>m</i>/<i>z</i> 339 [M + H]<sup>+</sup>. Following method B, <i>tert</i>-butyl 6-(naphth-2-ylmethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (0.96 mmol) was stirred in 4 M HCl (2 mL) in dioxane at room temperature for 0.5 h to give <i>N</i>-naphth-2-ylmethyl-3-azabicyclo[3.1.0]hexan-6-amine hydrochloride <b>19a</b> which was used in the next step without purification, <i>m</i>/<i>z</i> 239 [M + H]<sup>+</sup>. Following method C, <i>N</i>-naphth-2-ylmethyl-3-azabicyclo[3.1.0]hexan-6-amine hydrochloride (0.96 mmol), ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b> (221 mg, 0.96 mmol), and potassium carbonate (1.32 g, 9.6 mmol) gave ethyl 2-[6-(naphth-2-ylmethyl)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylate as a yellow oil which was used in the next step without purification. <i>m</i>/<i>z</i> 389 [M + H]<sup>+</sup>. Ethyl 2-[6-(naphth-2-ylmethyl)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylate (0.96 mmol) was hydrolyzed with 1 M NaOH (10 mL, 10 mmol) in THF (10 mL) to give 2-[6-(naphth-2-ylmethyl)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylic acid <b>20a</b> (70 mg, 19% over 4 steps) as a colorless solid which was used in the subsequent step without purification. <i>m</i>/<i>z</i> 361 [M + H]<sup>+</sup>. Following method D, 2-{6-[(2-naphth-2-ylmethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylic acid (70 mg, 0.194 mmol) was stirred with EDC hydrochloride (56 mg, 0.29 mmol) and HOBt (39 mg, 0.29 mmol), triethylamine (135 μL, 0.97 mmol), and <i>O</i>-(1-isobutoxyethyl)hydroxylamine (270 μL, 1.94 mmol). In this case after quenching the reaction with water (10 mL) the layers were separated and the aqueous layer was re-extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers were washed with 0.5 M HCl and the organic layer was dried (MgSO<sub>4</sub>) and evaporated in vacuo to give <i>N</i>-hydroxy-2-{6-[(2-naphthylmethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide <b>21a</b> (15 mg, 20%). <i>m</i>/<i>z</i> 376 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.10 (1H, br s), 9.61 (1H, br s), 9.01 (1H, br s), 8.66 (2H, s), 8.07 (1H, s), 7.97 (3H, m), 7.67 (1H, dd, <i>J =</i> 8.4, 1.8 Hz), 7.57 (2H, m), 4.41 (2H, s), 3.80 (2H, d, <i>J =</i> 11.7 Hz), 3.56 (2H, d, <i>J =</i> 11.7 Hz), 2.57 (1H, m), 2.22 (2H, br s).</div></div><div id="sec7_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 2-{6-[(4-Chlorobenzyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}-<i>N</i>-hydroxypyrimidine-5-carboxamide Bistrifluoroacetate <b>21f</b></h3><div class="NLM_p last">Following method A, <i>tert</i>-butyl 6-aminoazabicyclo[3.1.0]hexane-3-carboxylate <b>8</b> (200 mg, 1.01 mmol), 4-chlorobenzaldehyde (135 mg, 0.96 mmol), and sodium borohydride (36 mg, 0.96 mmol) gave <i>tert</i>-butyl 6-(4-chlorobenzylamino)-3-azabicyclo[3.1.0]hexane-3-carboxylate which was used in the subsequent step without purification. <i>m</i>/<i>z</i> 323/325 [M + H]<sup>+</sup>. Following method B, <i>tert</i>-butyl 6-(4-chlorobenzylamino)-3-azabicyclo[3.1.0]hexane-3-carboxylate (0.96 mmol) was stirred in 4 M HCl in dioxane (2 mL) at room temperature for 0.5 h to give <i>N</i>-(4-chlorobenzyl)-3-azabicyclo[3.1.0]hexan-6-amine hydrochloride <b>19f</b> which was used in the next step without purification. <i>m</i>/<i>z</i> 223/225 [M + H]<sup>+</sup>. Following method C, <i>N</i>-6-(4-chlorobenzyl)-3-azabicyclo[3.1.0]hexan-6-amine hydrochloride <b>19f</b> (0.96 mmol), ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b> (221 mg, 0.96 mmol), and potassium carbonate (1.32 g, 9.6 mmol) gave ethyl 2-{6-[(4-chlorobenzyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylate as a yellow oil which was used in the next step without purification. <i>m</i>/<i>z</i> 373/375 [M + H]<sup>+</sup>. Ethyl 2-{6-[(4-chlorobenzyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylate (0.96 mmol) was hydrolyzed with 1 M NaOH (10 mL, 10 mmol) in THF (10 mL) to give 2-{6-[(4-chlorobenzyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylic acid <b>20f</b> (166 mg, 50% over four steps) as a colorless solid which was used in the subsequent step without purification. <i>m</i>/<i>z</i> 345/347 [M + H]<sup>+</sup>. Following method D, 2-{6-[(4-chlorobenzyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylic acid <b>20f</b> (122 mg, 0.14 mmol), EDC hydrochloride (121 mg, 0.63 mmol), HOBt (81 mg, 0.63 mmol), <i>O</i>-(1-isobutoxyethyl)hydroxylamine (373 μL, 2.62 mmol), and triethylamine (365 μL, 2.62 mmol) gave 2-{6-[(4-chlorobenzyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}-<i>N</i>-(1-isobutoxyethoxy)pyrimidine-5-carboxamide (128 mg, 58%) after purification by flash column chromatography [eluting with 0−10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>]. <i>m</i>/<i>z</i> 460/462 [M + H]<sup>+</sup>. 2-{6-[(4-chlorobenzyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}-<i>N</i>-(1-isobutoxyethoxy)pyrimidine-5-carboxamide (128 mg, 0.28 mmol) was stirred with TFA (0.5 mL) in 1:1 v/v CH<sub>2</sub>Cl<sub>2</sub>/MeOH (4 mL) overnight. The solvent was removed in vacuo and the residue purified by preparative HPLC to give 2-{6-[(4-chlorobenzyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}-<i>N</i>-hydroxypyrimidine-5-carboxamide bistrifluoroacetate <b>21f</b> (41 mg, 25%) as a colorless solid. <i>m</i>/<i>z</i> 360/362 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.07 (1H, br s), 9.26 (1H, br s), 9.04 (1H, br s), 8.67 (2H, s), 7.54 (4H, m), 4.27 (2H, s), 3.71 (2H, d, <i>J =</i> 11.7 Hz), 3.57 (2H, d, <i>J =</i> 11.7 Hz) 2.57 (1H, br s), 2.13 (2H, br s).</div></div><div id="sec7_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-<i>N</i>-hydroxypyrimidine-5-carboxamide Trifluoroacetate <b>21r</b></h3><div class="NLM_p last">Following method A, 6-fluoroquinoline-2-carbaldehyde <b>10</b> (265 mg, 1.51 mmol) was stirred in MeOH (10 mL) with <i>tert</i>-butyl 6-amino-3-azabicyclo[3,1,0]hexane-3-carboxylate <b>8</b> (300 mg, 1.51 mmol) at room temperature for 3 h. NaBH<sub>4</sub> (91 mg, 2.42 mmol) was then added in one portion and stirring continued for 10 min. The reaction was then carefully quenched with 1 M NaOH (5 mL), and stirring continued for 20 min. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with Et<sub>2</sub>O (2 × 100 mL). The combined organic layers were dried over MgSO<sub>4</sub> and solvent was removed in vacuo to give <i>tert</i>-butyl 6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hexane-3-carboxylate as a colorless oil which was used in the next step without purification. <i>m</i>/<i>z</i> 358 [M + H] <sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.30 (1H, d, <i>J</i> = 8.7 Hz), 8.02 (1H, m), 7.79−7.61 (3H, m), 4.72 (1H, d, <i>J</i> = 6.5 Hz), 3.98 (2H, s), 1.78 (1H, s), 1.50 (2H, s), 1.31 (9H, s). Following method B, <i>tert</i>-butyl 6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hexane-3-carboxylate (1.51 mmol) was stirred in 4 M HCl in dioxane (3 mL) at room temperature for 30 min. Solvent was then removed in vacuo and the residue dried to give <i>N</i>-[(6-fluoroquinolin-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-amine hydrochloride <b>19r</b> which was used in the next step without purification. <i>m</i>/<i>z</i> 258 [M<sup>+</sup>+H]. Following method C, <i>N</i>-[(6-fluoroquinolin-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-amine hydrochloride <b>19r</b> (1.51 mmol) was stirred in a 1:1 v/v DMF/CH<sub>3</sub>CN (20 mL) with K<sub>2</sub>CO<sub>3</sub> (2.1 g, 15.1 mmol) at room temperature under a nitrogen atmosphere for 10 min. Ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b> (350 mg, 1.51 mmol) was then added and the mixture stirred for a further 10 min. The reaction was the quenched with H<sub>2</sub>O (50 mL) and extracted with EtOAc (2 × 100 mL). The combined organic layers were dried over MgSO<sub>4</sub> and solvent was removed in vacuo to give the ethyl 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxylate as an orange oil which was used in the next step without purification. <i>m</i>/<i>z</i> 408 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.71 (2H, s), 8.32 (1H, d, <i>J</i> = 9.8 Hz), 8.07−7.95 (2H, m), 7.81−7.71 (2H, m), 4.72 (1H, d, <i>J</i> = 7.6 Hz), 4.23 (2H, q, <i>J</i> = 8.7 Hz), 3.53 (2H, d, <i>J</i> = 12 Hz), 3.33 (2H, s), 1.88 (1H, br s), 1.71 (2H, br s), 1.24 (3H, t, <i>J</i> = 8.7 Hz). Ethyl 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxylate was stirred in 1 M NaOH/THF (7 mL/7 mL) at room temperature for 16 h. The mixture was the acidified to pH 3 with 1 M HCl which caused a precipitate to form. This was filtered off and dried to give 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxylic acid <b>20r</b> (193 mg, 34% over three steps) as a light yellow solid and used without purification. <i>m</i>/<i>z</i> 380 [M + H]<sup>+</sup>. Following method D, 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxylic acid <b>20r</b> (193 mg, 0.51 mmol) was stirred with EDC hydrochloride (117 mg, 0.61 mmol) and HOBt (117 mg, 0.61 mmol) in DMF (10 mL) at room temperature under a nitrogen atmosphere. <i>O</i>-(1-Isobutoxyethyl)hydroxylamine (352 μL, 2.55 mmol) was then added followed by triethylamine (355 μL, 2.55 mmol). The mixture was stirred for 16 h, then diluted with H<sub>2</sub>O (50 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 100 mL). The combined organic layers were dried over MgSO<sub>4</sub>, and solvent was removed in vacuo. The residue was purified by flash column chromatography [eluting with 0−10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>] to give 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-<i>N</i>-(1-isobutoxyethoxy)pyrimidine-;5-carboxamide (130 mg, 52%) as a light yellow oil. <i>m</i>/<i>z</i> 495 [M + H]. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.69 (2H, s), 8.30 (1H, d, <i>J</i> = 9.8 Hz), 8.02 (1H, dd, <i>J</i> = 6.5, 9.8 Hz), 7.74 (1H, dd, <i>J</i> = 3.3, 9.8 Hz), 7.67−7.60 (2H, m), 4.90 (1H, q, <i>J</i> = 5.4, 9.7 Hz), 4.01 (2H, br s), 3.63 (2H, s), 3.49 (2H, d, <i>J</i> = 10.1 Hz), 1.87 (1H, br s), 1.70 (2H, br s), 1.30 (3H, d, <i>J</i> = 5.4 Hz), 0.85 (3H, s), 0.83 (3H, s). 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-<i>N</i>-(1-isobutoxyethoxy)pyrimidine-5-carboxamide (130 mg, 0.26 mmol) was stirred in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at room temperature, and 4 M HCl in dioxane (130 μL, 0.52 mmol) added. The mixture was stirred for 10 min and then the solvent removed in vacuo. The residue was purified by preparative HPLC to give 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-<i>N</i>-hydroxypyrimidine-5-carboxamide trifluoroaceate <b>21r</b> as a light orange solid (25 mg, 19%). <i>m</i>/<i>z</i> 395 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.09 (1H, br s), 9.61 (1H, br s), 9.01 (1H, br s), 8.67 (2H, s), 8.48 (1H, d, <i>J</i> = 8.4 Hz), 7.88 (1H, dd, <i>J</i> = 9.3 Hz, 2.7 Hz), 7.75 (1H, td, <i>J</i> = 8.7 Hz, 3.0 Hz), 7.66 (1H, d, <i>J</i> = 8.4 Hz), 4.69 (2H, bs), 3.88 (2H, d, <i>J</i> = 11.7 Hz), 3.60 (2H, d, <i>J</i> = 11.7 Hz), 2.30 (2H, s,), 2.75 (1H, s).</div></div><div id="sec7_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-Hydroxy-2-{6-[methyl(naphthalene-2-sulfonyl)amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide <b>23</b>: Step 1. Preparation of <i>N</i>-(Tetrahydro-2<i>H</i>-pyran-2-yloxy)-2-{6-[(naphthalene-2-sulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide <b>22</b></h3><div class="NLM_p">2-{6-[(2-Naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxylic acid <b>14a</b> (1.0 g, 2.4 mmol) was stirred with EDC hydrochloride (556 mg, 2.9 mmol) and HOBt (392 mg, 2.9 mmol) in DMF at room temperature under a nitrogen atmosphere. 2-(Tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (1.4 g, 12 mmol) was then added followed by triethylamine (1.66 mL, 12 mmol), and the mixture was left to stir for 16 h. The mixture was then diluted with H<sub>2</sub>O and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried (MgSO<sub>4</sub>), and solvent was removed in vacuo. The residue was purified by flash column chromatography [eluting with 0−10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>] to give <b>22</b> (1.11 g, 90%). <i>m</i>/<i>z</i> 511 [M + H]<sup>+</sup>.</div><div id="seci" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Step 2. Preparation of <i>N</i>-(Tetrahydro-2<i>H</i>-pyran-2-yloxy)-2-{6-[methyl(naphthalene-2-sulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide</h4><div class="NLM_p last">NaH (147 mg, 3.75 mmol) was washed with heptanes and suspended in THF (10 mL). <i>N</i>-(Tetrahydro-2<i>H</i>-pyran-2-yloxy)-2-[6-(naphthalene-2-sulfonylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxamide <b>22</b> (1.11 g, 2.2 mmol) was then added, followed by addition of dimethyl sulfate (0.22 mL, 2.3 mmol). The mixture was stirred for 48 h and then poured into CH<sub>2</sub>Cl<sub>2</sub> (150 mL), and 2.4 M ammonium chloride (50 mL) was added. The aqueous layer was further extracted with CH<sub>2</sub>Cl<sub>2</sub> (150 mL). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated in vacuo to give an orange oil. This was carried forward without purification.</div></div><div id="sech" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Step 3. Preparation of <i>N</i>-Hydroxy-2-{6-[methyl(naphthalene-2-sulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide <b>23</b></h4><div class="NLM_p last">To <i>N</i>-(tetrahydro-2H-pyran-2-yloxy)-2-{6-[methyl(naphthalene-2-sulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide was added TFA/CH<sub>2</sub>Cl<sub>2</sub>/MeOH (5 mL, 1:1:1 v/v/v mixture). The solution was stirred at room temperature for 2 h. The mixture was then concentrated under reduced pressure and purified by reverse phase HPLC to yield <b>23</b> (34 mg, 3% yield over two steps). <i>m</i>/<i>z</i> 440 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.05 (1H, br s), 9.01 (1H, br s), 8.61 (2H, s), 8.52−8.49 (1H, m), 8.28−8.22 (1H, m), 8.18 (1H, d, <i>J</i> = 8.7 Hz), 8.06 (1H, m), 7.82 (1H, dd, <i>J</i> = 1.8, 8.6 Hz), 7.66−7.84 (2H, m), 3.78 (2H, d, <i>J</i> = 11.8 Hz), 3.58 (2H, m), 2.77 (3H, s), 2.25 (2H, m), 1.55 (1H, m).</div></div></div><div id="sec7_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-Hydroxy-2-[6-(quinolin-2-ylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxamide <b>25</b>: Step 1. Preparation of <i>tert</i>-Butyl 6-(quinolin-2-ylamino)-3-azabicyclo[3.1.0]hexane-3-carboxylate <b>24</b></h3><div class="NLM_p"><i>tert</i>-Butyl 6-aminoazabicyclo[3.1.0]hexane-3-carboxylate <b>8</b> (200 mg, 1.01 mmol) was combined with 2-chloroquinoline (328 mg, 2.02 mmol), and the two solids melted at 100 °C for 16 h. The mixture was then cooled and the residue purified by flash column chromatography [eluting with, 0−3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>] to give compound <b>24</b> as a brown oil (320 mg, 97%). <i>m</i>/<i>z</i> 326 [M + H]<sup>+</sup>.</div><div id="secn" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Step 2. Preparation of (3-Azabicyclo[3.1.0]hex-6-yl)quinolin-2-yl-amine</h4><div class="NLM_p last">Following method B, <i>tert</i>-butyl 6-(quinolin-2-ylamino)-3-azabicyclo[3.1.0]hexane-3-carboxylate (320 mg, 0.98 mmol) was stirred in 4 M HCl in dioxane (2 mL) at room temperature under N<sub>2</sub> for 15 min. The solvent was then removed in vacuo and the residue dried under high-vacuum to give crude (3-azabicyclo[3.1.0]hex-6-yl)quinolin-2-yl-amine (220 mg) which was used in the next step without purification. <i>m</i>/<i>z</i> 226 [M + H]<sup>+</sup>.</div></div><div id="seco" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Step 3. Preparation of Ethyl 2-[6-(Quinolin-2-ylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylate</h4><div class="NLM_p last">(3-Azabicyclo[3.1.0] hex-6-yl)quinolin-2-ylamine (220 mg, 0.98 mmol) was stirred in CH<sub>3</sub>CN (10 mL) and DMF (10 mL) at room temperature under N<sub>2</sub>. Potassium carbonate (1.35 g, 9.8 mmol) was then added and the mixture stirred for 15 min. Ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b> (227 mg, 0.98 mmol) was then added to the reaction mixture, and stirring continued for 30 min. The mixture was then diluted with H<sub>2</sub>O (100 mL) and extracted twice with EtOAc (2 × 100 mL). The combined organic extracts were dried (MgSO<sub>4</sub>) and solvent was removed in vacuo to give ethyl 2-[6-(quinolin-2-ylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylate as a light brown solid which was used in the next step without purification. <i>m</i>/<i>z</i> 376 [M + H]<sup>+</sup>.</div></div><div id="secn0" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Step 4. Preparation of 2-[6-(Quinolin-2-ylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylic Acid</h4><div class="NLM_p last">Ethyl 2-[6-(quinolin-2-ylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylate (0.98 mmol) was stirred in THF (10 mL) and H<sub>2</sub>O (10 mL) at room temperature for 64 h. The mixture was then acidified to pH 3 using 1 M HCl and the solvent removed in vacuo to give a brown solid. The solid was collected and washed with a little H<sub>2</sub>O to give the title compound as a brown solid (103 mg, 30% over three steps). <i>m</i>/<i>z</i> 348 [M + H]<sup>+</sup>.</div></div><div id="secm" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Step 5. Preparation of <i>N</i>-(1-Isobutoxyethoxy)-2-[6-(quinolin-2-ylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxyamide</h4><div class="NLM_p last">2-[6-(Quinolin-2-ylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylic acid (103 mg, 0.29 mmol) was stirred in DMF (10 mL) at room temperature under a nitrogen atmosphere. EDC hydrochloride (67 mg, 0.35 mmol) and HOBt (47 mg, 0.35 mmol) were added, and the mixture was stirred for 10 min. <i>O</i>-(1-Isobutoxyethyl)hydroxylamine (200 μL, 1.45 mmol) and triethylamine (202 μL, 1.45 mmol) were then added, and the mixture was stirred for 16 h. The mixture was then diluted with H<sub>2</sub>O (100 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 100 mL). The combined organic extracts were dried (MgSO<sub>4</sub>), and solvent was removed in vacuo. The residue was purified by column chromatography [eluting with 0−10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>] to give the title compound as a white solid (48 mg, 36%). <i>m</i>/<i>z</i> 463 [M + H]<sup>+</sup>.</div></div><div id="secl" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Step 6 Preparation of <i>N</i>-Hydroxy-2-[6-(quinolin-2-ylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxamide <b>25</b></h4><div class="NLM_p last"><i>N</i>-(1-Isobutoxyethoxy)-2-[6-(quinolin-2-ylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxyamide (48 mg, 0.1 mmol) was stirred in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at room temperature under a nitrogen atmosphere. Then 4 M HCl in dioxane (20 μL, 0.2 mmol) was added, immediately causing a solid to precipitate. The mixture was stirred for 10 min and then solvent removed in vacuo. CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added to the residue and the precipitate filtered and dried to give compound <b>25</b> as a white solid (21 mg, 58%). <i>m</i>/<i>z</i> 363 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.96 (1H, br s), 11.12 (1H, br s), 10.24 (1H, br s), 8.33 (1H, d, <i>J</i> = 8.8 Hz), 8.28 (2H, s), 8.09 (1H, d, <i>J</i> = 8.0 Hz), 7.94 (1H, d, <i>J</i> = 8.0 Hz), 7.81 (1H, t, <i>J</i> = 7.6 Hz), 7.53 (1H, t, <i>J</i> = 7.6 Hz), 7.15 (1H, d, <i>J</i> = 8.8 Hz), 4.27 (2H, d, <i>J</i> = 11.7 Hz), 3.63 (2H, d, <i>J</i> = 11.7 Hz), 2.99 (1H, m), 2.19 (2H, br s).</div></div></div><div id="sec7_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-Hydroxy-2-{6-[(naphthalen-2-ylmethylamino)methyl]-3-azabicyclo[3.1.0]hex-3-ylpyrimidine-5-carboxamide <b>27</b>: Step 1. Preparation of Ethyl 2-(6-{[(<i>tert</i>-Butoxycarbonyl)amino]methyl}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxylate</h3><div class="NLM_p">Compound <b>12</b> (2.27 g, 10.7 mmol) was stirred in CH<sub>3</sub>CN/DMF (60 mL, 1:1) with potassium carbonate (4.44 g, 32.1 mmol) at room temperature under a nitrogen atmosphere for 10 min. Ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b> (2.48 g, 10.7 mmol) was then added and the mixture stirred for 30 min. The mixture was then diluted with H<sub>2</sub>O (100 mL) and extracted with EtOAc (2 × 100 mL). The combined organic extracts were dried (MgSO<sub>4</sub>), and the solvent was removed in vacuo. The residue was purified by column chromatography [eluting with 0−5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>] to give the title compound as a white solid (3.5 g, 90%). <i>m</i>/<i>z</i> 363 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.76 (2H, s), 6.92 (1H, m), 4.26 (2H, q, <i>J</i> = 7.2 Hz), 3.82 (2H, d, <i>J</i> = 11.7 Hz), 3.54 (2H, d, <i>J</i> = 11.7 Hz), 2.93 (2H, m), 1.61 (2H, m), 1.38 (9H, s), 1.28 (3H, t, <i>J</i> = 7.2 Hz), 0.70 (1H, m).</div><div id="sect" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Step 2. Preparation of Ethyl 2-[6-(Aminomethyl)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylate</h4><div class="NLM_p last">Ethyl 2-(6-{[(<i>tert</i>-butoxycarbonyl)amino]methyl}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxylate (1.7 g, 4.7 mmol) was stirred in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at room temperature under a nitrogen atmosphere. Then 4 M HCl in dioxane (2.35 mL, 9.4 mmol) was added, immediately causing a solid to precipitate. The mixture was left to stir for 30 min, and then the solvent was removed in vacuo. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and washed with saturated NaHCO<sub>3</sub> (100 mL). The organic layer was then dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent removed in vacuo to give the title compound as an orange solid (1.2 g, 97%). <i>m</i>/<i>z</i> 263 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.76 (2H, s), 4.26 (2H, q, <i>J</i> = 7.2 Hz), 3.82 (2H, d, <i>J</i> = 11.7 Hz), 3.55 (2H, d, <i>J</i> = 11.7 Hz), 3.33 (4H, m), 1.58 (2H, m), 1.29 (3H, t, <i>J</i> = 7.2 Hz), 0.64 (1H, m).</div></div><div id="secq" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Step 3. Preparation of 2-[6-(Aminomethyl)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylic Acid <b>26</b></h4><div class="NLM_p last">Ethyl 2-[6-(aminomethyl)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylate (200 mg, 0.76 mmol) was stirred with 2-naphthaldehyde (119 mg, 0.76 mmol) in MeOH (10 mL) at room temperature under a nitrogen atmosphere for 16 h. Sodium borohydride (46 mg, 1.22 mmol) was then added and the mixture stirred for 10 min. Saturated aqueous NH<sub>4</sub>Cl (20 mL) was added and the mixture stirred for 20 min. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with Et<sub>2</sub>O (2 × 100 mL). The combined organic layers were dried (MgSO<sub>4</sub>) and the solvent was removed in vacuo to give the title compound as a yellow oil which was used in the next step without purification. <i>m</i>/<i>z</i> 403 [M + H]<sup>+</sup>.</div></div><div id="secr" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Step 4. Preparation of 2-(6-{[(Naphthalen-2-ylmethyl)amino]methyl}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxylic Acid</h4><div class="NLM_p last">2-[6-(Aminomethyl)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-5-carboxylic acid <b>26</b> (0.76 mmol) was stirred in THF (6 mL) and 1 M NaOH (6 mL) at room temperature for 16 h. The mixture was then acidified to pH 3 with 2 M HCl, causing a solid to precipitate. This was collected and dried to give the title compound as a white solid (72 mg, 25% over two steps) which was used in the next step without purification. <i>m</i>/<i>z</i> 375 [M + H]<sup>+</sup>.</div></div><div id="secq0" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Step 5. Preparation of <i>N</i>-(1-Isobutoxyethoxy)-2-(6-{[(naphthalen-2-ylmethyl)amino]methyl}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxamide</h4><div class="NLM_p last">2-(6-{[(Naphthalen-2-ylmethyl)amino]methyl}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxylic acid (72 mg, 0.19 mmol) was stirred with EDC hydrochloride (44 mg, 0.23 mmol) and HOBt (31 mg, 0.23 mmol) in DMF (10 mL) at room temperature under a nitrogen atmosphere for 10 min. <i>O</i>-(1-Isobutoxyethyl)hydroxylamine (131 μL, 0.95 mmol) was then added followed by triethylamine (132 μL, 0.95 mmol) and the mixture allowed to stir for 64 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 100 mL). The combined organic layers were dried (MgSO<sub>4</sub>), and the solvent was removed in vacuo. The residue was purified by column chromatography [eluting with 0−10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>] to give the title compound as a colorless oil (43 mg, 46%). <i>m</i>/<i>z</i> 490 [M + H]<sup>+</sup>.</div></div><div id="secp" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Step 6. Preparation of <i>N</i>-Hydroxy-2-{6-[(naphthalen-2-ylmethylamino)methyl]-3-azabicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide <b>27</b></h4><div class="NLM_p last"><i>N</i>-(1-Isobutoxyethoxy)-2-(6-{[(naphthalene-2-ylmethyl) amino]methyl}-3-azabicyclo[3.1.0]hex-3-yl)pyrimidine-5-carboxamide (43 mg, 0.09 mmol) was stirred in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at room temperature under a nitrogen atmosphere, and 4 M HCl in dioxane (45 μL, 0.18 mmol) was added. This immediately caused a solid to precipitate. The mixture was allowed to stir for 10 min and then the solvent was removed in vacuo to give the title compound <b>27</b> as a white solid (16 mg, 50%). <i>m</i>/<i>z</i> 390 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.07 (1H, br s), 9.11 (2H, br s), 8.66 (2H, s), 8.03 (2H, m), 7.95 (2H, m), 7.68 (1H, m), 7.58 (2H, m), 4.34 (2H, m), 3.88 (2H, d, <i>J</i> = 11.7 Hz), 3.55 (2H, m), 2.99 (2H, m), 2.50 (1H, m), 1.91 (2H, m).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63"><a href="/doi/suppl/10.1021/jm101177s">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Methods for fixed cell and electrochemiluminescent ELISA; results showing effects of <b>21f</b> and <b>21r</b> on proliferation of a P-glycoprotein isogenic cancer cell line pair; in vitro effects on histone and α-tubulin acetylation; in vivo PK of <b>21f</b> and effects on histone H3 and α-tubulin acetylation in samples from a HCT116 human tumor mouse xenograft efficacy study; synthesis and analytical data for <b>15b</b>, <b>18b</b>−<b>c</b>, <b>21b</b>−<b>e</b>, and <b>21g</b>−<b>21q</b>; single crystal X-ray structure of <b>21r</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm101177s/suppl_file/jm101177s_si_001.pdf">jm101177s_si_001.pdf (455.18 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm101177s" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60135" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60135" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Moffat</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a1c5c0d7c8c58fcccec7c7c0d5e1c2c9d3ceccc0d5c9c4d3c0d1c4d4d5c8c2d28fc2cecc"><span class="__cf_email__" data-cfemail="187c796e717c3675777e7e796c587b706a7775796c707d6a79687d6d6c717b6b367b7775">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sanjay Patel</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Day</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Belfield</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alastair Donald</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Rowlands</span> - <span class="hlFld-Affiliation affiliation">Haddow Laboratories, Cancer Research UK, Centre for Cancer Therapeutics, The Institute for Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judata Wibawa</span> - <span class="hlFld-Affiliation affiliation">Haddow Laboratories, Cancer Research UK, Centre for Cancer Therapeutics, The Institute for Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deborah Brotherton</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lindsay Stimson</span> - <span class="hlFld-Affiliation affiliation">Haddow Laboratories, Cancer Research UK, Centre for Cancer Therapeutics, The Institute for Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vanessa Clark</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jo Owen</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lindsay Bawden</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary Box</span> - <span class="hlFld-Affiliation affiliation">Haddow Laboratories, Cancer Research UK, Centre for Cancer Therapeutics, The Institute for Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elisabeth Bone</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Mortenson</span> - <span class="hlFld-Affiliation affiliation">Evotec (UK) Ltd., 114 Milton Park, Abingdon, OX14 4SA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthea Hardcastle</span> - <span class="hlFld-Affiliation affiliation">Haddow Laboratories, Cancer Research UK, Centre for Cancer Therapeutics, The Institute for Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra van Meurs</span> - <span class="hlFld-Affiliation affiliation">Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, OX14 4RY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suzanne Eccles</span> - <span class="hlFld-Affiliation affiliation">Haddow Laboratories, Cancer Research UK, Centre for Cancer Therapeutics, The Institute for Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florence Raynaud</span> - <span class="hlFld-Affiliation affiliation">Haddow Laboratories, Cancer Research UK, Centre for Cancer Therapeutics, The Institute for Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wynne Aherne</span> - <span class="hlFld-Affiliation affiliation">Haddow Laboratories, Cancer Research UK, Centre for Cancer Therapeutics, The Institute for Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, U.K.</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Alan Drummond, Dr. Alan Davidson (both of Chroma Therapeutics), and Professor Paul Workman (Institute of Cancer Research) for their help during the course of this work and in the preparation of this manuscript. We are grateful to Evotec (UK) Ltd. (assistance in the preparation of intermediates and <b>15a</b>), EpiStem Ltd. (in vivo efficacy studies on <b>21r</b>), and Dr. Michael Charlton (Chroma Therapeutics, computational chemistry). The work of the Cancer Therapeutics Unit was supported by Cancer Research UK Grant Numbers C309/A2187, C309/A2874, C309/A8365, and C302/A8265 and Infrastructure Support Grant Number C302/A7803 and by The Institute of Cancer Research. We acknowledge NHS funding to the NIHR Biomedical Research Centre. The authors from the Institute of Cancer Research (ICR) declare a conflict of interest. The ICR has a commercial interest in the development of HDAC inhibitors and operates a reward to inventors’ scheme. The ICR has had a research collaboration with Chroma Therapeutics and is a shareholder in the company, as is Cancer Research Technology. Wynne Aherne has been a consultant to Chroma Therapeutics.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74118" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74118" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Thiagalingam, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineva, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiagalingam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponte, J. F.</span><span> </span><span class="NLM_article-title">Histone deacetylases: unique players in shaping the epigenetic histone code</span> <span class="citation_source-journal">Ann. N.Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">983</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=983&publication_year=2003&pages=84-100&author=S+Thiagalingamauthor=K.+H.+Chengauthor=H.+J.+Leeauthor=N.+Minevaauthor=A.+Thiagalingamauthor=J.+F.+Ponte&title=Histone+deacetylases%3A+unique+players+in+shaping+the+epigenetic+histone+code"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThiagalingam%26aufirst%3DS%26aulast%3DCheng%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DMineva%26aufirst%3DN.%26aulast%3DThiagalingam%26aufirst%3DA.%26aulast%3DPonte%26aufirst%3DJ.%2BF.%26atitle%3DHistone%2520deacetylases%253A%2520unique%2520players%2520in%2520shaping%2520the%2520epigenetic%2520histone%2520code%26jtitle%3DAnn.%2520N.Y.%2520Acad.%2520Sci.%26date%3D2003%26volume%3D983%26spage%3D84%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bolden, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peart, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">Anticancer activities of histone deacetylase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+activities+of+histone+deacetylase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0lh3VfgpVRjAsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520activities%2520of%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Miller, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvedere, S.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5097</span><span class="NLM_x">–</span> <span class="NLM_lpage">5116</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0303094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5097-5116&author=T.+A.+Millerauthor=D.+J.+Witterauthor=S.+Belvedere&title=Histone+deacetylase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors</span></div><div class="casAuthors">Miller, Thomas A.; Witter, David J.; Belvedere, Sandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5097-5116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the medicinal chem. and structure-activity relationships underlying advances in histone deacetylase (HDAC) class I/II inhibitor discovery, design, and optimization.  HDAC structural studies and HDAC inhibitory activity of small-mol. hydroxamic acids, carboxylates, benzamides, electrophilic ketones, and cyclic peptides are described.  Miscellaneousness and selectivity of the class I/II HDACs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU5UlOsBUF7rVg90H21EOLACvtfcHk0liy_M4jYIShdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D&md5=d2d0a95d87d699334c1630df5deda38a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm0303094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0303094%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%2BA.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DBelvedere%26aufirst%3DS.%26atitle%3DHistone%2520deacetylase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5097%26epage%3D5116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Paris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcelloni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattori, D.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: from bench to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1505</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+deacetylase+inhibitors%3A+from+bench+to+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0lhTmijS5s7Nzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520from%2520bench%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers</span> <span class="citation_source-journal">Blood Cells, Mol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">264</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1006%2Fbcmd.2000.0376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=11358386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A280%3ADC%252BD3M3ms1Wmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2001&pages=260-264&author=V.+M.+Richonauthor=X.+Zhouauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitors%3A+development+of+suberoylanilide+hydroxamic+acid+%28SAHA%29+for+the+treatment+of+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers</span></div><div class="casAuthors">Richon V M; Zhou X; Rifkind R A; Marks P A</div><div class="citationInfo"><span class="NLM_cas:title">Blood cells, molecules & diseases</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">260-4</span>
        ISSN:<span class="NLM_cas:issn">1079-9796</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnQr2wosrbMP6BottYdIAWfW6udTcc2eZRGdth8bltO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3ms1Wmtw%253D%253D&md5=cc25725dc35de4d98a52115fdad0faf2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1006%2Fbcmd.2000.0376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbcmd.2000.0376%26sid%3Dliteratum%253Aachs%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520development%2520of%2520suberoylanilide%2520hydroxamic%2520acid%2520%2528SAHA%2529%2520for%2520the%2520treatment%2520of%2520cancers%26jtitle%3DBlood%2520Cells%252C%2520Mol.%2520Dis.%26date%3D2001%26volume%3D27%26spage%3D260%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Discovery and development of SAHA as an anticancer agent</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1351</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=1351-1356&author=P.+A.+Marks&title=Discovery+and+development+of+SAHA+as+an+anticancer+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520and%2520development%2520of%2520SAHA%2520as%2520an%2520anticancer%2520agent%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D1351%26epage%3D1356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lhTmijS5s7Nzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1186%2F1756-8722-3-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=20132536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A280%3ADC%252BC3c7jtFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=5&author=J.+Tanauthor=S.+Cangauthor=Y.+Maauthor=R.+L.+Petrilloauthor=D.+Liu&title=Novel+histone+deacetylase+inhibitors+in+clinical+trials+as+anti-cancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents</span></div><div class="casAuthors">Tan Jiahuai; Cang Shundong; Ma Yuehua; Petrillo Richard L; Liu Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin.  Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs.  One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combination with other anti-tumor drugs in CTCL and other malignancies.  At least 80 clinical trials are underway, testing more than eleven different HDAC inhibitory agents including both hematological and solid malignancies.  This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnASThrmiLG50d-O_J5C0AfW6udTcc2eZb-xg7A_k__Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7jtFejtg%253D%253D&md5=399a6c058fd597450221aff2648d8c0f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-3-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-3-5%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DPetrillo%26aufirst%3DR.%2BL.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DNovel%2520histone%2520deacetylase%2520inhibitors%2520in%2520clinical%2520trials%2520as%2520anti-cancer%2520agents%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">de Ruijter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gennip, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kuilenburg, A. B.</span><span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterisation of the classical HDAC family</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+de+Ruijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+van+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterisation+of+the+classical+HDAC+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRuijter%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DA.%2BB.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterisation%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Balasubramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">Isoform-specific histone deacetylase inhibitors: The next step?</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2Fj.canlet.2009.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19289255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=211-221&author=S.+Balasubramanianauthor=E.+Vernerauthor=J.+J.+Buggy&title=Isoform-specific+histone+deacetylase+inhibitors%3A+The+next+step%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-specific histone deacetylase inhibitors: The next step?</span></div><div class="casAuthors">Balasubramanian, Sriram; Verner, Erik; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) have emerged as attractive drug targets, particularly for neoplastic indications.  This large family is divided into four classes, of which three consist of zinc-dependent enzymes, and inhibitors of these are the subject of this review.  Currently, there are several inhibitors advancing through clin. trials, all of which inhibit multiple isoforms of these three classes.  While promising, these compds. have exhibited toxicities in the clinic that might limit their potential, particularly in solid tumors.  It may be possible to reduce some of the toxicity by specifically targeting only the isoform(s) involved in maintaining that particular tumor and spare other isoforms that are uninvolved or even beneficial.  This review examines the selectivity and toxicity of HDAC inhibitors currently in clinic, comparing pan-HDAC inhibitors to Class I selective compds.  The rationale for isoform-specific inhibitors is examd.  The current status of isoform-specific inhibitor development is analyzed, esp. inhibitors of HDAC1, 2, 4 and 8 enzymes, and the potential clin. utility of these compds. is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdfcwWUCyVErVg90H21EOLACvtfcHk0lhb5YGR6JCpPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt7Y%253D&md5=8f9a4437bc69f1274a889f0e85b3600a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DIsoform-specific%2520histone%2520deacetylase%2520inhibitors%253A%2520The%2520next%2520step%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D211%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Weichert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roske, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gekeler, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pross, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocken, C.</span><span> </span><span class="NLM_article-title">Association patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2FS1470-2045%2808%2970004-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=18207460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=139-148&author=W.+Weichertauthor=A.+Roskeauthor=V.+Gekelerauthor=T.+Beckersauthor=M.+P.+Ebertauthor=M.+Prossauthor=M.+Dietelauthor=C.+Denkertauthor=C.+Rocken&title=Association+patterns+of+class+I+histone+deacetylase+expression+with+patient+prognosis+in+gastric+cancer%3A+a+retrospective+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis</span></div><div class="casAuthors">Weichert, Wilko; Roeske, Annika; Gekeler, Volker; Beckers, Thomas; Ebert, Matthias PA; Pross, Matthias; Dietel, Manfred; Denkert, Carsten; Roecken, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-148</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Although histone deacetylases (HDACs) are known to have an important regulatory role in cancer cells, and HDAC inhibitors (HDIs) have entered late-phase clin. trials for the treatment of several cancers, little is known about the expression patterns of HDAC isoforms in tumors.  We aimed to clarify these expression patterns and identify potential diagnostic and prognostic uses of selected class I HDAC isoforms in gastric cancer.  Tissue samples from a training cohort and a validation cohort of patients with gastric cancer from two German institutions were used for analyses.  Tissue microarrays were generated from tumor tissue collected from patients in the training group, whereas tissue slides were used in the validation group.  The tissues were scored for expression of class I HDAC isoforms 1, 2, and 3.  Overall expression patterns (gHDAC) were grouped as being neg. (all three isoforms neg.), partially pos. (one or two isoforms pos.), or completely pos. (all isoforms pos.), and correlated with clinicopathol. parameters and patient survival.  The main endpoints were amt. of expression of each of the three HDAC isoforms, patterns of expression of gHDAC, effect of metastasis on expression of HDAC and gHDAC, and overall survival according to HDAC expression patterns.  With 2617 tissue microarray spots from 143 patients in the training cohort and 606 tissue slides from 150 patients in the validation cohort were studied. 52 of the 143 (36%) gastric tumors in the training cohort and 32 of the 150 (21%) gastric tumors in the validation cohort showed nuclear expression of all three HDAC isoforms. 60 (42%) of tumors in the training cohort and 65 (43%) in the validation cohort expressed one or two isoforms in the nuclei, whereas 31 (22%) of tumors in the training cohort and 53 (35%) in the validation cohort were scored neg. for all three proteins. gHDAC expression in both cohorts was higher when lymph-node metastases were present (p=0.0175 for the training group and p=0.0242 for the validation group).  Survival data were available for 49 patients in the training group and 123 patients in the validation group.  In the validation cohort, 3-yr survival was 44% (95% CI 34-57) in the HDAC1-neg. group, 50% (39-64) in the HDAC2-neg. group, and 48% (34-67) in the gHDAC-neg. group. 3-yr survival decreased to 21% (11-37) when HDAC1 was pos., 16% (9-31) when HDAC2 was pos., and 5% (1-31) when gHDAC (all isoforms) were pos.  Those patients highly expressing one or two isoforms (the gHDAC-intermediate group) had an estd. 3-yr survival of 40% (29-56).  In multivariate analyses, high gHDAC and HDAC2 expression were assocd. with shorter survival in the training cohort (gHDAC: hazard ratio [HR] 4.15 [1.23-13.99], p=0.0250; HDAC2: HR 3.58 [1.36-9.44], p=0.0100) and in the validation cohort (gHDAC: HR 2.18 [1.19-4.01], p=0.0433; HDAC2: HR 1.72 [1.08-2.73], p=0.0225), independent of std. clin. predictors.  High HDAC expression is significantly assocd. with nodal spread and is an independent prognostic marker for gastric cancer.  Addnl., we postulate that immunohistochem. detection of HDAC as a companion diagnostic method might predict treatment response to HDIs, thereby enabling selection of patients for this specific targeted treatment in gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS-sW_bc85KLVg90H21EOLACvtfcHk0liTC8DrRkt0xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOnu7c%253D&md5=8be9de726d97c67924e3cd3543b94c73</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2808%2970004-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252808%252970004-4%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DW.%26aulast%3DRoske%26aufirst%3DA.%26aulast%3DGekeler%26aufirst%3DV.%26aulast%3DBeckers%26aufirst%3DT.%26aulast%3DEbert%26aufirst%3DM.%2BP.%26aulast%3DPross%26aufirst%3DM.%26aulast%3DDietel%26aufirst%3DM.%26aulast%3DDenkert%26aufirst%3DC.%26aulast%3DRocken%26aufirst%3DC.%26atitle%3DAssociation%2520patterns%2520of%2520class%2520I%2520histone%2520deacetylase%2520expression%2520with%2520patient%2520prognosis%2520in%2520gastric%2520cancer%253A%2520a%2520retrospective%2520analysis%26jtitle%3DLancet%2520Oncol.%26date%3D2008%26volume%3D9%26spage%3D139%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Angibaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncelet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Brandt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Winter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Holte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marien, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssens, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aerts, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Gompel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaurrand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queguiner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argoullon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hijfte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span> </span><span class="NLM_article-title">Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">606</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=597-606&author=P.+Angibaudauthor=J.+Artsauthor=K.+Van+Emelenauthor=V.+Ponceletauthor=I.+Pilatteauthor=B.+Rouxauthor=S.+Van+Brandtauthor=M.+Verdonckauthor=H.+De+Winterauthor=P.+Ten+Holteauthor=A.+Marienauthor=W.+Florenauthor=B.+Janssensauthor=J.+Van+Dunauthor=A.+Aertsauthor=J.+Van+Gompelauthor=S.+Gaurrandauthor=L.+Queguinerauthor=J.+M.+Argoullonauthor=L.+Van+Hijfteauthor=E.+Freyneauthor=M.+Janicot&title=Discovery+of+pyrimidyl-5-hydroxamic+acids+as+new+potent+histone+deacetylase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DPoncelet%26aufirst%3DV.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DVan%2BBrandt%26aufirst%3DS.%26aulast%3DVerdonck%26aufirst%3DM.%26aulast%3DDe%2BWinter%26aufirst%3DH.%26aulast%3DTen%2BHolte%26aufirst%3DP.%26aulast%3DMarien%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DJanssens%26aufirst%3DB.%26aulast%3DVan%2BDun%26aufirst%3DJ.%26aulast%3DAerts%26aufirst%3DA.%26aulast%3DVan%2BGompel%26aufirst%3DJ.%26aulast%3DGaurrand%26aufirst%3DS.%26aulast%3DQueguiner%26aufirst%3DL.%26aulast%3DArgoullon%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BHijfte%26aufirst%3DL.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DJanicot%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520pyrimidyl-5-hydroxamic%2520acids%2520as%2520new%2520potent%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2005%26volume%3D40%26spage%3D597%26epage%3D606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angibaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssens, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geerts, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Emelen, K.</span><span> </span><span class="NLM_article-title">R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum anti-tumoural activity against solid and haematological malignancies</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1344</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1038%2Fsj.bjc.6604025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=18000499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=1344-1353&author=J.+Artsauthor=P.+Angibaudauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=B.+Janssensauthor=P.+Kingauthor=J.+van+Dunauthor=L.+Janssenauthor=T.+Geertsauthor=R.+W.+Tumanauthor=D.+L.+Johnsonauthor=L.+Andriesauthor=M.+Jungauthor=M.+Janicotauthor=K.+van+Emelen&title=R306465+is+a+novel+potent+inhibitor+of+class+I+histone+deacetylases+with+broad-spectrum+anti-tumoural+activity+against+solid+and+haematological+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and hematological malignancies</span></div><div class="casAuthors">Arts, J.; Angibaud, P.; Marien, A.; Floren, W.; Janssens, B.; King, P.; van Dun, J.; Janssen, L.; Geerts, T.; Tuman, R. W.; Johnson, D. L.; Andries, L.; Jung, M.; Janicot, M.; van Emelen, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1344-1353</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">R306465 is a novel hydroxamate-based histone deacetylase (HDAC) inhibitor with broad-spectrum antitumor activity against solid and haematol. malignancies in preclin. models.  R306465 was found to be a potent inhibitor of HDAC1 and -8 (class I) in vitro.  It rapidly induced histone 3 (H3) acetylation and strongly upregulated expression of p21waf1,cip1, a downstream component of HDAC1 signalling, in A2780 ovarian carcinoma cells.  R306465 showed class I HDAC isotype selectivity as evidenced by poor inhibition of HDAC6 (class IIb) confirmed by the absence of downregulation of Hsp90 chaperone c-raf protein expression and tubulin acetylation.  This distinguished it from other HDAC inhibitors currently in clin. development that were either more potent towards HDAC6 (e.g. vorinostat) or had a broader HDAC inhibition spectrum (e.g. panobinostat).  R306465 potently inhibited cell proliferation of all main solid tumor indications, including ovarian, lung, colon, breast and prostate cancer cell lines, with IC50 values ranging from 30 to 300 n.  Haematol. cell lines, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphoblastic leukemia, chronic myeloid leukemia, lymphoma and myeloma, were potently inhibited at a similar concn. range.  R306465 induced apoptosis and inhibited angiogenesis in cell-based assays and had potent oral in vivo antitumoral activity in xenograft models.  Once-daily oral administration of R306465 at well-tolerated doses inhibited the growth of A2780 ovarian, H460 lung and HCT116 colon carcinomas in immunodeficient mice.  The high activity of R306465 in cell-based assays and in vivo after oral administration makes R306465 a promising novel antitumoral agent with potential applicability in a broad spectrum of human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZf5Lr-OdBOrVg90H21EOLACvtfcHk0liTC8DrRkt0xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yku7fJ&md5=f073a66b403e486a17d8b5478196f193</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604025%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DJanssens%26aufirst%3DB.%26aulast%3DKing%26aufirst%3DP.%26aulast%3Dvan%2BDun%26aufirst%3DJ.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DGeerts%26aufirst%3DT.%26aulast%3DTuman%26aufirst%3DR.%2BW.%26aulast%3DJohnson%26aufirst%3DD.%2BL.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3Dvan%2BEmelen%26aufirst%3DK.%26atitle%3DR306465%2520is%2520a%2520novel%2520potent%2520inhibitor%2520of%2520class%2520I%2520histone%2520deacetylases%2520with%2520broad-spectrum%2520anti-tumoural%2520activity%2520against%2520solid%2520and%2520haematological%2520malignancies%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D97%26spage%3D1344%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beliën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decrane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vreys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talloen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goris, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Jardin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angibaud, P.</span><span> </span><span class="NLM_article-title">JNJ-26481585, a novel “second-generation” oral histone deacetylase inhibitor, shows broad-spectrum preclinical anti-tumoural activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6841</span><span class="NLM_x">–</span> <span class="NLM_lpage">6851</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1158%2F1078-0432.CCR-09-0547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19861438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6841-6851&author=J.+Artsauthor=P.+Kingauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=A.+Beli%C3%ABnauthor=L.+Janssenauthor=I.+Pilatteauthor=B.+Rouxauthor=L.+Decraneauthor=R.+Gilissenauthor=I.+Hicksonauthor=V.+Vreysauthor=E.+Coxauthor=K.+Bolauthor=W.+Talloenauthor=I.+Gorisauthor=L.+Andriesauthor=M.+Du+Jardinauthor=M.+Janicotauthor=M.+Pageauthor=K.+van+Emelenauthor=P.+Angibaud&title=JNJ-26481585%2C+a+novel+%E2%80%9Csecond-generation%E2%80%9D+oral+histone+deacetylase+inhibitor%2C+shows+broad-spectrum+preclinical+anti-tumoural+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span></div><div class="casAuthors">Arts, Janine; King, Peter; Marien, Ann; Floren, Wim; Belien, Ann; Janssen, Lut; Pilatte, Isabelle; Roux, Bruno; Decrane, Laurence; Gilissen, Ron; Hickson, Ian; Vreys, Veronique; Cox, Eugene; Bol, Kees; Talloen, Willem; Goris, Ilse; Andries, Luc; Du Jardin, Marc; Janicot, Michel; Page, Martin; van Emelen, Kristof; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6841-6851</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase (HDAC) inhibitors have shown promising clin. activity in the treatment of hematol. malignancies, but their activity in solid tumor indications has been limited.  Most HDAC inhibitors in clin. development only transiently induce histone acetylation in tumor tissue.  Here, we sought to identify a "second-generation" class I HDAC inhibitor with prolonged pharmacodynamic response in vivo, to assess whether this results in superior antitumoral efficacy.  Exptl. Design: To identify novel HDAC inhibitors with superior pharmacodynamic properties, we developed a preclin. in vivo tumor model, in which tumor cells have been engineered to express fluorescent protein dependent on HDAC1 inhibition, thereby allowing noninvasive real-time evaluation of the tumor response to HDAC inhibitors.  Results: In vivo pharmacodynamic anal. of 140 potent pyrimidyl-hydroxamic acid analogs resulted in the identification of JNJ-26481585.  Once daily oral administration of JNJ-26481585 induced continuous histone H3 acetylation.  The prolonged pharmacodynamic response translated into complete tumor growth inhibition in Ras mutant HCT116 colon carcinoma xenografts, whereas 5-fluorouracil was less active.  JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity.  Further characterization revealed that JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC50, 0.16 nmol/L).  Conclusions: The potent antitumor activity as a single agent in preclin. models combined with its favorable pharmacodynamic profile makes JNJ-26481585 a promising "second-generation" HDAC inhibitor.  The compd. is currently in clin. studies, to evaluate its potential applicability in a broad spectrum of both solid and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKc9hyMiADZrVg90H21EOLACvtfcHk0lgU9wsILBxb-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE&md5=8f199c25c92c967a76f273d879d6c577</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0547%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DBeli%25C3%25ABn%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DVreys%26aufirst%3DV.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DBol%26aufirst%3DK.%26aulast%3DTalloen%26aufirst%3DW.%26aulast%3DGoris%26aufirst%3DI.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DM.%26aulast%3Dvan%2BEmelen%26aufirst%3DK.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DJNJ-26481585%252C%2520a%2520novel%2520%25E2%2580%259Csecond-generation%25E2%2580%259D%2520oral%2520histone%2520deacetylase%2520inhibitor%252C%2520shows%2520broad-spectrum%2520preclinical%2520anti-tumoural%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6841%26epage%3D6851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Moffat, D. F. C.; Patel, S. R.; Mazzei, F. A.; Belfield, A. J.; Van Meurs, S.</span><span> </span><span class="NLM_article-title">Preparation of Hydroxamic Acids as Histone Deacetylase Inhibitors for Use against Proliferative Diseases Including Cancers</span>. WO 06123121,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+F.+C.+Moffat&author=S.+R.+Patel&author=F.+A.+Mazzei&author=A.+J.+Belfield&author=S.+Van+Meurs&title=Preparation+of+Hydroxamic+Acids+as+Histone+Deacetylase+Inhibitors+for+Use+against+Proliferative+Diseases+Including+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DD.%2BF.%2BC.%26atitle%3DPreparation%2520of%2520Hydroxamic%2520Acids%2520as%2520Histone%2520Deacetylase%2520Inhibitors%2520for%2520Use%2520against%2520Proliferative%2520Diseases%2520Including%2520Cancers%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Angibaud., P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decrane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Brandt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Holte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncelet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speybrouck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queguiner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaurrand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gompel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Jardin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noppe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hijfte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arts, J.</span><span> </span><span class="NLM_article-title">Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=294-298&author=P.+Angibaud.author=K.+Van+Emelenauthor=L.+Decraneauthor=S.+van+Brandtauthor=P.+Ten+Holteauthor=I.+Pilatteauthor=B.+Rouxauthor=V.+Ponceletauthor=D.+Speybrouckauthor=L.+Queguinerauthor=S.+Gaurrandauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=L.+Janssenauthor=M.+Verdonckauthor=J.+van+Dunauthor=J.+van+Gompelauthor=R.+Gilissenauthor=C.+Mackieauthor=M.+Du+Jardinauthor=J.+Peetersauthor=M.+Noppeauthor=L.+Van+Hijfteauthor=E.+Freyneauthor=M.+Pageauthor=M.+Janicotauthor=J.+Arts&title=Identification+of+a+series+of+substituted+2-piperazinyl-5-pyrimidylhydroxamic+acids+as+potent+histone+deacetylase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAngibaud.%26aufirst%3DP.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3Dvan%2BBrandt%26aufirst%3DS.%26aulast%3DTen%2BHolte%26aufirst%3DP.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DPoncelet%26aufirst%3DV.%26aulast%3DSpeybrouck%26aufirst%3DD.%26aulast%3DQueguiner%26aufirst%3DL.%26aulast%3DGaurrand%26aufirst%3DS.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DVerdonck%26aufirst%3DM.%26aulast%3Dvan%2BDun%26aufirst%3DJ.%26aulast%3Dvan%2BGompel%26aufirst%3DJ.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DPeeters%26aufirst%3DJ.%26aulast%3DNoppe%26aufirst%3DM.%26aulast%3DVan%2BHijfte%26aufirst%3DL.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DArts%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520a%2520series%2520of%2520substituted%25202-piperazinyl-5-pyrimidylhydroxamic%2520acids%2520as%2520potent%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D294%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Vannini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filocamo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavola, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brumetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzoni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, S.</span><span> </span><span class="NLM_article-title">Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">15064</span><span class="NLM_x">–</span> <span class="NLM_lpage">15069</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1073%2Fpnas.0404603101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=15477595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVShurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=15064-15069&author=A.+Vanniniauthor=C.+Volpariauthor=G.+Filocamoauthor=E.+C.+Casavolaauthor=M.+Brumettiauthor=D.+Renzoniauthor=P.+Chakravartyauthor=C.+Paoliniauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=S.+Di+Marco&title=Crystal+structure+of+a+eukaryotic+zinc-dependent+histone+deacetylase%2C+human+HDAC8%2C+complexed+with+a+hydroxamic+acid+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor</span></div><div class="casAuthors">Vannini, Alessandro; Volpari, Cinzia; Filocamo, Gessica; Casavola, Elena Caroli; Brunetti, Mirko; Renzoni, Debora; Chakravarty, Prasun; Paolini, Chantal; De Francesco, Raffaele; Gallinari, Paola; Steinkuehler, Christian; Di Marco, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">15064-15069</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of enzymes involved in the regulation of gene expression, DNA repair, and stress response.  These processes often are altered in tumors, and HDAC inhibitors have had pronounced antitumor activity with promising results in clin. trials.  Here, we report the crystal structure of human HDAC8 in complex with a hydroxamic acid inhibitor.  Such a structure of a eukaryotic zinc-dependent HDAC has not be described previously.  Similar to bacterial HDAC-like protein, HDAC8 folds in a single α/β domain.  The inhibitor and the zinc-binding sites are similar in both proteins.  However, significant differences are obsd. in the length and structure of the loops surrounding the active site, including the presence of two potassium ions in HDAC8 structure, one of which interacts with key catalytic residues.  CD data suggest a direct role of potassium in the fold stabilization of HDAC8.  Knockdown of HDAC8 by RNA interference inhibits growth of human lung, colon, and cervical cancer cell lines, highlighting the importance of this HDAC subtype for tumor cell proliferation.  Our findings open the way for the design and development of selective inhibitors of HDAC8 as possible antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs_auq2Wf8RLVg90H21EOLACvtfcHk0lhSzAleZItZ9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVShurY%253D&md5=86bf33830743d2169514f686b7a30ed8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0404603101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0404603101%26sid%3Dliteratum%253Aachs%26aulast%3DVannini%26aufirst%3DA.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DFilocamo%26aufirst%3DG.%26aulast%3DCasavola%26aufirst%3DE.%2BC.%26aulast%3DBrumetti%26aufirst%3DM.%26aulast%3DRenzoni%26aufirst%3DD.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DPaolini%26aufirst%3DC.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520a%2520eukaryotic%2520zinc-dependent%2520histone%2520deacetylase%252C%2520human%2520HDAC8%252C%2520complexed%2520with%2520a%2520hydroxamic%2520acid%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D15064%26epage%3D15069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Donald, A. D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wibata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stimson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Needham, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, D. F.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6657</span><span class="NLM_x">–</span> <span class="NLM_lpage">6660</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6657-6660&author=A.+D.+G.+Donaldauthor=V.+L.+Clarkauthor=S.+Patelauthor=F.+A.+Dayauthor=M.+G.+Rowlandsauthor=J.+Wibataauthor=L.+Stimsonauthor=S.+A.+Ecclesauthor=L.+A.+Needhamauthor=F.+I.+Raynaudauthor=W.+Aherneauthor=D.+F.+Moffat&title=Design+and+synthesis+of+novel+pyrimidine+hydroxamic+acid+inhibitors+of+histone+deacetylases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDonald%26aufirst%3DA.%2BD.%2BG.%26aulast%3DClark%26aufirst%3DV.%2BL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DDay%26aufirst%3DF.%2BA.%26aulast%3DRowlands%26aufirst%3DM.%2BG.%26aulast%3DWibata%26aufirst%3DJ.%26aulast%3DStimson%26aufirst%3DL.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DNeedham%26aufirst%3DL.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DMoffat%26aufirst%3DD.%2BF.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520pyrimidine%2520hydroxamic%2520acid%2520inhibitors%2520of%2520histone%2520deacetylases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6657%26epage%3D6660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Norris, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braish, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vries, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massett, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santafianos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sklavounos, C.</span><span> </span><span class="NLM_article-title">Synthesis of trovafloxacin using various (1α,5α,6α)-3-azabicyclo[3,1,0]hexane derivatives</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_fpage">1615</span><span class="NLM_x">–</span> <span class="NLM_lpage">1622</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=1615-1622&author=T.+Norrisauthor=T.+F.+Braishauthor=M.+Buttersauthor=K.+M.+De+Vriesauthor=J.+M.+Hawkinsauthor=S.+S.+Massettauthor=P.+R.+Roseauthor=D.+Santafianosauthor=C.+Sklavounos&title=Synthesis+of+trovafloxacin+using+various+%281%CE%B1%2C5%CE%B1%2C6%CE%B1%29-3-azabicyclo%5B3%2C1%2C0%5Dhexane+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNorris%26aufirst%3DT.%26aulast%3DBraish%26aufirst%3DT.%2BF.%26aulast%3DButters%26aufirst%3DM.%26aulast%3DDe%2BVries%26aufirst%3DK.%2BM.%26aulast%3DHawkins%26aufirst%3DJ.%2BM.%26aulast%3DMassett%26aufirst%3DS.%2BS.%26aulast%3DRose%26aufirst%3DP.%2BR.%26aulast%3DSantafianos%26aufirst%3DD.%26aulast%3DSklavounos%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520trovafloxacin%2520using%2520various%2520%25281%25CE%25B1%252C5%25CE%25B1%252C6%25CE%25B1%2529-3-azabicyclo%255B3%252C1%252C0%255Dhexane%2520derivatives%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D2000%26spage%3D1615%26epage%3D1622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Brighty, K. E.</span><span> </span><span class="NLM_article-title">Azabicycloquinoline Carboxylic Acids</span>. WO 9102526,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=K.+E.+Brighty&title=Azabicycloquinoline+Carboxylic+Acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrighty%26aufirst%3DK.%2BE.%26atitle%3DAzabicycloquinoline%2520Carboxylic%2520Acids%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Pratt, L. M.; Keavey, K. N.; Pain, G. D.; Mounier, L. F.</span><span> </span><span class="NLM_article-title">Preparation of Hydroxamic and <i>N</i>-Formyl Hydroxylamine Derivatives as Antibacterial Agents</span>. WO 01010834,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=L.+M.+Pratt&author=K.+N.+Keavey&author=G.+D.+Pain&author=L.+F.+Mounier&title=Preparation+of+Hydroxamic+and+N-Formyl+Hydroxylamine+Derivatives+as+Antibacterial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPratt%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520Hydroxamic%2520and%2520N-Formyl%2520Hydroxylamine%2520Derivatives%2520as%2520Antibacterial%2520Agents%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Renslo, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaishankar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatachalam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackbarth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordeev, M. F.</span><span> </span><span class="NLM_article-title">Conformational constraint in oxazolidinone antibacterials. Synthesis and structure−activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5009</span><span class="NLM_x">–</span> <span class="NLM_lpage">5024</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058204j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5009-5024&author=A.+R.+Rensloauthor=P.+Jaishankarauthor=R.+Venkatachalamauthor=C.+Hackbarthauthor=S.+Lopezauthor=D.+V.+Patelauthor=M.+F.+Gordeev&title=Conformational+constraint+in+oxazolidinone+antibacterials.+Synthesis+and+structure%E2%88%92activity+studies+of+%28azabicyclo%5B3.1.0%5Dhexylphenyl%29oxazolidinones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm058204j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058204j%26sid%3Dliteratum%253Aachs%26aulast%3DRenslo%26aufirst%3DA.%2BR.%26aulast%3DJaishankar%26aufirst%3DP.%26aulast%3DVenkatachalam%26aufirst%3DR.%26aulast%3DHackbarth%26aufirst%3DC.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DD.%2BV.%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26atitle%3DConformational%2520constraint%2520in%2520oxazolidinone%2520antibacterials.%2520Synthesis%2520and%2520structure%25E2%2588%2592activity%2520studies%2520of%2520%2528azabicyclo%255B3.1.0%255Dhexylphenyl%2529oxazolidinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5009%26epage%3D5024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Kerns, E. H.; Di, L.</span><span> </span><span class="NLM_article-title">Drug-like Properties: Concepts, Structure Design and Methods</span>; <span class="NLM_publisher-name">Academic Press, Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">228</span>− <span class="NLM_lpage">241</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2FB978-012369520-8.50020-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kerns%2C+E.+H.%3B+Di%2C+L.+Drug-like+Properties%3A+Concepts%2C+Structure+Design+and+Methods%3B+Academic+Press%2C+Elsevier%3A+Amsterdam%2C+2008%3B+pp+228%E2%88%92241."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FB978-012369520-8.50020-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-012369520-8.50020-6%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DDrug-like%2520Properties%253A%2520Concepts%252C%2520Structure%2520Design%2520and%2520Methods%26pub%3DAcademic%2520Press%252C%2520Elsevier%26date%3D2008%26spage%3D228%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mol, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynands, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knuth, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tari, L. W.</span><span> </span><span class="NLM_article-title">Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1325</span><span class="NLM_x">–</span> <span class="NLM_lpage">1334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2Fj.str.2004.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=15242608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFyrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=1325-1334&author=J.+R.+Somozaauthor=R.+J.+Skeneauthor=B.+A.+Katzauthor=C.+Molauthor=J.+D.+Hoauthor=A.+J.+Jenningsauthor=C.+Luongauthor=A.+Arvaiauthor=J.+J.+Buggyauthor=E.+Chiauthor=J.+Tangauthor=B.+C.+Sangauthor=E.+Vernerauthor=R.+Wynandsauthor=E.+M.+Leahyauthor=D.+R.+Douganauthor=G.+Snellauthor=M.+Navreauthor=M.+W.+Knuthauthor=R.+V.+Swansonauthor=D.+E.+McReeauthor=L.+W.+Tari&title=Structural+snapshots+of+human+HDAC8+provide+insights+into+the+class+I+histone+deacetylases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases</span></div><div class="casAuthors">Somoza, John R.; Skene, Robert J.; Katz, Bradley A.; Mol, Clifford; Ho, Joseph D.; Jennings, Andy J.; Luong, Christine; Arvai, Andrew; Buggy, Joseph J.; Chi, Ellen; Tang, Jie; Sang, Bi-Ching; Verner, Erik; Wynands, Robert; Leahy, Ellen M.; Dougan, Douglas R.; Snell, Gyorgy; Navre, Marc; Knuth, Mark W.; Swanson, Ronald V.; McRee, Duncan E.; Tari, Leslie W.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1325-1334</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Modulation of the acetylation state of histones plays a pivotal role in the regulation of gene expression.  Histone deacetylases (HDACs) catalyze the removal of acetyl groups from lysines near the N termini of histones.  This reaction promotes the condensation of chromatin, leading to repression of transcription.  HDAC deregulation has been linked to several types of cancer, suggesting a potential use for HDAC inhibitors in oncol.  Here we describe the first crystal structures of a human HDAC: the structures of human HDAC8 complexed with four structurally diverse hydroxamate inhibitors.  This work sheds light on the catalytic mechanism of the HDACs, and on differences in substrate specificity across the HDAC family.  The structure also suggests how phosphorylation of Ser39 affects HDAC8 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPLrZup76hGLVg90H21EOLACvtfcHk0lhAwpBRC5hPVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFyrsLc%253D&md5=3f1842802bac2543509a25f5ddbea5f6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DMol%26aufirst%3DC.%26aulast%3DHo%26aufirst%3DJ.%2BD.%26aulast%3DJennings%26aufirst%3DA.%2BJ.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DArvai%26aufirst%3DA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChi%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DWynands%26aufirst%3DR.%26aulast%3DLeahy%26aufirst%3DE.%2BM.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DKnuth%26aufirst%3DM.%2BW.%26aulast%3DSwanson%26aufirst%3DR.%2BV.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26aulast%3DTari%26aufirst%3DL.%2BW.%26atitle%3DStructural%2520snapshots%2520of%2520human%2520HDAC8%2520provide%2520insights%2520into%2520the%2520class%2520I%2520histone%2520deacetylases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D1325%26epage%3D1334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">Equilibrium solubility was measured by resuspension of amorphous compound at 200 μg/mL in either 100% DMSO or 100% phosphate buffer at pH 5.5 and 7.4. Phosphate buffered samples were mixed for 24 h at room temperature using a PTFE magnetic stirrer bar. DMSO samples were mixed for 24 h at room temperature on an orbital shaker. Calibration lines were prepared using the 200 μg/mL DMSO stock which was diluted with DMSO to final concentrations of 100, 50, 25, 10, and 1 μg/mL. Two 250 μL aliquots of the phosphate buffered samples were removed and filtered using a Multiscreen HTS solubility filter plate (Millipore). Filtrate was analyzed in tandem with calibration samples by LC−UV and LC−MS/MS. Quantification of test compound solubility was by extrapolation from calibration lines.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_contrib-group">Shabason, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofilon, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camphausen, K.</span><span> </span><span class="NLM_article-title">HDAC inhibitors in cancer care</span> <span class="citation_source-journal">Oncology (Williston Park)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=20361469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A280%3ADC%252BC3c3jtlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=180-185&author=J.+E.+Shabasonauthor=P.+J.+Tofilonauthor=K.+Camphausen&title=HDAC+inhibitors+in+cancer+care"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors in cancer care</span></div><div class="casAuthors">Shabason Jacob E; Tofilon Philip J; Camphausen Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-5</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">The epigenetic control of gene expression has been shown to play an important role in cancer initiation, progression, and resistance.  Thus, agents that modify the epigenetic environment of tumors will likely be an important addition to the anticancer arsenal.  Specifically, there is much interest in modulating histone acetylation using a new class of drugs, histone deacetylase (HDAC) inhibitors.  Preclinical data have demonstrated the efficacy of various HDAC inhibitors as anticancer agents, with the greatest effects shown when HDAC inhibitors are used in combination with other therapies.  As a result of encouraging preclinical data, numerous HDAC inhibitors are being investigated in clinical trials either as monotherapies or in conjunction with other treatments such as chemotherapy, biologic therapy, or radiation therapy.  In fact, vorinostat and depsipeptide, two actively studied HDAC inhibitors, were recently approved for the treatment of refractory cutaneous T-cell lymphoma.  Although the use of HDAC inhibitors has generated great enthusiasm, a significant amount of work still needs to be done in order to understand their mechanisms of action, as well as to determine the appropriate patient characteristics and subsets of cancer for which HDAC inhibitors hold the most potential for effective treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnp5mHHevMSXELvajU9pjPfW6udTcc2eaVIB_8EflFHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3jtlGkug%253D%253D&md5=d9b04c5ce177d55e9f2cea3a60640821</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShabason%26aufirst%3DJ.%2BE.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26aulast%3DCamphausen%26aufirst%3DK.%26atitle%3DHDAC%2520inhibitors%2520in%2520cancer%2520care%26jtitle%3DOncology%2520%2528Williston%2520Park%2529%26date%3D2010%26volume%3D24%26spage%3D180%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezzeldin, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diasio, R. B.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: current status and overview of recent clinical trials</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1911-1934&author=X.+Maauthor=H.+H.+Ezzeldinauthor=R.+B.+Diasio&title=Histone+deacetylase+inhibitors%3A+current+status+and+overview+of+recent+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DEzzeldin%26aufirst%3DH.%2BH.%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520current%2520status%2520and%2520overview%2520of%2520recent%2520clinical%2520trials%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1911%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_contrib-group">Bots, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">Rational combinations using HDAC inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3970</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1158%2F1078-0432.CCR-08-2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19509171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlOis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3970-3977&author=M.+Botsauthor=R.+W.+Johnstone&title=Rational+combinations+using+HDAC+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Combinations Using HDAC Inhibitors</span></div><div class="casAuthors">Bots, Michael; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3970-3977</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  In addn. to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis.  As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as anticancer drugs.  In numerous in vitro and preclin. settings, these compds. have shown their vast potential as single agent anticancer therapies, but unfortunately equiv. responses have not always been obsd. in patients.  Given the pleiotropic effects HDACi have on malignant cells, their true therapeutic potential most likely lies in combination with other anticancer drugs.  In this review we will focus on the anticancer effects of HDACi when combined with other cancer therapeutics with an emphasis on those combinations based on a strong mol. rationale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLnwCXjHtPbVg90H21EOLACvtfcHk0lgjf-_8aYyXNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlOis7w%253D&md5=117c52a204aa45615eb04c8600e51c10</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2786%26sid%3Dliteratum%253Aachs%26aulast%3DBots%26aufirst%3DM.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DRational%2520combinations%2520using%2520HDAC%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3970%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_contrib-group">Campbell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalitin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berenson, J. R.</span><span> </span><span class="NLM_article-title">Vorinostat enhances the antimyeloma effects of melphalan and bortezomib</span> <span class="citation_source-journal">Eur. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1111%2Fj.1600-0609.2009.01384.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19929977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlGmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=201-211&author=R.+A.+Campbellauthor=E.+Sanchezauthor=J.+Steinbergauthor=D.+Shalitinauthor=Z.+W.+Liauthor=H.+Chenauthor=J.+R.+Berenson&title=Vorinostat+enhances+the+antimyeloma+effects+of+melphalan+and+bortezomib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat enhances the antimyeloma effects of melphalan and bortezomib</span></div><div class="casAuthors">Campbell, Richard A.; Sanchez, Eric; Steinberg, Jeffrey; Shalitin, Dror; Li, Zhi-Wei; Chen, Haiming; Berenson, James R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-211</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives: Examine the antitumor activity of the histone deacetylase inhibitor vorinostat's antitumor activity against multiple myeloma (MM) using cell lines and a murine xenograft model.  Methods: RPMI8226, U266, and MM1S cells were cultured for 48 h in the presence of media, vorinostat, melphalan, or bortezomib alone, or combinations of vorinostat with melphalan or bortezomib.  Cell proliferation was measured using the MTS [3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfphophenyl)-2H-tetrazolium, inner salt] assay.  Severe combined immunodeficient mice bearing LAGκ-1B tumors were treated with vorinostat [30, 60, or 100 mg/kg daily for five consecutive days per wk (qd×5d), 100 or 300 mg/kg daily for 2 d/wk (qd×2d)], melphalan (1, 3, or 10 mg/kg qd×1d), bortezomib (0.25 or 0.5 mg/kg qd×2d), or combinations thereof for 35 d.  Tumor growth was detd. via measurement of human IgG (hIgG) levels and tumor vol.  Results and Conclusions: Vorinostat enhanced the anti-MM effects of melphalan and bortezomib in vitro.  Synergism was obsd. with vorinostat and melphalan in RPMI8226 and U266 cell lines.  Vorinostat 100 mg/kg in combination with melphalan 3 mg/kg resulted in significant inhibition of tumor growth in vivo, compared with control (tumor vol. P = 0.0001; hIgG P = 0.0001), single-agent vorinostat (tumor vol. P = 0.0025; hIgG P = 0.0137), and single-agent melphalan (tumor vol. P = 0.0043; hIgG P = 0.0426).  Vorinostat also enhanced the antimyeloma effects of bortezomib in vivo.  Vorinostat enhances the anti-MM activity of melphalan and bortezomib in vitro and in vivo.  This study provides rationale for further evaluation of vorinostat in combination with chemotherapeutic agents and bortezomib for the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoikDxI2DIkUrVg90H21EOLACvtfcHk0lhzZLNUW0SO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlGmt7g%253D&md5=003b86234a2cb9d588d7f9d9aca08a4c</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0609.2009.01384.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0609.2009.01384.x%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DR.%2BA.%26aulast%3DSanchez%26aufirst%3DE.%26aulast%3DSteinberg%26aufirst%3DJ.%26aulast%3DShalitin%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBerenson%26aufirst%3DJ.%2BR.%26atitle%3DVorinostat%2520enhances%2520the%2520antimyeloma%2520effects%2520of%2520melphalan%2520and%2520bortezomib%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2010%26volume%3D84%26spage%3D201%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27c"><span><span class="NLM_contrib-group">Owonikoko, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanterewicz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balius, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belani, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hershberger, P. A.</span><span> </span><span class="NLM_article-title">Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">743</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1002%2Fijc.24759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19621389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGjs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=743-755&author=T.+K.+Owonikokoauthor=S.+S.+Ramalingamauthor=B.+Kanterewiczauthor=T.+E.+Baliusauthor=C.+P.+Belaniauthor=P.+A.+Hershberger&title=Vorinostat+increases+carboplatin+and+paclitaxel+activity+in+non-small-cell+lung+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells</span></div><div class="casAuthors">Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Kanterewicz, Beatriz; Balius, Trent E.; Belani, Chandra P.; Hershberger, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">743-755</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We obsd. a 53% response rate in non-small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial.  Studies were undertaken to investigate the mechanism (s) underlying this activity.  Growth inhibition was assessed in NSCLC cells by MTT assay after 72 h of continuous drug exposure.  Vorinostat (1 μM) inhibited growth by: 17% ± 7% in A549, 28% ± 6% in 128-88T, 39% ± 8% in Calu1 and 41% ± 7% in 201T cells.  Vorinostat addn. to carboplatin or paclitaxel led to significantly greater growth inhibition than chemotherapy alone in all 4 cell lines.  Vorinostat (1 μM) synergistically increased the growth inhibitory effects of carboplatin/paclitaxel in 128-88T cells.  When colony formation was measured after drug withdrawal, vorinostat significantly increased the effects of carboplatin but not paclitaxel.  The % colony formation was control 100%; 1 μM vorinostat, 83% ± 10%; 5 μM carboplatin, 41% ± 11%; carboplatin/vorinostat, 8% ± 4%; 2 nM paclitaxel, 53% ± 11%; paclitaxel/vorinostat, 46% ± 21%.  In A549 and 128-88T, vorinostat potentiated carboplatin induction of gamma-H2AX (a DNA damage marker) and increased α-tubulin acetylation (a marker for stabilized mictrotubules).  In A549, combination of vorinostat with paclitaxel resulted in a synergistic increase in α-tubulin acetylation, which reversed upon drug washout.  We conclude that vorinostat interacts favorably with carboplatin and paclitaxel in NSCLC cells, which may explain the provocative response obsd. in our clin. trial.  This likely involves a vorinostat-mediated irreversible increase in DNA damage in the case of carboplatin and a reversible increase in microtubule stability in the case of paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZe4FtU9T3ILVg90H21EOLACvtfcHk0lhzZLNUW0SO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGjs7bO&md5=2c84fdb0ba2c555073be96ad947c5048</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1002%2Fijc.24759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24759%26sid%3Dliteratum%253Aachs%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DKanterewicz%26aufirst%3DB.%26aulast%3DBalius%26aufirst%3DT.%2BE.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DHershberger%26aufirst%3DP.%2BA.%26atitle%3DVorinostat%2520increases%2520carboplatin%2520and%2520paclitaxel%2520activity%2520in%2520non-small-cell%2520lung%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D126%26spage%3D743%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27d"><span><span class="NLM_contrib-group">Venturelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armeanu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathil, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonthein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehrmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauer, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitzer, M.</span><span> </span><span class="NLM_article-title">Epigenetic combination therapy as a tumour-selective treatment approach for hepatocellular carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">2132</span><span class="NLM_x">–</span> <span class="NLM_lpage">2141</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=2132-2141&author=S.+Venturelliauthor=S.+Armeanuauthor=A.+Pathilauthor=C.+J.+Hsiehauthor=T.+S.+Weissauthor=R.+Vontheinauthor=M.+Wehrmannauthor=M.+Gregorauthor=U.+M.+Lauerauthor=M.+Bitzer&title=Epigenetic+combination+therapy+as+a+tumour-selective+treatment+approach+for+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenturelli%26aufirst%3DS.%26aulast%3DArmeanu%26aufirst%3DS.%26aulast%3DPathil%26aufirst%3DA.%26aulast%3DHsieh%26aufirst%3DC.%2BJ.%26aulast%3DWeiss%26aufirst%3DT.%2BS.%26aulast%3DVonthein%26aufirst%3DR.%26aulast%3DWehrmann%26aufirst%3DM.%26aulast%3DGregor%26aufirst%3DM.%26aulast%3DLauer%26aufirst%3DU.%2BM.%26aulast%3DBitzer%26aufirst%3DM.%26atitle%3DEpigenetic%2520combination%2520therapy%2520as%2520a%2520tumour-selective%2520treatment%2520approach%2520for%2520hepatocellular%2520carcinoma%26jtitle%3DCancer%26date%3D2007%26volume%3D109%26spage%3D2132%26epage%3D2141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Chou, T-C</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talalay, P.</span><span> </span><span class="NLM_article-title">Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors</span> <span class="citation_source-journal">Adv. Enzyme Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2F0065-2571%2884%2990007-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=6382953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADyaL2cXktlaksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1984&pages=27-55&author=T-C+Chouauthor=P.+Talalay&title=Quantitative+analysis+of+dose-effect+relationships%3A+the+combined+effects+of+multiple+drugs+or+enzyme+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of dose-effect relationships:  the combined effects of multiple drugs or enzyme inhibitors</span></div><div class="casAuthors">Chou, Ting Chao; Talalay, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Enzyme Regulation</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-55</span>CODEN:
                <span class="NLM_cas:coden">AEZRA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-2571</span>.
    </div><div class="casAbstract">A simplified exptl. design method for the anal. of multiple drug effects and for detg. summation, synergism, and antagonism is described.  The method is not limited by: whether the dose-effect relations are hyperbolic or sigmoidal, whether the effects are mutually exclusive or nonexclusive, whether the ligand interactions are competitive, noncompetitive, or uncompetitive, or whether the drugs are agonists or antagonists.  The method is independent of the no. of drugs involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX4wNupCqgpbVg90H21EOLACvtfcHk0lgcpGVMDRRDyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktlaksLk%253D&md5=055a2711b52dde49389c3f526352333d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0065-2571%2884%2990007-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0065-2571%252884%252990007-4%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DT-C%26aulast%3DTalalay%26aufirst%3DP.%26atitle%3DQuantitative%2520analysis%2520of%2520dose-effect%2520relationships%253A%2520the%2520combined%2520effects%2520of%2520multiple%2520drugs%2520or%2520enzyme%2520inhibitors%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D1984%26volume%3D22%26spage%3D27%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Smith, J.</span><span> </span><span class="NLM_article-title">Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1513</span><span class="NLM_x">–</span> <span class="NLM_lpage">1534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2Fj.clinthera.2005.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=16330289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWhu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2005&pages=1513-1534&author=J.+Smith&title=Erlotinib%3A+small-molecule+targeted+therapy+in+the+treatment+of+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer</span></div><div class="casAuthors">Smith, Janine</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1513-1534</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Erlotinib is an oral tyrosine kinase inhibitor, targeting the human epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) after the failure of more than 1 or 2 previous chemotherapeutic regimens.  The purpose of this article is to summarize the development, pharmacol., pharmacokinetics, efficacy, and adverse effects of erlotinib.  A literature search was conducted with the MEDLINE and EMBASE (1999-2005) databases using the search terms non-small-cell lung cancer, erlotinib, and epidermal growth factor receptor inhibitor.  Abstrs. from the American Society of Clin. Oncol. and documents submitted to the FDA also were reviewed.  BR.21, a randomized, placebo-controlled, multinational Phase III trial demonstrated clin. and statistically improved overall survival in patients with advanced or metastatic NSCLC treated with erlotinib vs. placebo as second-line therapy.  The erlotinib group had a median survival of 6.7 mo vs. a median survival of 4.7 mo in the placebo group (P < 0.001).  The toxicity profile of erlotinib was moderately benign, with the most commonly documented adverse events requiring dose redns. including skin rash (12%) and diarrhea (5%).  Interstitial lung disease and relative fatalities were reported infrequently (0.8%) in patients receiving erlotinib.  Two randomized, placebo-controlled, multicenter Phase III trials conducted in patients with locally advanced and metastatic NSCLC showed no clin. benefit with first-line administration of erlotinib plus concurrent platinum-based chemotherapy.  For patients with NSCLC in whom more than 1 or 2 previous chemotherapeutic regimens have failed, erlotinib is an effective therapy with significant overall survival benefits.  The use of erlotinib as first-line therapy in combination with platinum-based chemotherapeutic regimens, however, has failed to demonstrate efficacy in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ8XxLfuXqJbVg90H21EOLACvtfcHk0lgcpGVMDRRDyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWhu7%252FK&md5=ccf04e1ffdfb147e172b5943a7f0d245</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2005.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2005.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DJ.%26atitle%3DErlotinib%253A%2520small-molecule%2520targeted%2520therapy%2520in%2520the%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DClin.%2520Ther.%26date%3D2005%26volume%3D27%26spage%3D1513%26epage%3D1534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Daskalakis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagitko-Dorfs, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackanson, B.</span><span> </span><span class="NLM_article-title">Decitabine</span> <span class="citation_source-journal">Recent Results Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1007%2F978-3-642-01222-8_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=20072836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=131-157&author=M.+Daskalakisauthor=N.+Blagitko-Dorfsauthor=B.+Hackanson&title=Decitabine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Decitabine</span></div><div class="casAuthors">Daskalakis, Michael; Blagitko-Dorfs, Nadja; Hackanson, Bjoern</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">131-157</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">0080-0015</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy deriv., 5-aza-2'-deoxycytidine (decitabine, Dacogen), are the most widely used inhibitors of DNA methylation which trigger demethylation leading to a consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.  Although the antileukemic capacity of decitabine has been known for almost 40 years, its therapeutic potential in hematol. malignancies is still under intensive investigation.  Multiple clin. trials have shown the promising activity of low-dose decitabine in AML, MDS, CML, and hemoglobinopathies, whereas its efficacy in solid tumors is rather limited.  Clin. responses appear to be induced by both epigenetic alterations and the induction of cell-cycle arrest and/or apoptosis.  Recent clin. trials have been investigating new dosing schedules, routes of administration, and combination of decitabine with other agents, including histone deacetylase (HDAC) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlEhCFh3GKLVg90H21EOLACvtfcHk0lgcpGVMDRRDyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsLnF&md5=0e1fc9576bed410a64d778bb10fe0544</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-01222-8_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-01222-8_10%26sid%3Dliteratum%253Aachs%26aulast%3DDaskalakis%26aufirst%3DM.%26aulast%3DBlagitko-Dorfs%26aufirst%3DN.%26aulast%3DHackanson%26aufirst%3DB.%26atitle%3DDecitabine%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2010%26volume%3D184%26spage%3D131%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Krige, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Needham, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bawden, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirwin-Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legris, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laber, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odedra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bone, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayscough, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, A. H.</span><span> </span><span class="NLM_article-title">CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">6669</span><span class="NLM_x">–</span> <span class="NLM_lpage">6679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=6669-6679&author=D.+Krigeauthor=L.+A.+Needhamauthor=L.+J.+Bawdenauthor=N.+Floresauthor=H.+Farmerauthor=L.+E.+Milesauthor=E.+Stoneauthor=J.+Callaghanauthor=S.+Chandlerauthor=V.+L.+Clarkauthor=P.+Kirwin-Jonesauthor=V.+Legrisauthor=J.+Owenauthor=T.+Patelauthor=S.+Woodauthor=G.+Boxauthor=D.+Laberauthor=R.+Odedraauthor=A.+Wrightauthor=L.+M.+Woodauthor=S.+A.+Ecclesauthor=E.+A.+Boneauthor=A.+Ayscoughauthor=A.+H.+Drummond&title=CHR-2797%3A+an+antiproliferative+aminopeptidase+inhibitor+that+leads+to+amino+acid+deprivation+in+human+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrige%26aufirst%3DD.%26aulast%3DNeedham%26aufirst%3DL.%2BA.%26aulast%3DBawden%26aufirst%3DL.%2BJ.%26aulast%3DFlores%26aufirst%3DN.%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMiles%26aufirst%3DL.%2BE.%26aulast%3DStone%26aufirst%3DE.%26aulast%3DCallaghan%26aufirst%3DJ.%26aulast%3DChandler%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DV.%2BL.%26aulast%3DKirwin-Jones%26aufirst%3DP.%26aulast%3DLegris%26aufirst%3DV.%26aulast%3DOwen%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DLaber%26aufirst%3DD.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DWright%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DL.%2BM.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DBone%26aufirst%3DE.%2BA.%26aulast%3DAyscough%26aufirst%3DA.%26aulast%3DDrummond%26aufirst%3DA.%2BH.%26atitle%3DCHR-2797%253A%2520an%2520antiproliferative%2520aminopeptidase%2520inhibitor%2520that%2520leads%2520to%2520amino%2520acid%2520deprivation%2520in%2520human%2520leukemic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D6669%26epage%3D6679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Chou, T.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motzer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosl, G. J.</span><span> </span><span class="NLM_article-title">Computerized quantitation of synergism and antagonism of Taxol, topetecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">–</span> <span class="NLM_lpage">1524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1093%2Fjnci%2F86.20.1517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=7932806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFWru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1994&pages=1517-1524&author=T.-C.+Chouauthor=R.+J.+Motzerauthor=Y.+Tongauthor=G.+J.+Bosl&title=Computerized+quantitation+of+synergism+and+antagonism+of+Taxol%2C+topetecan+and+cisplatin+against+human+teratocarcinoma+cell+growth%3A+a+rational+approach+to+clinical+protocol+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design</span></div><div class="casAuthors">Chou, Ting-Chao; Motzer, Robert J.; Tong, Youzhi; Bosl, George J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1517-24</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">Cisplatin-based induction chemotherapy may achieve a complete response (i.e., no sign of tumor following treatment) in 70%-80% of patients with germ cell tumors.  However, only a minority of patients in whom the firstline regimens fail are cured with the salvage regimens.  The aim of these studies was to identify new agents or new regimens for the treatment of germ cell tumors by carrying out quant. assessment in vitro of two promising new antitumor agents (paclitaxel [Taxol] and topotecan) and three more established agents (cisplatin, vincristine, and etoposide).  These agents were used singly or in two- and three-drug combinations and were selected because they represent five distinct categories of antineoplastic mechanisms.  The combination index-isobologram method, which is based on the median-effect principle developed by Chou and Talalay, was used for computerized data anal.  This method was selected because it takes into account both the potencies of each drug and combinations of these drugs and the shapes of their dose-effect curves.  Synergism against the growth of teratocarcinoma cells resistant to cisplatin (833K/64CP10 cells) was greater than against the growth of parent 833K cells.  The degrees of synergism were in the following order: cisplatin + topotecan ≥ paclitaxel + cisplatin + topotecan > paclitaxel + topotecan ≥ paclitaxel + etoposide > paclitaxel + cisplatin + etoposide > paclitaxel + cisplatin.  All other combinations showed nearly additive effects or moderate antagonism.  The degrees of antagonism were as follows: cisplatin + etoposide ≥ paclitaxel + vincristine > paclitaxel + cisplatin + vincristine > cisplatin + vincristine.  The combination of paclitaxel and cisplatin was synergistic against 833K/64CP10 cells and moderately antagonistic against 833K cells.  Since the combination of paclitaxel, cisplatin, and topotecan and the two-component combinations of these drugs (cisplatin + topotecan and paclitaxel + topotecan) showed synergism stronger than that of other combinations, these three drugs were selected for illustrating detailed data anal., using a computer software program developed in this institute.  The authors' findings suggest that, as a result of synergy, the doses of these agents needed to achieve an antitumor effect may be reduced by two-fold to eight-fold when these agents are given in combination.  The present quant. data analyses for synergism or antagonism provide a basis for a rational design of clin. protocols for combination chemotherapy in patients with advanced germ cell tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYyr-a9pkBELVg90H21EOLACvtfcHk0liEhDpQbmdkiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFWru7w%253D&md5=faf1f3e4ba16b9869baac8c23716bf6f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F86.20.1517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F86.20.1517%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DT.-C.%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DBosl%26aufirst%3DG.%2BJ.%26atitle%3DComputerized%2520quantitation%2520of%2520synergism%2520and%2520antagonism%2520of%2520Taxol%252C%2520topetecan%2520and%2520cisplatin%2520against%2520human%2520teratocarcinoma%2520cell%2520growth%253A%2520a%2520rational%2520approach%2520to%2520clinical%2520protocol%2520design%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1994%26volume%3D86%26spage%3D1517%26epage%3D1524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1<i>H</i>-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Moreno-Farre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span> </span><span class="NLM_article-title">Analysis of potential drug−drug interactions for anticancer agents in human liver microsomes by high throughput liquid chromatography/mass spectrometry assay</span> <span class="citation_source-journal">Recent Adv. Res. Updates</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=207-224&author=J.+Moreno-Farreauthor=P.+Workmanauthor=F.+I.+Raynaud&title=Analysis+of+potential+drug%E2%88%92drug+interactions+for+anticancer+agents+in+human+liver+microsomes+by+high+throughput+liquid+chromatography%2Fmass+spectrometry+assay"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno-Farre%26aufirst%3DJ.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26atitle%3DAnalysis%2520of%2520potential%2520drug%25E2%2588%2592drug%2520interactions%2520for%2520anticancer%2520agents%2520in%2520human%2520liver%2520microsomes%2520by%2520high%2520throughput%2520liquid%2520chromatography%252Fmass%2520spectrometry%2520assay%26jtitle%3DRecent%2520Adv.%2520Res.%2520Updates%26date%3D2006%26volume%3D7%26spage%3D207%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':[],'ref26':['cit26a','cit26b'],'ref27':['cit27a','cit27b','cit27c','cit27d'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 58 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Terence C. S. Ho, Alex H. Y. Chan, <span class="NLM_string-name hlFld-ContribAuthor">A. Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12460-12484. <a href="https://doi.org/10.1021/acs.jmedchem.0c00830" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00830</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00830%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThirty%252BYears%252Bof%252BHDAC%252BInhibitors%25253A%252B2020%252BInsight%252Band%252BHindsight%26aulast%3DHo%26aufirst%3DTerence%2BC.%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15052020%26date%3D16072020%26date%3D01072020%26volume%3D63%26issue%3D21%26spage%3D12460%26epage%3D12484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexander
S. Filatov, Siqi Wang, Olesya V. Khoroshilova, Stanislav V. Lozovskiy, Anna G. Larina, Vitali M. Boitsov, <span class="NLM_string-name hlFld-ContribAuthor">Alexander V. Stepakov</span>. </span><span class="cited-content_cbyCitation_article-title">Stereo- and Regioselective 1,3-Dipolar Cycloaddition of the Stable Ninhydrin-Derived Azomethine Ylide to Cyclopropenes: Trapping of Unstable Cyclopropene Dipolarophiles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (11)
                                     , 7017-7036. <a href="https://doi.org/10.1021/acs.joc.9b00753" title="DOI URL">https://doi.org/10.1021/acs.joc.9b00753</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b00753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b00753%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereo-%252Band%252BRegioselective%252B1%25252C3-Dipolar%252BCycloaddition%252Bof%252Bthe%252BStable%252BNinhydrin-Derived%252BAzomethine%252BYlide%252Bto%252BCyclopropenes%25253A%252BTrapping%252Bof%252BUnstable%252BCyclopropene%252BDipolarophiles%26aulast%3DFilatov%26aufirst%3DAlexander%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D16032019%26date%3D22052019%26date%3D08052019%26volume%3D84%26issue%3D11%26spage%3D7017%26epage%3D7036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lauren E. Sirois, Jie Xu, Remy Angelaud, David Lao, <span class="NLM_string-name hlFld-ContribAuthor">Francis Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">Practical Synthesis of a 6-Triazolylazabicyclo[3.1.0]hexane. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (6)
                                     , 728-735. <a href="https://doi.org/10.1021/acs.oprd.8b00101" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00101%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DPractical%252BSynthesis%252Bof%252Ba%252B6-Triazolylazabicyclo%25255B3.1.0%25255Dhexane%26aulast%3DSirois%26aufirst%3DLauren%2BE.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05042018%26date%3D01062018%26volume%3D22%26issue%3D6%26spage%3D728%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atanu  Bhaumik</span> and <span class="hlFld-ContribAuthor ">Tanmaya  Pathak</span>  . </span><span class="cited-content_cbyCitation_article-title">Methyl-α-d-2-selenonyl Pent-2-enofuranoside: A Reactive Selenosugar for the Diversity Oriented Synthesis of Enantiomerically Pure Heterocycles, Carbocycles, and Isonucleosides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>80 </em>
                                    (21)
                                     , 11057-11064. <a href="https://doi.org/10.1021/acs.joc.5b01192" title="DOI URL">https://doi.org/10.1021/acs.joc.5b01192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b01192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b01192%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMethyl-%2525CE%2525B1-d-2-selenonyl%252BPent-2-enofuranoside%25253A%252BA%252BReactive%252BSelenosugar%252Bfor%252Bthe%252BDiversity%252BOriented%252BSynthesis%252Bof%252BEnantiomerically%252BPure%252BHeterocycles%25252C%252BCarbocycles%25252C%252Band%252BIsonucleosides%26aulast%3DBhaumik%26aufirst%3DAtanu%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D27052015%26date%3D28102015%26date%3D06112015%26volume%3D80%26issue%3D21%26spage%3D11057%26epage%3D11064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyang  Li</span>, <span class="hlFld-ContribAuthor ">Elizabeth S.  Inks</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Li</span>, <span class="hlFld-ContribAuthor ">Jinning  Hou</span>, <span class="hlFld-ContribAuthor ">C. James  Chou</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuqi  Jiang</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>, and <span class="hlFld-ContribAuthor ">Wenfang  Xu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (8)
                                     , 3324-3341. <a href="https://doi.org/10.1021/jm401877m" title="DOI URL">https://doi.org/10.1021/jm401877m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401877m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401877m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BFirst%252BN-Hydroxycinnamamide-Based%252BHistone%252BDeacetylase%252B1%25252F3%252BDual%252BInhibitors%252Bwith%252BPotent%252BOral%252BAntitumor%252BActivity%26aulast%3DLi%26aufirst%3DXiaoyang%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D05122013%26date%3D15042014%26date%3D24042014%26date%3D02042014%26volume%3D57%26issue%3D8%26spage%3D3324%26epage%3D3341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antonino  Lauria</span>, <span class="hlFld-ContribAuthor ">Gabriele  La Monica</span>, <span class="hlFld-ContribAuthor ">Alessia  Bono</span>, <span class="hlFld-ContribAuthor ">Annamaria  Martorana</span>. </span><span class="cited-content_cbyCitation_article-title">Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113555. <a href="https://doi.org/10.1016/j.ejmech.2021.113555" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113555</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113555%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DQuinoline%252Banticancer%252Bagents%252Bactive%252Bon%252BDNA%252Band%252BDNA-interacting%252Bproteins%25253A%252BFrom%252Bclassical%252Bto%252Bemerging%252Btherapeutic%252Btargets%26aulast%3DLauria%26aufirst%3DAntonino%26date%3D2021%26volume%3D220%26spage%3D113555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shalini</span>, <span class="hlFld-ContribAuthor ">Vipan  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 335-363. <a href="https://doi.org/10.1080/17460441.2021.1850686" title="DOI URL">https://doi.org/10.1080/17460441.2021.1850686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1850686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1850686%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DHave%252Bmolecular%252Bhybrids%252Bdelivered%252Beffective%252Banti-cancer%252Btreatments%252Band%252Bwhat%252Bshould%252Bfuture%252Bdrug%252Bdiscovery%252Bfocus%252Bon%25253F%26aulast%3DShalini%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D335%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengrui  Feng</span>, <span class="hlFld-ContribAuthor ">Daniel D.  De Carvalho</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical advances in targeting epigenetics for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">The FEBS Journal</span><span> <strong>2021,</strong> <em>158 </em><a href="https://doi.org/10.1111/febs.15750" title="DOI URL">https://doi.org/10.1111/febs.15750</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/febs.15750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffebs.15750%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FEBS%2520Journal%26atitle%3DClinical%252Badvances%252Bin%252Btargeting%252Bepigenetics%252Bfor%252Bcancer%252Btherapy%26aulast%3DFeng%26aufirst%3DShengrui%26date%3D2021%26date%3D2021%26volume%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">立园  张</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the Research of Selective Histone deacetylase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Advances in Material Chemistry</span><span> <strong>2021,</strong> <em>09 </em>
                                    (01)
                                     , 9-23. <a href="https://doi.org/10.12677/AMC.2021.91002" title="DOI URL">https://doi.org/10.12677/AMC.2021.91002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12677/AMC.2021.91002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12677%2FAMC.2021.91002%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvances%2520in%2520Material%2520Chemistry%26atitle%3DProgress%252Bin%252Bthe%252BResearch%252Bof%252BSelective%252BHistone%252Bdeacetylase%252BInhibitors%26aulast%3D%25E5%25BC%25A0%26aufirst%3D%25E7%25AB%258B%25E5%259B%25AD%26date%3D2021%26volume%3D09%26issue%3D01%26spage%3D9%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Colleen E.  Quaas</span>, <span class="hlFld-ContribAuthor ">David T.  Long</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting (de)acetylation: A Diversity of Mechanism and Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00076-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00076-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00076-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00076-1%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252B%252528de%252529acetylation%25253A%252BA%252BDiversity%252Bof%252BMechanism%252Band%252BDisease%26aulast%3DQuaas%26aufirst%3DColleen%2BE.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">I. N.  Bardasov</span>, <span class="hlFld-ContribAuthor ">A. Yu.  Alekseeva</span>, <span class="hlFld-ContribAuthor ">O. V.  Ershov</span>, <span class="hlFld-ContribAuthor ">M. A.  Mar’yasov</span>. </span><span class="cited-content_cbyCitation_article-title">Antiproliferative Activity Missing in 6-Substituted Polycarbonitrile Derivatives of 3-Azabicyclo[3.1.0]Hexane. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Chemistry Journal</span><span> <strong>2020,</strong> <em>54 </em>
                                    (8)
                                     , 781-783. <a href="https://doi.org/10.1007/s11094-020-02273-0" title="DOI URL">https://doi.org/10.1007/s11094-020-02273-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11094-020-02273-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11094-020-02273-0%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Chemistry%2520Journal%26atitle%3DAntiproliferative%252BActivity%252BMissing%252Bin%252B6-Substituted%252BPolycarbonitrile%252BDerivatives%252Bof%252B3-Azabicyclo%25255B3.1.0%25255DHexane%26aulast%3DBardasov%26aufirst%3DI.%2BN.%26date%3D2020%26date%3D2020%26volume%3D54%26issue%3D8%26spage%3D781%26epage%3D783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolei  Huang</span>, <span class="hlFld-ContribAuthor ">Minh Hieu  Nguyen</span>, <span class="hlFld-ContribAuthor ">Maoping  Pu</span>, <span class="hlFld-ContribAuthor ">Luoqiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yonggui Robin  Chi</span>, <span class="hlFld-ContribAuthor ">Yun‐Dong  Wu</span>, <span class="hlFld-ContribAuthor ">Jianrong Steve  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Reductive and Alkynylative Heck Bicyclization of Enynes to Access Conformationally Restricted Aza[3.1.0]bicycles. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (27)
                                     , 10906-10910. <a href="https://doi.org/10.1002/ange.202000859" title="DOI URL">https://doi.org/10.1002/ange.202000859</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202000859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202000859%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DAsymmetric%252BReductive%252Band%252BAlkynylative%252BHeck%252BBicyclization%252Bof%252BEnynes%252Bto%252BAccess%252BConformationally%252BRestricted%252BAza%25255B3.1.0%25255Dbicycles%26aulast%3DHuang%26aufirst%3DXiaolei%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D27%26spage%3D10906%26epage%3D10910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolei  Huang</span>, <span class="hlFld-ContribAuthor ">Minh Hieu  Nguyen</span>, <span class="hlFld-ContribAuthor ">Maoping  Pu</span>, <span class="hlFld-ContribAuthor ">Luoqiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yonggui Robin  Chi</span>, <span class="hlFld-ContribAuthor ">Yun‐Dong  Wu</span>, <span class="hlFld-ContribAuthor ">Jianrong Steve  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Reductive and Alkynylative Heck Bicyclization of Enynes to Access Conformationally Restricted Aza[3.1.0]bicycles. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (27)
                                     , 10814-10818. <a href="https://doi.org/10.1002/anie.202000859" title="DOI URL">https://doi.org/10.1002/anie.202000859</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202000859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202000859%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DAsymmetric%252BReductive%252Band%252BAlkynylative%252BHeck%252BBicyclization%252Bof%252BEnynes%252Bto%252BAccess%252BConformationally%252BRestricted%252BAza%25255B3.1.0%25255Dbicycles%26aulast%3DHuang%26aufirst%3DXiaolei%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D27%26spage%3D10814%26epage%3D10818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giorgio  Milazzo</span>, <span class="hlFld-ContribAuthor ">Daniele  Mercatelli</span>, <span class="hlFld-ContribAuthor ">Giulia  Di Muzio</span>, <span class="hlFld-ContribAuthor ">Luca  Triboli</span>, <span class="hlFld-ContribAuthor ">Piergiuseppe  De Rosa</span>, <span class="hlFld-ContribAuthor ">Giovanni  Perini</span>, <span class="hlFld-ContribAuthor ">Federico M.  Giorgi</span>. </span><span class="cited-content_cbyCitation_article-title">Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability. </span><span class="cited-content_cbyCitation_journal-name">Genes</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 556. <a href="https://doi.org/10.3390/genes11050556" title="DOI URL">https://doi.org/10.3390/genes11050556</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/genes11050556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fgenes11050556%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%26atitle%3DHistone%252BDeacetylases%252B%252528HDACs%252529%25253A%252BEvolution%25252C%252BSpecificity%25252C%252BRole%252Bin%252BTranscriptional%252BComplexes%25252C%252Band%252BPharmacological%252BActionability%26aulast%3DMilazzo%26aufirst%3DGiorgio%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D5%26spage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Talia M.  Mota</span>, <span class="hlFld-ContribAuthor ">Chase D.  McCann</span>, <span class="hlFld-ContribAuthor ">Ali  Danesh</span>, <span class="hlFld-ContribAuthor ">Szu-Han  Huang</span>, <span class="hlFld-ContribAuthor ">Dean B.  Magat</span>, <span class="hlFld-ContribAuthor ">Yanqin  Ren</span>, <span class="hlFld-ContribAuthor ">Louise  Leyre</span>, <span class="hlFld-ContribAuthor ">Tracy D.  Bui</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Rohwetter</span>, <span class="hlFld-ContribAuthor ">Colin M.  Kovacs</span>, <span class="hlFld-ContribAuthor ">Erika  Benko</span>, <span class="hlFld-ContribAuthor ">Lynsay  MacLaren</span>, <span class="hlFld-ContribAuthor ">Avery  Wimpelberg</span>, <span class="hlFld-ContribAuthor ">Christopher M.  Cannon</span>, <span class="hlFld-ContribAuthor ">W. David  Hardy</span>, <span class="hlFld-ContribAuthor ">Jeffrey T.  Safrit</span>, <span class="hlFld-ContribAuthor ">R. Brad  Jones</span>, . </span><span class="cited-content_cbyCitation_article-title">Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8
              +
              T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal. </span><span class="cited-content_cbyCitation_journal-name">Journal of Virology</span><span> <strong>2020,</strong> <em>94 </em>
                                    (9)
                                     <a href="https://doi.org/10.1128/JVI.01845-19" title="DOI URL">https://doi.org/10.1128/JVI.01845-19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/JVI.01845-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FJVI.01845-19%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Virology%26atitle%3DIntegrated%252BAssessment%252Bof%252BViral%252BTranscription%25252C%252BAntigen%252BPresentation%25252C%252Band%252BCD8%252B%25252B%252BT%252BCell%252BFunction%252BReveals%252BMultiple%252BLimitations%252Bof%252BClass%252BI-Selective%252BHistone%252BDeacetylase%252BInhibitors%252Bduring%252BHIV-1%252BLatency%252BReversal%26aulast%3DMota%26aufirst%3DTalia%2BM.%26date%3D2020%26volume%3D94%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC inhibitors in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 19-49. <a href="https://doi.org/10.1016/B978-0-12-816422-8.00002-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-816422-8.00002-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816422-8.00002-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816422-8.00002-7%26sid%3Dliteratum%253Aachs%26atitle%3DHDAC%252Binhibitors%252Bin%252Bcancer%252Btherapy%26aulast%3DGanesan%26aufirst%3DA.%26date%3D2020%26spage%3D19%26epage%3D49%26pub%3DElsevier%26atitle%3DHistone%252BModifications%252Bin%252BTherapy%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">San José-Enériz</span>, <span class="hlFld-ContribAuthor ">Gimenez-Camino</span>, <span class="hlFld-ContribAuthor ">Agirre</span>, <span class="hlFld-ContribAuthor ">Prosper</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC Inhibitors in Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (11)
                                     , 1794. <a href="https://doi.org/10.3390/cancers11111794" title="DOI URL">https://doi.org/10.3390/cancers11111794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11111794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11111794%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DHDAC%252BInhibitors%252Bin%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DSan%2BJos%25C3%25A9-En%25C3%25A9riz%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D11%26spage%3D1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anshika N.  Singh</span>, <span class="hlFld-ContribAuthor ">Neeti  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic Modulators as Potential Multi-targeted Drugs Against Hedgehog Pathway for Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">The Protein Journal</span><span> <strong>2019,</strong> <em>38 </em>
                                    (5)
                                     , 537-550. <a href="https://doi.org/10.1007/s10930-019-09832-9" title="DOI URL">https://doi.org/10.1007/s10930-019-09832-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10930-019-09832-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10930-019-09832-9%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Protein%2520Journal%26atitle%3DEpigenetic%252BModulators%252Bas%252BPotential%252BMulti-targeted%252BDrugs%252BAgainst%252BHedgehog%252BPathway%252Bfor%252BTreatment%252Bof%252BCancer%26aulast%3DSingh%26aufirst%3DAnshika%2BN.%26date%3D2019%26date%3D2019%26volume%3D38%26issue%3D5%26spage%3D537%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoxue  Chen</span>, <span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Yonglong  Zhao</span>, <span class="hlFld-ContribAuthor ">Yongjun  Li</span>, <span class="hlFld-ContribAuthor ">Bin  He</span>. </span><span class="cited-content_cbyCitation_article-title">Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (3)
                                     , 223-241. <a href="https://doi.org/10.2174/1568026619666190122144949" title="DOI URL">https://doi.org/10.2174/1568026619666190122144949</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190122144949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190122144949%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DZinc-dependent%252BDeacetylase%252B%252528HDAC%252529%252BInhibitors%252Bwith%252BDifferent%252BZinc%252BBinding%252BGroups%26aulast%3DLi%26aufirst%3DYan%26date%3D2019%26volume%3D19%26issue%3D3%26spage%3D223%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helle M. E.  Kristensen</span>, <span class="hlFld-ContribAuthor ">Andreas S.  Madsen</span>, <span class="hlFld-ContribAuthor ">Christian A.  Olsen</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of the Zinc‐Dependent Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 153-184. <a href="https://doi.org/10.1002/9783527809257.ch7" title="DOI URL">https://doi.org/10.1002/9783527809257.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527809257.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527809257.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DInhibitors%252Bof%252Bthe%252BZinc%2525E2%252580%252590Dependent%252BHistone%252BDeacetylases%26aulast%3DKristensen%26aufirst%3DHelle%2BM.%2BE.%26date%3D2019%26date%3D2019%26spage%3D153%26epage%3D184%26pub%3DWiley%26atitle%3DEpigenetic%252BDrug%252BDiscovery%26aulast%3DSippl%26aufirst%3DWolfgang%26date%3D2019%26date%3D2019%26volume%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 1-27. <a href="https://doi.org/10.1007/7355_2019_68" title="DOI URL">https://doi.org/10.1007/7355_2019_68</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2019_68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2019_68%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252Bthe%252BZinc-Dependent%252BHistone%252BDeacetylases%252B%252528HDACs%252529%252Bfor%252BDrug%252BDiscovery%26aulast%3DGanesan%26aufirst%3DA.%26date%3D2019%26date%3D2020%26spage%3D1%26epage%3D27%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DChemical%252BEpigenetics%26aulast%3DMai%26aufirst%3DAntonello%26date%3D2020%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. S.  Filatov</span>, <span class="hlFld-ContribAuthor ">N. A.  Knyazev</span>, <span class="hlFld-ContribAuthor ">M. N.  Ryazantsev</span>, <span class="hlFld-ContribAuthor ">V. V.  Suslonov</span>, <span class="hlFld-ContribAuthor ">A. G.  Larina</span>, <span class="hlFld-ContribAuthor ">A. P.  Molchanov</span>, <span class="hlFld-ContribAuthor ">R. R.  Kostikov</span>, <span class="hlFld-ContribAuthor ">V. M.  Boitsov</span>, <span class="hlFld-ContribAuthor ">A. V.  Stepakov</span>. </span><span class="cited-content_cbyCitation_article-title">A highly diastereoselective one-pot three-component 1,3-dipolar cycloaddition of cyclopropenes with azomethine ylides generated from 11
              H
              -indeno[1,2-
              b
              ]-quinoxalin-11-ones. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2018,</strong> <em>5 </em>
                                    (4)
                                     , 595-605. <a href="https://doi.org/10.1039/C7QO00888K" title="DOI URL">https://doi.org/10.1039/C7QO00888K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7QO00888K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7QO00888K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DA%252Bhighly%252Bdiastereoselective%252Bone-pot%252Bthree-component%252B1%25252C3-dipolar%252Bcycloaddition%252Bof%252Bcyclopropenes%252Bwith%252Bazomethine%252Bylides%252Bgenerated%252Bfrom%252B11%252BH%252B-indeno%25255B1%25252C2-%252Bb%252B%25255D-quinoxalin-11-ones%26aulast%3DFilatov%26aufirst%3DA.%2BS.%26date%3D2018%26date%3D2018%26volume%3D5%26issue%3D4%26spage%3D595%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengquan  Chen</span>, <span class="hlFld-ContribAuthor ">Chuanle  Zhu</span>, <span class="hlFld-ContribAuthor ">Rui  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhiming  Lin</span>, <span class="hlFld-ContribAuthor ">Wanqing  Wu</span>, <span class="hlFld-ContribAuthor ">Huanfeng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 3-azabicyclo[3.1.0]hexane derivatives via palladium-catalyzed cyclopropanation of maleimides with N-tosylhydrazones: practical and facile access to CP-866,087. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (5)
                                     , 1228-1235. <a href="https://doi.org/10.1039/C6OB02137A" title="DOI URL">https://doi.org/10.1039/C6OB02137A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6OB02137A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6OB02137A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252B3-azabicyclo%25255B3.1.0%25255Dhexane%252Bderivatives%252Bvia%252Bpalladium-catalyzed%252Bcyclopropanation%252Bof%252Bmaleimides%252Bwith%252BN-tosylhydrazones%25253A%252Bpractical%252Band%252Bfacile%252Baccess%252Bto%252BCP-866%25252C087%26aulast%3DChen%26aufirst%3DPengquan%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D5%26spage%3D1228%26epage%3D1235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yixuan  Li</span>, <span class="hlFld-ContribAuthor ">Edward  Seto</span>. </span><span class="cited-content_cbyCitation_article-title">HDACs and HDAC Inhibitors in Cancer Development and Therapy. </span><span class="cited-content_cbyCitation_journal-name">Cold Spring Harbor Perspectives in Medicine</span><span> <strong>2016,</strong> <em>6 </em>
                                    (10)
                                     , a026831. <a href="https://doi.org/10.1101/cshperspect.a026831" title="DOI URL">https://doi.org/10.1101/cshperspect.a026831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1101/cshperspect.a026831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1101%2Fcshperspect.a026831%26sid%3Dliteratum%253Aachs%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspectives%2520in%2520Medicine%26atitle%3DHDACs%252Band%252BHDAC%252BInhibitors%252Bin%252BCancer%252BDevelopment%252Band%252BTherapy%26aulast%3DLi%26aufirst%3DYixuan%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D10%26spage%3Da026831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Murat  Bingul</span>, <span class="hlFld-ContribAuthor ">Owen  Tan</span>, <span class="hlFld-ContribAuthor ">Christopher  Gardner</span>, <span class="hlFld-ContribAuthor ">Selina  Sutton</span>, <span class="hlFld-ContribAuthor ">Greg  Arndt</span>, <span class="hlFld-ContribAuthor ">Glenn  Marshall</span>, <span class="hlFld-ContribAuthor ">Belamy  Cheung</span>, <span class="hlFld-ContribAuthor ">Naresh  Kumar</span>, <span class="hlFld-ContribAuthor ">David  Black</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Characterization and Anti-Cancer Activity of Hydrazide Derivatives Incorporating a Quinoline Moiety. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (7)
                                     , 916. <a href="https://doi.org/10.3390/molecules21070916" title="DOI URL">https://doi.org/10.3390/molecules21070916</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21070916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21070916%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%25252C%252BCharacterization%252Band%252BAnti-Cancer%252BActivity%252Bof%252BHydrazide%252BDerivatives%252BIncorporating%252Ba%252BQuinoline%252BMoiety%26aulast%3DBingul%26aufirst%3DMurat%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D7%26spage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinbao  Xiang</span>, <span class="hlFld-ContribAuthor ">Crystal  Leung</span>, <span class="hlFld-ContribAuthor ">Zhuoqi  Zhang</span>, <span class="hlFld-ContribAuthor ">Cassie  Hu</span>, <span class="hlFld-ContribAuthor ">Chao  Geng</span>, <span class="hlFld-ContribAuthor ">Lili  Liu</span>, <span class="hlFld-ContribAuthor ">Lang  Yi</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Li</span>, <span class="hlFld-ContribAuthor ">James  Berenson</span>, <span class="hlFld-ContribAuthor ">Xu  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of 2-Alkylthio-4-(
              N
              -substituted sulfonamide)pyrimidine Hydroxamic Acids as Anti-myeloma Agents. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>87 </em>
                                    (3)
                                     , 472-477. <a href="https://doi.org/10.1111/cbdd.12678" title="DOI URL">https://doi.org/10.1111/cbdd.12678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12678%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252B2-Alkylthio-4-%252528%252BN%252B-substituted%252Bsulfonamide%252529pyrimidine%252BHydroxamic%252BAcids%252Bas%252BAnti-myeloma%252BAgents%26aulast%3DXiang%26aufirst%3DJinbao%26date%3D2016%26date%3D2015%26volume%3D87%26issue%3D3%26spage%3D472%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virendra  Kachhadia</span>, <span class="hlFld-ContribAuthor ">Sridharan  Rajagopal</span>, <span class="hlFld-ContribAuthor ">Thanasekaran  Ponpandian</span>, <span class="hlFld-ContribAuthor ">Radhakrishnan  Vignesh</span>, <span class="hlFld-ContribAuthor ">Karnambaram  Anandhan</span>, <span class="hlFld-ContribAuthor ">Daivasigamani  Prabhu</span>, <span class="hlFld-ContribAuthor ">Praveen  Rajendran</span>, <span class="hlFld-ContribAuthor ">Saranya  Nidhyanandan</span>, <span class="hlFld-ContribAuthor ">Anshu Mittal  Roy</span>, <span class="hlFld-ContribAuthor ">Fakrudeen Ali  Ahamed</span>, <span class="hlFld-ContribAuthor ">Narayanan  Surendran</span>, <span class="hlFld-ContribAuthor ">Sriram  Rajagopal</span>, <span class="hlFld-ContribAuthor ">Shridhar  Narayanan</span>, <span class="hlFld-ContribAuthor ">Balasubramanian  Gopalan</span>. </span><span class="cited-content_cbyCitation_article-title">Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>108 </em>, 274-286. <a href="https://doi.org/10.1016/j.ejmech.2015.11.014" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.11.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.11.014%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOrally%252Bavailable%252Bstilbene%252Bderivatives%252Bas%252Bpotent%252BHDAC%252Binhibitors%252Bwith%252Bantiproliferative%252Bactivities%252Band%252Bantitumor%252Beffects%252Bin%252Bhuman%252Btumor%252Bxenografts%26aulast%3DKachhadia%26aufirst%3DVirendra%26date%3D2016%26volume%3D108%26spage%3D274%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramakrishna  Nirogi</span>, <span class="hlFld-ContribAuthor ">Abdul Rasheed  Mohammed</span>, <span class="hlFld-ContribAuthor ">Anil K.  Shinde</span>, <span class="hlFld-ContribAuthor ">Narsimha  Bogaraju</span>, <span class="hlFld-ContribAuthor ">Shankar Reddy  Gagginapalli</span>, <span class="hlFld-ContribAuthor ">Srinivasa Rao  Ravella</span>, <span class="hlFld-ContribAuthor ">Laxman  Kota</span>, <span class="hlFld-ContribAuthor ">Gopinadh  Bhyrapuneni</span>, <span class="hlFld-ContribAuthor ">Nageswara Rao  Muddana</span>, <span class="hlFld-ContribAuthor ">Vijay  Benade</span>, <span class="hlFld-ContribAuthor ">Raghava Chowdary  Palacharla</span>, <span class="hlFld-ContribAuthor ">Pradeep  Jayarajan</span>, <span class="hlFld-ContribAuthor ">Ramkumar  Subramanian</span>, <span class="hlFld-ContribAuthor ">Vinod Kumar  Goyal</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>103 </em>, 289-301. <a href="https://doi.org/10.1016/j.ejmech.2015.08.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.08.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.08.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.08.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BSAR%252Bof%252BImidazo%25255B1%25252C5-a%25255Dpyridine%252Bderivatives%252Bas%252B5-HT4%252Breceptor%252Bpartial%252Bagonists%252Bfor%252Bthe%252Btreatment%252Bof%252Bcognitive%252Bdisorders%252Bassociated%252Bwith%252BAlzheimer%252527s%252Bdisease%26aulast%3DNirogi%26aufirst%3DRamakrishna%26date%3D2015%26volume%3D103%26spage%3D289%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Xuben  Hou</span>, <span class="hlFld-ContribAuthor ">Huansheng  Fu</span>, <span class="hlFld-ContribAuthor ">Xiaole  Pan</span>, <span class="hlFld-ContribAuthor ">Wenfang  Xu</span>, <span class="hlFld-ContribAuthor ">Weiping  Tang</span>, <span class="hlFld-ContribAuthor ">Hao  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (15)
                                     , 4364-4374. <a href="https://doi.org/10.1016/j.bmc.2015.06.024" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.06.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.06.024%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpreliminary%252Bbioactivity%252Bevaluations%252Bof%252Bsubstituted%252Bquinoline%252Bhydroxamic%252Bacid%252Bderivatives%252Bas%252Bnovel%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitors%26aulast%3DWang%26aufirst%3DLei%26date%3D2015%26volume%3D23%26issue%3D15%26spage%3D4364%26epage%3D4374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Obaid  Afzal</span>, <span class="hlFld-ContribAuthor ">Suresh  Kumar</span>, <span class="hlFld-ContribAuthor ">Md Rafi  Haider</span>, <span class="hlFld-ContribAuthor ">Md Rahmat  Ali</span>, <span class="hlFld-ContribAuthor ">Rajiv  Kumar</span>, <span class="hlFld-ContribAuthor ">Manu  Jaggi</span>, <span class="hlFld-ContribAuthor ">Sandhya  Bawa</span>. </span><span class="cited-content_cbyCitation_article-title">A review on anticancer potential of bioactive heterocycle quinoline. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>97 </em>, 871-910. <a href="https://doi.org/10.1016/j.ejmech.2014.07.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Banticancer%252Bpotential%252Bof%252Bbioactive%252Bheterocycle%252Bquinoline%26aulast%3DAfzal%26aufirst%3DObaid%26date%3D2015%26volume%3D97%26spage%3D871%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laia  Simó-Riudalbas</span>, <span class="hlFld-ContribAuthor ">Manel  Esteller</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the histone orthography of cancer: drugs for writers, erasers and readers. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2015,</strong> <em>172 </em>
                                    (11)
                                     , 2716-2732. <a href="https://doi.org/10.1111/bph.12844" title="DOI URL">https://doi.org/10.1111/bph.12844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.12844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.12844%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DTargeting%252Bthe%252Bhistone%252Borthography%252Bof%252Bcancer%25253A%252Bdrugs%252Bfor%252Bwriters%25252C%252Berasers%252Band%252Breaders%26aulast%3DSim%25C3%25B3-Riudalbas%26aufirst%3DLaia%26date%3D2015%26date%3D2014%26volume%3D172%26issue%3D11%26spage%3D2716%26epage%3D2732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erika  HÃ©ninger</span>, <span class="hlFld-ContribAuthor ">Timothy E. G.  Krueger</span>, <span class="hlFld-ContribAuthor ">Joshua M.  Lang</span>. </span><span class="cited-content_cbyCitation_article-title">Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2015,</strong> <em>6 </em><a href="https://doi.org/10.3389/fimmu.2015.00029" title="DOI URL">https://doi.org/10.3389/fimmu.2015.00029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2015.00029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2015.00029%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DAugmenting%252BAntitumor%252BImmune%252BResponses%252Bwith%252BEpigenetic%252BModifying%252BAgents%26aulast%3DH%25C3%2583%25C2%25A9ninger%26aufirst%3DErika%26date%3D2015%26date%3D2015%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yantao  Han</span>, <span class="hlFld-ContribAuthor ">Qixiao  Jiang</span>, <span class="hlFld-ContribAuthor ">Chunbo  Wang</span>, <span class="hlFld-ContribAuthor ">Xuehong  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Li</span>, <span class="hlFld-ContribAuthor ">Fuming  Xu</span>, <span class="hlFld-ContribAuthor ">Yuqi  Jiang</span>, <span class="hlFld-ContribAuthor ">Qiang  Wang</span>, <span class="hlFld-ContribAuthor ">Wenfang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2015,</strong> <em>35 </em>
                                    (1)
                                     , 63-84. <a href="https://doi.org/10.1002/med.21320" title="DOI URL">https://doi.org/10.1002/med.21320</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21320%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTrend%252Bof%252BHistone%252BDeacetylase%252BInhibitors%252Bin%252BCancer%252BTherapy%25253A%252BIsoform%252BSelectivity%252Bor%252BMultitargeted%252BStrategy%26aulast%3DZhang%26aufirst%3DLei%26date%3D2015%26date%3D2014%26volume%3D35%26issue%3D1%26spage%3D63%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">I. V.  Chestkov</span>, <span class="hlFld-ContribAuthor ">E. A.  Khomyakova</span>, <span class="hlFld-ContribAuthor ">E. A.  Vasilieva</span>, <span class="hlFld-ContribAuthor ">M. A.  Lagarkova</span>, <span class="hlFld-ContribAuthor ">S. L.  Kiselev</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular barriers to processes of genetic reprogramming and cell transformation. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry (Moscow)</span><span> <strong>2014,</strong> <em>79 </em>
                                    (12)
                                     , 1297-1307. <a href="https://doi.org/10.1134/S0006297914120037" title="DOI URL">https://doi.org/10.1134/S0006297914120037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S0006297914120037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS0006297914120037%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26atitle%3DMolecular%252Bbarriers%252Bto%252Bprocesses%252Bof%252Bgenetic%252Breprogramming%252Band%252Bcell%252Btransformation%26aulast%3DChestkov%26aufirst%3DI.%2BV.%26date%3D2014%26date%3D2014%26volume%3D79%26issue%3D12%26spage%3D1297%26epage%3D1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiwu  Yao</span>, <span class="hlFld-ContribAuthor ">Chenzhong  Liao</span>, <span class="hlFld-ContribAuthor ">Zheng  Li</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Qiao  Sun</span>, <span class="hlFld-ContribAuthor ">Chunping  Liu</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Sheng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>86 </em>, 639-652. <a href="https://doi.org/10.1016/j.ejmech.2014.09.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.09.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.09.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252B1%25252C%252B3-disubstituted-pyrazole%252Bderivatives%252Bas%252Bnew%252Bclass%252BI%252Band%252BIIb%252Bhistone%252Bdeacetylase%252Binhibitors%26aulast%3DYao%26aufirst%3DYiwu%26date%3D2014%26volume%3D86%26spage%3D639%26epage%3D652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vaishali  Patil</span>, <span class="hlFld-ContribAuthor ">Satya  Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">Oncolytic Viruses and Histone Deacetylase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 437-466. <a href="https://doi.org/10.1201/b16780-15" title="DOI URL">https://doi.org/10.1201/b16780-15</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1201/b16780-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1201%2Fb16780-15%26sid%3Dliteratum%253Aachs%26atitle%3DOncolytic%252BViruses%252Band%252BHistone%252BDeacetylase%252BInhibitors%26aulast%3DPatil%26aufirst%3DVaishali%26date%3D2014%26date%3D2014%26spage%3D437%26epage%3D466%26pub%3DCRC%2520Press%26atitle%3DCancer-Causing%252BViruses%252Band%252BTheir%252BInhibitors%26aulast%3DGupta%26aufirst%3DSatya%26date%3D2014%26date%3D2014%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergio  Valente</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (4)
                                     , 401-415. <a href="https://doi.org/10.1517/13543776.2014.877446" title="DOI URL">https://doi.org/10.1517/13543776.2014.877446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.877446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.877446%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall-molecule%252Binhibitors%252Bof%252Bhistone%252Bdeacetylase%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%252Band%252Bnon-cancer%252Bdiseases%25253A%252Ba%252Bpatent%252Breview%252B%2525282011%252B%2525E2%252580%252593%252B2013%252529%26aulast%3DValente%26aufirst%3DSergio%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D4%26spage%3D401%26epage%3D415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kristina  Keller</span>, <span class="hlFld-ContribAuthor ">Manfred  Jung</span>. </span><span class="cited-content_cbyCitation_article-title">Histone Deacetylase (HDAC) Inhibitors in Recent Clinical Trials for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 227-255. <a href="https://doi.org/10.1007/978-3-642-38404-2_10" title="DOI URL">https://doi.org/10.1007/978-3-642-38404-2_10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-642-38404-2_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-642-38404-2_10%26sid%3Dliteratum%253Aachs%26atitle%3DHistone%252BDeacetylase%252B%252528HDAC%252529%252BInhibitors%252Bin%252BRecent%252BClinical%252BTrials%252Bfor%252BCancer%252BTherapy%26aulast%3DKeller%26aufirst%3DKristina%26date%3D2014%26date%3D2013%26spage%3D227%26epage%3D255%26pub%3DSpringer%2520Berlin%2520Heidelberg%26atitle%3DEpigenetic%252BTherapy%252Bof%252BCancer%26aulast%3DL%25C3%25BCbbert%26aufirst%3DMichael%26date%3D2014%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.  Nishiwaki</span>. </span><span class="cited-content_cbyCitation_article-title">6.03 Synthesis of Nitroso, Nitro, and Related Compounds. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 100-130. <a href="https://doi.org/10.1016/B978-0-08-097742-3.00604-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-097742-3.00604-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-097742-3.00604-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-097742-3.00604-2%26sid%3Dliteratum%253Aachs%26atitle%3D6.03%252BSynthesis%252Bof%252BNitroso%25252C%252BNitro%25252C%252Band%252BRelated%252BCompounds%26aulast%3DNishiwaki%26aufirst%3DN.%26date%3D2014%26spage%3D100%26epage%3D130%26pub%3DElsevier%26atitle%3DComprehensive%252BOrganic%252BSynthesis%252BII%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shu-Yun  Huang</span>, <span class="hlFld-ContribAuthor ">Jian-Qiang  Li</span>, <span class="hlFld-ContribAuthor ">Shu-Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yang  Ning</span>, <span class="hlFld-ContribAuthor ">Li-Na  Meng</span>, <span class="hlFld-ContribAuthor ">Jin-Yuan  Li</span>, <span class="hlFld-ContribAuthor ">Ming-Biao  Luo</span>, <span class="hlFld-ContribAuthor ">Feng  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Construction and modulation of structural diversity in acylamide-MOFs. </span><span class="cited-content_cbyCitation_journal-name">CrystEngComm</span><span> <strong>2014,</strong> <em>16 </em>
                                    (25)
                                     , 5608-5618. <a href="https://doi.org/10.1039/C4CE00490F" title="DOI URL">https://doi.org/10.1039/C4CE00490F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4CE00490F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4CE00490F%26sid%3Dliteratum%253Aachs%26jtitle%3DCrystEngComm%26atitle%3DConstruction%252Band%252Bmodulation%252Bof%252Bstructural%252Bdiversity%252Bin%252Bacylamide-MOFs%26aulast%3DHuang%26aufirst%3DShu-Yun%26date%3D2014%26date%3D2014%26volume%3D16%26issue%3D25%26spage%3D5608%26epage%3D5618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuxiao  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Charles S.  Shanahan</span>, <span class="hlFld-ContribAuthor ">Xichen  Xu</span>, <span class="hlFld-ContribAuthor ">Michael P.  Doyle</span>. </span><span class="cited-content_cbyCitation_article-title">A survey of enoldiazo nucleophilicity in selective C–C bond forming reactions for the synthesis of natural product-like frameworks. </span><span class="cited-content_cbyCitation_journal-name">Org. Biomol. Chem.</span><span> <strong>2014,</strong> <em>12 </em>
                                    (28)
                                     , 5227-5234. <a href="https://doi.org/10.1039/C4OB00709C" title="DOI URL">https://doi.org/10.1039/C4OB00709C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4OB00709C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4OB00709C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26atitle%3DA%252Bsurvey%252Bof%252Benoldiazo%252Bnucleophilicity%252Bin%252Bselective%252BC%2525E2%252580%252593C%252Bbond%252Bforming%252Breactions%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bnatural%252Bproduct-like%252Bframeworks%26aulast%3DLiu%26aufirst%3DYuxiao%26date%3D2014%26date%3D2014%26volume%3D12%26issue%3D28%26spage%3D5227%26epage%3D5234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antonino  Grassadonia</span>, <span class="hlFld-ContribAuthor ">Pasquale  Cioffi</span>, <span class="hlFld-ContribAuthor ">Felice  Simiele</span>, <span class="hlFld-ContribAuthor ">Laura  Iezzi</span>, <span class="hlFld-ContribAuthor ">Marinella  Zilli</span>, <span class="hlFld-ContribAuthor ">Clara  Natoli</span>. </span><span class="cited-content_cbyCitation_article-title">Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2013,</strong> <em>5 </em>
                                    (4)
                                     , 919-942. <a href="https://doi.org/10.3390/cancers5030919" title="DOI URL">https://doi.org/10.3390/cancers5030919</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers5030919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers5030919%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DRole%252Bof%252BHydroxamate-Based%252BHistone%252BDeacetylase%252BInhibitors%252B%252528Hb-HDACIs%252529%252Bin%252Bthe%252BTreatment%252Bof%252BSolid%252BMalignancies%26aulast%3DGrassadonia%26aufirst%3DAntonino%26date%3D2013%26date%3D2013%26volume%3D5%26issue%3D4%26spage%3D919%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiao  Sun</span>, <span class="hlFld-ContribAuthor ">Yiwu  Yao</span>, <span class="hlFld-ContribAuthor ">Chunping  Liu</span>, <span class="hlFld-ContribAuthor ">Hua  Li</span>, <span class="hlFld-ContribAuthor ">Hequan  Yao</span>, <span class="hlFld-ContribAuthor ">Xiaowen  Xue</span>, <span class="hlFld-ContribAuthor ">Jinsong  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Sheng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (11)
                                     , 3295-3299. <a href="https://doi.org/10.1016/j.bmcl.2013.03.102" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.03.102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.03.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.03.102%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bhistone%252Bdeacetylase%252B1%252Binhibitors%252Bthrough%252Bclick%252Bchemistry%26aulast%3DSun%26aufirst%3DQiao%26date%3D2013%26volume%3D23%26issue%3D11%26spage%3D3295%26epage%3D3299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Thaler</span>, <span class="hlFld-ContribAuthor ">Vaishali M.  Patil</span>, <span class="hlFld-ContribAuthor ">Satya P.  Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxamic Acids as Histone Deacetylase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 99-151. <a href="https://doi.org/10.1007/978-3-642-38111-9_5" title="DOI URL">https://doi.org/10.1007/978-3-642-38111-9_5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-642-38111-9_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-642-38111-9_5%26sid%3Dliteratum%253Aachs%26atitle%3DHydroxamic%252BAcids%252Bas%252BHistone%252BDeacetylase%252BInhibitors%26aulast%3DThaler%26aufirst%3DFlorian%26date%3D2013%26date%3D2013%26spage%3D99%26epage%3D151%26pub%3DSpringer%2520Berlin%2520Heidelberg%26atitle%3DHydroxamic%252BAcids%26aulast%3DGupta%26aufirst%3DSatya%2BP.%26date%3D2013%26volume%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angela  Nebbioso</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Carafa</span>, <span class="hlFld-ContribAuthor ">Rosaria  Benedetti</span>, <span class="hlFld-ContribAuthor ">Lucia  Altucci</span>. </span><span class="cited-content_cbyCitation_article-title">Trials with ‘epigenetic’ drugs: An update. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2012,</strong> <em>6 </em>
                                    (6)
                                     , 657-682. <a href="https://doi.org/10.1016/j.molonc.2012.09.004" title="DOI URL">https://doi.org/10.1016/j.molonc.2012.09.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molonc.2012.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molonc.2012.09.004%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3DTrials%252Bwith%252B%2525E2%252580%252598epigenetic%2525E2%252580%252599%252Bdrugs%25253A%252BAn%252Bupdate%26aulast%3DNebbioso%26aufirst%3DAngela%26date%3D2012%26date%3D2012%26volume%3D6%26issue%3D6%26spage%3D657%26epage%3D682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carole  Seidel</span>, <span class="hlFld-ContribAuthor ">Cristina  Florean</span>, <span class="hlFld-ContribAuthor ">Michael  Schnekenburger</span>, <span class="hlFld-ContribAuthor ">Mario  Dicato</span>, <span class="hlFld-ContribAuthor ">Marc  Diederich</span>. </span><span class="cited-content_cbyCitation_article-title">Chromatin-modifying agents in anti-cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Biochimie</span><span> <strong>2012,</strong> <em>94 </em>
                                    (11)
                                     , 2264-2279. <a href="https://doi.org/10.1016/j.biochi.2012.05.012" title="DOI URL">https://doi.org/10.1016/j.biochi.2012.05.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biochi.2012.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biochi.2012.05.012%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimie%26atitle%3DChromatin-modifying%252Bagents%252Bin%252Banti-cancer%252Btherapy%26aulast%3DSeidel%26aufirst%3DCarole%26date%3D2012%26volume%3D94%26issue%3D11%26spage%3D2264%26epage%3D2279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhai  Li</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis of 1-aminoisoquinolines via the tandem reactions of 2-alkynylbenzaldoximes with isothiocyanates. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2012,</strong> <em>68 </em>
                                    (34)
                                     , 6843-6848. <a href="https://doi.org/10.1016/j.tet.2012.06.030" title="DOI URL">https://doi.org/10.1016/j.tet.2012.06.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2012.06.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2012.06.030%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DFacile%252Bsynthesis%252Bof%252B1-aminoisoquinolines%252Bvia%252Bthe%252Btandem%252Breactions%252Bof%252B2-alkynylbenzaldoximes%252Bwith%252Bisothiocyanates%26aulast%3DLi%26aufirst%3DWenhai%26date%3D2012%26volume%3D68%26issue%3D34%26spage%3D6843%26epage%3D6848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bissan  Al-Lazikani</span>, <span class="hlFld-ContribAuthor ">Udai  Banerji</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>. </span><span class="cited-content_cbyCitation_article-title">Combinatorial drug therapy for cancer in the post-genomic era. </span><span class="cited-content_cbyCitation_journal-name">Nature Biotechnology</span><span> <strong>2012,</strong> <em>30 </em>
                                    (7)
                                     , 679-692. <a href="https://doi.org/10.1038/nbt.2284" title="DOI URL">https://doi.org/10.1038/nbt.2284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nbt.2284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnbt.2284%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Biotechnology%26atitle%3DCombinatorial%252Bdrug%252Btherapy%252Bfor%252Bcancer%252Bin%252Bthe%252Bpost-genomic%252Bera%26aulast%3DAl-Lazikani%26aufirst%3DBissan%26date%3D2012%26date%3D2012%26volume%3D30%26issue%3D7%26spage%3D679%26epage%3D692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuhong  Xiang</span>, <span class="hlFld-ContribAuthor ">Zhaoyan  Hou</span>, <span class="hlFld-ContribAuthor ">Zhuoyong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore and QSAR Studies to Design Novel Histone Deacetylase 2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2012,</strong> <em>79 </em>
                                    (5)
                                     , 760-770. <a href="https://doi.org/10.1111/j.1747-0285.2012.01341.x" title="DOI URL">https://doi.org/10.1111/j.1747-0285.2012.01341.x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/j.1747-0285.2012.01341.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fj.1747-0285.2012.01341.x%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DPharmacophore%252Band%252BQSAR%252BStudies%252Bto%252BDesign%252BNovel%252BHistone%252BDeacetylase%252B2%252BInhibitors%26aulast%3DXiang%26aufirst%3DYuhong%26date%3D2012%26date%3D2012%26volume%3D79%26issue%3D5%26spage%3D760%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Udai  Banerji</span>, <span class="hlFld-ContribAuthor ">Leni  van Doorn</span>, <span class="hlFld-ContribAuthor ">Dionysis  Papadatos-Pastos</span>, <span class="hlFld-ContribAuthor ">Rebecca  Kristeleit</span>, <span class="hlFld-ContribAuthor ">Phillip  Debnam</span>, <span class="hlFld-ContribAuthor ">Matthew  Tall</span>, <span class="hlFld-ContribAuthor ">Adam  Stewart</span>, <span class="hlFld-ContribAuthor ">Florence  Raynaud</span>, <span class="hlFld-ContribAuthor ">Michelle Dawn  Garrett</span>, <span class="hlFld-ContribAuthor ">Martin  Toal</span>, <span class="hlFld-ContribAuthor ">Leon  Hooftman</span>, <span class="hlFld-ContribAuthor ">Johann Sebastian  De Bono</span>, <span class="hlFld-ContribAuthor ">Jaap  Verweij</span>, <span class="hlFld-ContribAuthor ">Ferry ALM  Eskens</span>. </span><span class="cited-content_cbyCitation_article-title">A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2012,</strong> <em>18 </em>
                                    (9)
                                     , 2687-2694. <a href="https://doi.org/10.1158/1078-0432.CCR-11-3165" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-11-3165</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-11-3165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-11-3165%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DA%252BPhase%252BI%252BPharmacokinetic%252Band%252BPharmacodynamic%252BStudy%252Bof%252BCHR-3996%25252C%252Ban%252BOral%252BClass%252BI%252BSelective%252BHistone%252BDeacetylase%252BInhibitor%252Bin%252BRefractory%252BSolid%252BTumors%26aulast%3DBanerji%26aufirst%3DUdai%26date%3D2012%26date%3D2012%26volume%3D18%26issue%3D9%26spage%3D2687%26epage%3D2694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nitin T.  Patil</span>, <span class="hlFld-ContribAuthor ">Vivek S.  Raut</span>, <span class="hlFld-ContribAuthor ">Valmik S.  Shinde</span>, <span class="hlFld-ContribAuthor ">Gaddamanugu  Gayatri</span>, <span class="hlFld-ContribAuthor ">G. Narahari  Sastry</span>. </span><span class="cited-content_cbyCitation_article-title">Gold(I)-Catalyzed Unprecedented Rearrangement Reaction Between 2-Aminobenzaldehydes with Propargyl Amines: An Expedient Route to 3-Aminoquinolines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2012,</strong> <em>18 </em>
                                    (18)
                                     , 5530-5535. <a href="https://doi.org/10.1002/chem.201103668" title="DOI URL">https://doi.org/10.1002/chem.201103668</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201103668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201103668%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DGold%252528I%252529-Catalyzed%252BUnprecedented%252BRearrangement%252BReaction%252BBetween%252B2-Aminobenzaldehydes%252Bwith%252BPropargyl%252BAmines%25253A%252BAn%252BExpedient%252BRoute%252Bto%252B3-Aminoquinolines%26aulast%3DPatil%26aufirst%3DNitin%2BT.%26date%3D2012%26date%3D2012%26volume%3D18%26issue%3D18%26spage%3D5530%26epage%3D5535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philip  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Development of second generation epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2012,</strong> <em>3 </em>
                                    (2)
                                     , 135-161. <a href="https://doi.org/10.1039/C1MD00199J" title="DOI URL">https://doi.org/10.1039/C1MD00199J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C1MD00199J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC1MD00199J%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDevelopment%252Bof%252Bsecond%252Bgeneration%252Bepigenetic%252Bagents%26aulast%3DJones%26aufirst%3DPhilip%26date%3D2012%26date%3D2012%26volume%3D3%26issue%3D2%26spage%3D135%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ju-Hee  Lee</span>, <span class="hlFld-ContribAuthor ">Megan L.  Choy</span>, <span class="hlFld-ContribAuthor ">Paul A.  Marks</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of Resistance to Histone Deacetylase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 39-86. <a href="https://doi.org/10.1016/B978-0-12-394387-3.00002-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-394387-3.00002-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-394387-3.00002-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-394387-3.00002-1%26sid%3Dliteratum%253Aachs%26atitle%3DMechanisms%252Bof%252BResistance%252Bto%252BHistone%252BDeacetylase%252BInhibitors%26aulast%3DLee%26aufirst%3DJu-Hee%26date%3D2012%26spage%3D39%26epage%3D86%26pub%3DElsevier%26atitle%3DHistone%252BDeacetylase%252BInhibitors%252Bas%252BCancer%252BTherapeutics%26date%3D2012%26volume%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin-Ying  Liu</span>, <span class="hlFld-ContribAuthor ">Hong-Ying  Niu</span>, <span class="hlFld-ContribAuthor ">Shan  Wu</span>, <span class="hlFld-ContribAuthor ">Gui-Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Hai-Ming  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Metal catalyzed C(sp3)–H bond amination of 2-alkyl azaarenes with diethyl azodicarboxylate. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2012,</strong> <em>48 </em>
                                    (78)
                                     , 9723. <a href="https://doi.org/10.1039/c2cc35309a" title="DOI URL">https://doi.org/10.1039/c2cc35309a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c2cc35309a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc2cc35309a%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DMetal%252Bcatalyzed%252BC%252528sp3%252529%2525E2%252580%252593H%252Bbond%252Bamination%252Bof%252B2-alkyl%252Bazaarenes%252Bwith%252Bdiethyl%252Bazodicarboxylate%26aulast%3DLiu%26aufirst%3DJin-Ying%26date%3D2012%26volume%3D48%26issue%3D78%26spage%3D9723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Beckers</span>, <span class="hlFld-ContribAuthor ">Siavosh  Mahboobi</span>, <span class="hlFld-ContribAuthor ">Andreas  Sellmer</span>, <span class="hlFld-ContribAuthor ">Matthias  Winkler</span>, <span class="hlFld-ContribAuthor ">Emerich  Eichhorn</span>, <span class="hlFld-ContribAuthor ">Herwig  Pongratz</span>, <span class="hlFld-ContribAuthor ">Thomas  Maier</span>, <span class="hlFld-ContribAuthor ">Thomas  Ciossek</span>, <span class="hlFld-ContribAuthor ">Thomas  Baer</span>, <span class="hlFld-ContribAuthor ">Gerhard  Kelter</span>, <span class="hlFld-ContribAuthor ">Heinz-Herbert  Fiebig</span>, <span class="hlFld-ContribAuthor ">Mathias  Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2012,</strong> <em>3 </em>
                                    (7)
                                     , 829. <a href="https://doi.org/10.1039/c2md00317a" title="DOI URL">https://doi.org/10.1039/c2md00317a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c2md00317a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc2md00317a%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DChimerically%252Bdesigned%252BHDAC-%252Band%252Btyrosine%252Bkinase%252Binhibitors.%252BA%252Bseries%252Bof%252Berlotinib%252Bhybrids%252Bas%252Bdual-selective%252Binhibitors%252Bof%252BEGFR%25252C%252BHER2%252Band%252Bhistone%252Bdeacetylases%26aulast%3DBeckers%26aufirst%3DThomas%26date%3D2012%26volume%3D3%26issue%3D7%26spage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melissa M.  Kemp</span>, <span class="hlFld-ContribAuthor ">Qiu  Wang</span>, <span class="hlFld-ContribAuthor ">Jason H.  Fuller</span>, <span class="hlFld-ContribAuthor ">Nathan  West</span>, <span class="hlFld-ContribAuthor ">Nicole M.  Martinez</span>, <span class="hlFld-ContribAuthor ">Elizabeth M.  Morse</span>, <span class="hlFld-ContribAuthor ">Michel  Weïwer</span>, <span class="hlFld-ContribAuthor ">Stuart L.  Schreiber</span>, <span class="hlFld-ContribAuthor ">James E.  Bradner</span>, <span class="hlFld-ContribAuthor ">Angela N.  Koehler</span>. </span><span class="cited-content_cbyCitation_article-title">A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (14)
                                     , 4164-4169. <a href="https://doi.org/10.1016/j.bmcl.2011.05.098" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.05.098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.05.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.05.098%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DA%252Bnovel%252BHDAC%252Binhibitor%252Bwith%252Ba%252Bhydroxy-pyrimidine%252Bscaffold%26aulast%3DKemp%26aufirst%3DMelissa%2BM.%26date%3D2011%26volume%3D21%26issue%3D14%26spage%3D4164%26epage%3D4169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charles M.  Marson</span>. </span><span class="cited-content_cbyCitation_article-title">New and unusual scaffolds in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2011,</strong> <em>40 </em>
                                    (11)
                                     , 5514. <a href="https://doi.org/10.1039/c1cs15119c" title="DOI URL">https://doi.org/10.1039/c1cs15119c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c1cs15119c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc1cs15119c%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DNew%252Band%252Bunusual%252Bscaffolds%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DMarson%26aufirst%3DCharles%2BM.%26date%3D2011%26volume%3D40%26issue%3D11%26spage%3D5514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuqiang  Ding</span>, <span class="hlFld-ContribAuthor ">Biao  Xiong</span>, <span class="hlFld-ContribAuthor ">Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient One-Pot Synthesis of 2-Alkylquinolines under Solvent-Free Conditions Using Sulfonic Acid Functionalized Ionic Liquid as a Recoverable and Reusable Catalyst. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2011,</strong> <em>83 </em>
                                    (10)
                                     , 2289. <a href="https://doi.org/10.3987/COM-11-12289" title="DOI URL">https://doi.org/10.3987/COM-11-12289</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-11-12289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-11-12289%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DEfficient%252BOne-Pot%252BSynthesis%252Bof%252B2-Alkylquinolines%252Bunder%252BSolvent-Free%252BConditions%252BUsing%252BSulfonic%252BAcid%252BFunctionalized%252BIonic%252BLiquid%252Bas%252Ba%252BRecoverable%252Band%252BReusable%252BCatalyst%26aulast%3DZhang%26aufirst%3DMin%26date%3D2011%26volume%3D83%26issue%3D10%26spage%3D2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. HDAC inhibitors under clinical investigation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural components of pyrimidine hydroxamate HDAC inhibitors containing hexahydropyrrolo[3,4-<i>c</i>]pyrrole (A) and azabicyclo[3,1,0]hexane (B) linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Zn powder, H<sub>2</sub>O, <i>t</i>-BuOH, THF, 85 °C, 57%. (b) <i>m</i>CPBA, THF, 0 °C, 77%. (c) BrCH<sub>2</sub>NO<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temp, 42%. (d) NaBH<sub>4</sub>, BF<sub>3</sub>·THF, 45−50 °C, 42%. (e) CH<sub>3</sub>CHClOCOCl, ClCH<sub>2</sub>CH<sub>2</sub>Cl, 55−65 °C, 25%. (f) Boc<sub>2</sub>O, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 92%. (g) 10% Pd−C, H<sub>2</sub>, EtOH, room temp, 95%. (h) SeO<sub>2</sub>, dioxane, 100 °C, 87%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Pyrimidine Hydroxamate Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) RSO<sub>2</sub>Cl, triethylamine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp. (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, room temp. (c) Ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temp. (d) NaOH, MeOH, THF, room temp. (e) <i>O</i>-(1-Isobutoxyethyl)hydroxylamine, EDC hydrochoride, HOBt, triethylamine, room temp. (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, room temp or 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp. (g) ROCl, pyridine, 0 °C. (h) 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp. (i) RCHO, NaBH<sub>4</sub>, MeOH, NaOH, room temp, 58%. (j) 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0013.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Further Pyrimidine Hydroxamate Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, EDC hydrochloride, HOBt, DMF, room temp, 90%. (b) NaH, (MeO)<sub>2</sub>SO<sub>2</sub>, THF, room temp. (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, MeOH, room temp, 3% over two steps. (d) 1-Chloroisoquinoline, 100 °C. (e) Ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, DMF, room temp. (f) NaOH, THF, H<sub>2</sub>O, room temp, 30% over three steps. (g) <i>O</i>-(1-Isobutoxyethyl)hydroxylamine, EDC hydrochloride, HOBt, triethylamine, room temp, 36%. (h) 4 M HCl in dioxane, room temp, 58%. (i) Ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate <b>2</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, DMF, room temp, 90%. (j) 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 97%. (k) 2-Naphthaldehyde, NaBH<sub>4</sub>, MeOH, room temp. (l) NaOH, THF, H<sub>2</sub>O, room temp. (m) <i>O</i>-(1-Isobutoxyethyl)hydroxylamine, EDC hydrochloride, HOBt, triethylamine, room temp, 46% over two steps. (n) 4 M HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 50%.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Proposed binding mode of <b>15a</b> with HDAC8 (cross section). The Zn<sup>2+</sup> ion is shown as a sphere and the protein as a surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pie charts showing the percentage distribution of pyrimidine hydroxamate compounds in PSA bins. Compounds are divided between those with cell-to-enzyme ratio of <20 (a) and those with cell-to-enzyme ratio of >20 (b). Compounds with PSA of 70−100 Å<sup>2</sup> are represented in bright green, 100−130 Å<sup>2</sup> in light green, 130−160 Å<sup>2</sup> in amber, and 160−190 Å<sup>2</sup> in red. Pie charts were generated with Vortex (Dotmatics Ltd., U.K.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolism of <b>21f</b> and <b>21r</b> in the mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Substrate selectivity of <b>21f</b> and <b>21r</b> in HCT116 cells. Human HCT116 colon carcinoma cells were incubated with the indicated concentrations of <b>21f</b>, <b>21r</b>, and SAHA for 30 h. Total cell lysates were prepared and analyzed by SDS−PAGE and Western blotting using antibodies to acetylated H3K9 (Abcam 1:5000 dilution) and acetylated α-tubulin (Abcam, 1:500 dilution). GAPDH was used as a loading control. Similar results were obtained using a fixed cell ELISA (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Induction of PARP cleavage by <b>21f</b> and <b>21r</b> in comparison to SAHA. Human HCT-116 colon carcinoma cells were incubated with the indicated concentrations of <b>21f</b>, <b>21r</b>, and SAHA for 30 h. Total cell lysates were prepared and analyzed by SDS−PAGE and Western blotting using antibodies to PARP and cleaved PARP (both Cell Signaling, 1:1000 dilution). GAPDH was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Efficacy of <b>21f</b> 50 mg/kg po daily and (b) histone acetylation in HCT116 tumor tissue from mice treated with <b>21f</b>. (a) Relative tumor volumes in HCT116 human tumor mouse xenograft study. Compound <b>21f</b> (50 mg/kg po in 10% DMSO-saline) was administered for 16 days to female CrTac:NCr-<i>Fox1(nu)</i> mice bearing established HCT116 colon carcinoma xenografts. (b) Histone acetylation in HCT116 tumor tissue treated with <b>21f</b> as in (a). Tumour tissue was obtained, and lysates were prepared 0.5, 1.0, and 4 h following the last dose of <b>21f</b>. The samples were analyzed using a quantitative sandwich ELISA with electrochemiluminescent end point (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Histone acetylation was also measured by Western blot using an antibody to acetylated histone H3 (Abcam) and GAPDH as loading control (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Gray bars are <b>21f</b>-treated samples. Black bars show densitometry results from the Western blot normalized to GAPDH, and white bars represent the samples from vehicle control animals. C = samples from vehicle treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (a) Relative tumor volumes in HCT116 tumor xenografts after treatment with <b>21f</b> and <b>21r</b>. Compound <b>21f</b> (75 mg/kg po) and <b>21r</b> (50 mg/kg po) were administered for 14 days to female nude BALB/c mice in 5% DMSO-saline bearing the HCT116 colon carcinoma xenograft (EpiStem Ltd.). (b) Plasma and tumor concentrations of <b>21f</b> and <b>21r</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/medium/jm-2010-01177s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Growth curves of LoVo human colon xenografts after treatment with <b>21r</b>. Relative tumor volumes in LoVo tumor xenograft study. Compound <b>21r</b> (25 and 50 mg/kg po) was administered for 19 days to female nude BALB/c mice in 5% DMSO-saline bearing the LoVo colon carcinoma xenograft (EpiStem Ltd.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm101177s/production/images/large/jm-2010-01177s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101177s&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Thiagalingam, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineva, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiagalingam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponte, J. F.</span><span> </span><span class="NLM_article-title">Histone deacetylases: unique players in shaping the epigenetic histone code</span> <span class="citation_source-journal">Ann. N.Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">983</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=983&publication_year=2003&pages=84-100&author=S+Thiagalingamauthor=K.+H.+Chengauthor=H.+J.+Leeauthor=N.+Minevaauthor=A.+Thiagalingamauthor=J.+F.+Ponte&title=Histone+deacetylases%3A+unique+players+in+shaping+the+epigenetic+histone+code"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThiagalingam%26aufirst%3DS%26aulast%3DCheng%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DMineva%26aufirst%3DN.%26aulast%3DThiagalingam%26aufirst%3DA.%26aulast%3DPonte%26aufirst%3DJ.%2BF.%26atitle%3DHistone%2520deacetylases%253A%2520unique%2520players%2520in%2520shaping%2520the%2520epigenetic%2520histone%2520code%26jtitle%3DAnn.%2520N.Y.%2520Acad.%2520Sci.%26date%3D2003%26volume%3D983%26spage%3D84%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bolden, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peart, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">Anticancer activities of histone deacetylase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+activities+of+histone+deacetylase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0liNqb6m4MzARQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520activities%2520of%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Miller, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvedere, S.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5097</span><span class="NLM_x">–</span> <span class="NLM_lpage">5116</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0303094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5097-5116&author=T.+A.+Millerauthor=D.+J.+Witterauthor=S.+Belvedere&title=Histone+deacetylase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors</span></div><div class="casAuthors">Miller, Thomas A.; Witter, David J.; Belvedere, Sandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5097-5116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the medicinal chem. and structure-activity relationships underlying advances in histone deacetylase (HDAC) class I/II inhibitor discovery, design, and optimization.  HDAC structural studies and HDAC inhibitory activity of small-mol. hydroxamic acids, carboxylates, benzamides, electrophilic ketones, and cyclic peptides are described.  Miscellaneousness and selectivity of the class I/II HDACs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU5UlOsBUF7rVg90H21EOLACvtfcHk0lg1mQGTst-SVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D&md5=d2d0a95d87d699334c1630df5deda38a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm0303094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0303094%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%2BA.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DBelvedere%26aufirst%3DS.%26atitle%3DHistone%2520deacetylase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5097%26epage%3D5116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Paris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcelloni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattori, D.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: from bench to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1505</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+deacetylase+inhibitors%3A+from+bench+to+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0lg1mQGTst-SVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520from%2520bench%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers</span> <span class="citation_source-journal">Blood Cells, Mol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">264</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1006%2Fbcmd.2000.0376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=11358386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A280%3ADC%252BD3M3ms1Wmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2001&pages=260-264&author=V.+M.+Richonauthor=X.+Zhouauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitors%3A+development+of+suberoylanilide+hydroxamic+acid+%28SAHA%29+for+the+treatment+of+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers</span></div><div class="casAuthors">Richon V M; Zhou X; Rifkind R A; Marks P A</div><div class="citationInfo"><span class="NLM_cas:title">Blood cells, molecules & diseases</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">260-4</span>
        ISSN:<span class="NLM_cas:issn">1079-9796</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnQr2wosrbMP6BottYdIAWfW6udTcc2ebVM8Bqi9kJMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3ms1Wmtw%253D%253D&md5=cc25725dc35de4d98a52115fdad0faf2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1006%2Fbcmd.2000.0376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbcmd.2000.0376%26sid%3Dliteratum%253Aachs%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520development%2520of%2520suberoylanilide%2520hydroxamic%2520acid%2520%2528SAHA%2529%2520for%2520the%2520treatment%2520of%2520cancers%26jtitle%3DBlood%2520Cells%252C%2520Mol.%2520Dis.%26date%3D2001%26volume%3D27%26spage%3D260%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Discovery and development of SAHA as an anticancer agent</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1351</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=1351-1356&author=P.+A.+Marks&title=Discovery+and+development+of+SAHA+as+an+anticancer+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520and%2520development%2520of%2520SAHA%2520as%2520an%2520anticancer%2520agent%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D1351%26epage%3D1356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lioNF8X6PzDPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1186%2F1756-8722-3-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=20132536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A280%3ADC%252BC3c7jtFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=5&author=J.+Tanauthor=S.+Cangauthor=Y.+Maauthor=R.+L.+Petrilloauthor=D.+Liu&title=Novel+histone+deacetylase+inhibitors+in+clinical+trials+as+anti-cancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents</span></div><div class="casAuthors">Tan Jiahuai; Cang Shundong; Ma Yuehua; Petrillo Richard L; Liu Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin.  Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs.  One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combination with other anti-tumor drugs in CTCL and other malignancies.  At least 80 clinical trials are underway, testing more than eleven different HDAC inhibitory agents including both hematological and solid malignancies.  This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnASThrmiLG50d-O_J5C0AfW6udTcc2eZ-B5EhGd7pQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7jtFejtg%253D%253D&md5=399a6c058fd597450221aff2648d8c0f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-3-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-3-5%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DPetrillo%26aufirst%3DR.%2BL.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DNovel%2520histone%2520deacetylase%2520inhibitors%2520in%2520clinical%2520trials%2520as%2520anti-cancer%2520agents%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">de Ruijter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gennip, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kuilenburg, A. B.</span><span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterisation of the classical HDAC family</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+de+Ruijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+van+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterisation+of+the+classical+HDAC+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRuijter%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DA.%2BB.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterisation%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Balasubramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">Isoform-specific histone deacetylase inhibitors: The next step?</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2Fj.canlet.2009.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19289255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=211-221&author=S.+Balasubramanianauthor=E.+Vernerauthor=J.+J.+Buggy&title=Isoform-specific+histone+deacetylase+inhibitors%3A+The+next+step%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-specific histone deacetylase inhibitors: The next step?</span></div><div class="casAuthors">Balasubramanian, Sriram; Verner, Erik; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) have emerged as attractive drug targets, particularly for neoplastic indications.  This large family is divided into four classes, of which three consist of zinc-dependent enzymes, and inhibitors of these are the subject of this review.  Currently, there are several inhibitors advancing through clin. trials, all of which inhibit multiple isoforms of these three classes.  While promising, these compds. have exhibited toxicities in the clinic that might limit their potential, particularly in solid tumors.  It may be possible to reduce some of the toxicity by specifically targeting only the isoform(s) involved in maintaining that particular tumor and spare other isoforms that are uninvolved or even beneficial.  This review examines the selectivity and toxicity of HDAC inhibitors currently in clinic, comparing pan-HDAC inhibitors to Class I selective compds.  The rationale for isoform-specific inhibitors is examd.  The current status of isoform-specific inhibitor development is analyzed, esp. inhibitors of HDAC1, 2, 4 and 8 enzymes, and the potential clin. utility of these compds. is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdfcwWUCyVErVg90H21EOLACvtfcHk0ljwq3CnMk2HWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt7Y%253D&md5=8f9a4437bc69f1274a889f0e85b3600a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DIsoform-specific%2520histone%2520deacetylase%2520inhibitors%253A%2520The%2520next%2520step%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D211%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Weichert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roske, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gekeler, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pross, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocken, C.</span><span> </span><span class="NLM_article-title">Association patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2FS1470-2045%2808%2970004-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=18207460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=139-148&author=W.+Weichertauthor=A.+Roskeauthor=V.+Gekelerauthor=T.+Beckersauthor=M.+P.+Ebertauthor=M.+Prossauthor=M.+Dietelauthor=C.+Denkertauthor=C.+Rocken&title=Association+patterns+of+class+I+histone+deacetylase+expression+with+patient+prognosis+in+gastric+cancer%3A+a+retrospective+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis</span></div><div class="casAuthors">Weichert, Wilko; Roeske, Annika; Gekeler, Volker; Beckers, Thomas; Ebert, Matthias PA; Pross, Matthias; Dietel, Manfred; Denkert, Carsten; Roecken, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-148</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Although histone deacetylases (HDACs) are known to have an important regulatory role in cancer cells, and HDAC inhibitors (HDIs) have entered late-phase clin. trials for the treatment of several cancers, little is known about the expression patterns of HDAC isoforms in tumors.  We aimed to clarify these expression patterns and identify potential diagnostic and prognostic uses of selected class I HDAC isoforms in gastric cancer.  Tissue samples from a training cohort and a validation cohort of patients with gastric cancer from two German institutions were used for analyses.  Tissue microarrays were generated from tumor tissue collected from patients in the training group, whereas tissue slides were used in the validation group.  The tissues were scored for expression of class I HDAC isoforms 1, 2, and 3.  Overall expression patterns (gHDAC) were grouped as being neg. (all three isoforms neg.), partially pos. (one or two isoforms pos.), or completely pos. (all isoforms pos.), and correlated with clinicopathol. parameters and patient survival.  The main endpoints were amt. of expression of each of the three HDAC isoforms, patterns of expression of gHDAC, effect of metastasis on expression of HDAC and gHDAC, and overall survival according to HDAC expression patterns.  With 2617 tissue microarray spots from 143 patients in the training cohort and 606 tissue slides from 150 patients in the validation cohort were studied. 52 of the 143 (36%) gastric tumors in the training cohort and 32 of the 150 (21%) gastric tumors in the validation cohort showed nuclear expression of all three HDAC isoforms. 60 (42%) of tumors in the training cohort and 65 (43%) in the validation cohort expressed one or two isoforms in the nuclei, whereas 31 (22%) of tumors in the training cohort and 53 (35%) in the validation cohort were scored neg. for all three proteins. gHDAC expression in both cohorts was higher when lymph-node metastases were present (p=0.0175 for the training group and p=0.0242 for the validation group).  Survival data were available for 49 patients in the training group and 123 patients in the validation group.  In the validation cohort, 3-yr survival was 44% (95% CI 34-57) in the HDAC1-neg. group, 50% (39-64) in the HDAC2-neg. group, and 48% (34-67) in the gHDAC-neg. group. 3-yr survival decreased to 21% (11-37) when HDAC1 was pos., 16% (9-31) when HDAC2 was pos., and 5% (1-31) when gHDAC (all isoforms) were pos.  Those patients highly expressing one or two isoforms (the gHDAC-intermediate group) had an estd. 3-yr survival of 40% (29-56).  In multivariate analyses, high gHDAC and HDAC2 expression were assocd. with shorter survival in the training cohort (gHDAC: hazard ratio [HR] 4.15 [1.23-13.99], p=0.0250; HDAC2: HR 3.58 [1.36-9.44], p=0.0100) and in the validation cohort (gHDAC: HR 2.18 [1.19-4.01], p=0.0433; HDAC2: HR 1.72 [1.08-2.73], p=0.0225), independent of std. clin. predictors.  High HDAC expression is significantly assocd. with nodal spread and is an independent prognostic marker for gastric cancer.  Addnl., we postulate that immunohistochem. detection of HDAC as a companion diagnostic method might predict treatment response to HDIs, thereby enabling selection of patients for this specific targeted treatment in gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS-sW_bc85KLVg90H21EOLACvtfcHk0ljwq3CnMk2HWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOnu7c%253D&md5=8be9de726d97c67924e3cd3543b94c73</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2808%2970004-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252808%252970004-4%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DW.%26aulast%3DRoske%26aufirst%3DA.%26aulast%3DGekeler%26aufirst%3DV.%26aulast%3DBeckers%26aufirst%3DT.%26aulast%3DEbert%26aufirst%3DM.%2BP.%26aulast%3DPross%26aufirst%3DM.%26aulast%3DDietel%26aufirst%3DM.%26aulast%3DDenkert%26aufirst%3DC.%26aulast%3DRocken%26aufirst%3DC.%26atitle%3DAssociation%2520patterns%2520of%2520class%2520I%2520histone%2520deacetylase%2520expression%2520with%2520patient%2520prognosis%2520in%2520gastric%2520cancer%253A%2520a%2520retrospective%2520analysis%26jtitle%3DLancet%2520Oncol.%26date%3D2008%26volume%3D9%26spage%3D139%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Angibaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncelet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Brandt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Winter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Holte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marien, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssens, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aerts, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Gompel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaurrand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queguiner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argoullon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hijfte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span> </span><span class="NLM_article-title">Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">606</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=597-606&author=P.+Angibaudauthor=J.+Artsauthor=K.+Van+Emelenauthor=V.+Ponceletauthor=I.+Pilatteauthor=B.+Rouxauthor=S.+Van+Brandtauthor=M.+Verdonckauthor=H.+De+Winterauthor=P.+Ten+Holteauthor=A.+Marienauthor=W.+Florenauthor=B.+Janssensauthor=J.+Van+Dunauthor=A.+Aertsauthor=J.+Van+Gompelauthor=S.+Gaurrandauthor=L.+Queguinerauthor=J.+M.+Argoullonauthor=L.+Van+Hijfteauthor=E.+Freyneauthor=M.+Janicot&title=Discovery+of+pyrimidyl-5-hydroxamic+acids+as+new+potent+histone+deacetylase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DPoncelet%26aufirst%3DV.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DVan%2BBrandt%26aufirst%3DS.%26aulast%3DVerdonck%26aufirst%3DM.%26aulast%3DDe%2BWinter%26aufirst%3DH.%26aulast%3DTen%2BHolte%26aufirst%3DP.%26aulast%3DMarien%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DJanssens%26aufirst%3DB.%26aulast%3DVan%2BDun%26aufirst%3DJ.%26aulast%3DAerts%26aufirst%3DA.%26aulast%3DVan%2BGompel%26aufirst%3DJ.%26aulast%3DGaurrand%26aufirst%3DS.%26aulast%3DQueguiner%26aufirst%3DL.%26aulast%3DArgoullon%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BHijfte%26aufirst%3DL.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DJanicot%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520pyrimidyl-5-hydroxamic%2520acids%2520as%2520new%2520potent%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2005%26volume%3D40%26spage%3D597%26epage%3D606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angibaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssens, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geerts, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Emelen, K.</span><span> </span><span class="NLM_article-title">R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum anti-tumoural activity against solid and haematological malignancies</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1344</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1038%2Fsj.bjc.6604025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=18000499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=1344-1353&author=J.+Artsauthor=P.+Angibaudauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=B.+Janssensauthor=P.+Kingauthor=J.+van+Dunauthor=L.+Janssenauthor=T.+Geertsauthor=R.+W.+Tumanauthor=D.+L.+Johnsonauthor=L.+Andriesauthor=M.+Jungauthor=M.+Janicotauthor=K.+van+Emelen&title=R306465+is+a+novel+potent+inhibitor+of+class+I+histone+deacetylases+with+broad-spectrum+anti-tumoural+activity+against+solid+and+haematological+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and hematological malignancies</span></div><div class="casAuthors">Arts, J.; Angibaud, P.; Marien, A.; Floren, W.; Janssens, B.; King, P.; van Dun, J.; Janssen, L.; Geerts, T.; Tuman, R. W.; Johnson, D. L.; Andries, L.; Jung, M.; Janicot, M.; van Emelen, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1344-1353</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">R306465 is a novel hydroxamate-based histone deacetylase (HDAC) inhibitor with broad-spectrum antitumor activity against solid and haematol. malignancies in preclin. models.  R306465 was found to be a potent inhibitor of HDAC1 and -8 (class I) in vitro.  It rapidly induced histone 3 (H3) acetylation and strongly upregulated expression of p21waf1,cip1, a downstream component of HDAC1 signalling, in A2780 ovarian carcinoma cells.  R306465 showed class I HDAC isotype selectivity as evidenced by poor inhibition of HDAC6 (class IIb) confirmed by the absence of downregulation of Hsp90 chaperone c-raf protein expression and tubulin acetylation.  This distinguished it from other HDAC inhibitors currently in clin. development that were either more potent towards HDAC6 (e.g. vorinostat) or had a broader HDAC inhibition spectrum (e.g. panobinostat).  R306465 potently inhibited cell proliferation of all main solid tumor indications, including ovarian, lung, colon, breast and prostate cancer cell lines, with IC50 values ranging from 30 to 300 n.  Haematol. cell lines, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphoblastic leukemia, chronic myeloid leukemia, lymphoma and myeloma, were potently inhibited at a similar concn. range.  R306465 induced apoptosis and inhibited angiogenesis in cell-based assays and had potent oral in vivo antitumoral activity in xenograft models.  Once-daily oral administration of R306465 at well-tolerated doses inhibited the growth of A2780 ovarian, H460 lung and HCT116 colon carcinomas in immunodeficient mice.  The high activity of R306465 in cell-based assays and in vivo after oral administration makes R306465 a promising novel antitumoral agent with potential applicability in a broad spectrum of human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZf5Lr-OdBOrVg90H21EOLACvtfcHk0lh8uhHtGY8_LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yku7fJ&md5=f073a66b403e486a17d8b5478196f193</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604025%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DJanssens%26aufirst%3DB.%26aulast%3DKing%26aufirst%3DP.%26aulast%3Dvan%2BDun%26aufirst%3DJ.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DGeerts%26aufirst%3DT.%26aulast%3DTuman%26aufirst%3DR.%2BW.%26aulast%3DJohnson%26aufirst%3DD.%2BL.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3Dvan%2BEmelen%26aufirst%3DK.%26atitle%3DR306465%2520is%2520a%2520novel%2520potent%2520inhibitor%2520of%2520class%2520I%2520histone%2520deacetylases%2520with%2520broad-spectrum%2520anti-tumoural%2520activity%2520against%2520solid%2520and%2520haematological%2520malignancies%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D97%26spage%3D1344%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beliën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decrane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vreys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talloen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goris, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Jardin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angibaud, P.</span><span> </span><span class="NLM_article-title">JNJ-26481585, a novel “second-generation” oral histone deacetylase inhibitor, shows broad-spectrum preclinical anti-tumoural activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6841</span><span class="NLM_x">–</span> <span class="NLM_lpage">6851</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1158%2F1078-0432.CCR-09-0547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19861438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6841-6851&author=J.+Artsauthor=P.+Kingauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=A.+Beli%C3%ABnauthor=L.+Janssenauthor=I.+Pilatteauthor=B.+Rouxauthor=L.+Decraneauthor=R.+Gilissenauthor=I.+Hicksonauthor=V.+Vreysauthor=E.+Coxauthor=K.+Bolauthor=W.+Talloenauthor=I.+Gorisauthor=L.+Andriesauthor=M.+Du+Jardinauthor=M.+Janicotauthor=M.+Pageauthor=K.+van+Emelenauthor=P.+Angibaud&title=JNJ-26481585%2C+a+novel+%E2%80%9Csecond-generation%E2%80%9D+oral+histone+deacetylase+inhibitor%2C+shows+broad-spectrum+preclinical+anti-tumoural+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span></div><div class="casAuthors">Arts, Janine; King, Peter; Marien, Ann; Floren, Wim; Belien, Ann; Janssen, Lut; Pilatte, Isabelle; Roux, Bruno; Decrane, Laurence; Gilissen, Ron; Hickson, Ian; Vreys, Veronique; Cox, Eugene; Bol, Kees; Talloen, Willem; Goris, Ilse; Andries, Luc; Du Jardin, Marc; Janicot, Michel; Page, Martin; van Emelen, Kristof; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6841-6851</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase (HDAC) inhibitors have shown promising clin. activity in the treatment of hematol. malignancies, but their activity in solid tumor indications has been limited.  Most HDAC inhibitors in clin. development only transiently induce histone acetylation in tumor tissue.  Here, we sought to identify a "second-generation" class I HDAC inhibitor with prolonged pharmacodynamic response in vivo, to assess whether this results in superior antitumoral efficacy.  Exptl. Design: To identify novel HDAC inhibitors with superior pharmacodynamic properties, we developed a preclin. in vivo tumor model, in which tumor cells have been engineered to express fluorescent protein dependent on HDAC1 inhibition, thereby allowing noninvasive real-time evaluation of the tumor response to HDAC inhibitors.  Results: In vivo pharmacodynamic anal. of 140 potent pyrimidyl-hydroxamic acid analogs resulted in the identification of JNJ-26481585.  Once daily oral administration of JNJ-26481585 induced continuous histone H3 acetylation.  The prolonged pharmacodynamic response translated into complete tumor growth inhibition in Ras mutant HCT116 colon carcinoma xenografts, whereas 5-fluorouracil was less active.  JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity.  Further characterization revealed that JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC50, 0.16 nmol/L).  Conclusions: The potent antitumor activity as a single agent in preclin. models combined with its favorable pharmacodynamic profile makes JNJ-26481585 a promising "second-generation" HDAC inhibitor.  The compd. is currently in clin. studies, to evaluate its potential applicability in a broad spectrum of both solid and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKc9hyMiADZrVg90H21EOLACvtfcHk0lg2PA6xNqAy6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE&md5=8f199c25c92c967a76f273d879d6c577</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0547%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DBeli%25C3%25ABn%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DVreys%26aufirst%3DV.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DBol%26aufirst%3DK.%26aulast%3DTalloen%26aufirst%3DW.%26aulast%3DGoris%26aufirst%3DI.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DM.%26aulast%3Dvan%2BEmelen%26aufirst%3DK.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DJNJ-26481585%252C%2520a%2520novel%2520%25E2%2580%259Csecond-generation%25E2%2580%259D%2520oral%2520histone%2520deacetylase%2520inhibitor%252C%2520shows%2520broad-spectrum%2520preclinical%2520anti-tumoural%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6841%26epage%3D6851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Moffat, D. F. C.; Patel, S. R.; Mazzei, F. A.; Belfield, A. J.; Van Meurs, S.</span><span> </span><span class="NLM_article-title">Preparation of Hydroxamic Acids as Histone Deacetylase Inhibitors for Use against Proliferative Diseases Including Cancers</span>. WO 06123121,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+F.+C.+Moffat&author=S.+R.+Patel&author=F.+A.+Mazzei&author=A.+J.+Belfield&author=S.+Van+Meurs&title=Preparation+of+Hydroxamic+Acids+as+Histone+Deacetylase+Inhibitors+for+Use+against+Proliferative+Diseases+Including+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DD.%2BF.%2BC.%26atitle%3DPreparation%2520of%2520Hydroxamic%2520Acids%2520as%2520Histone%2520Deacetylase%2520Inhibitors%2520for%2520Use%2520against%2520Proliferative%2520Diseases%2520Including%2520Cancers%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Angibaud., P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decrane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Brandt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Holte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncelet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speybrouck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queguiner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaurrand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gompel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Jardin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noppe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hijfte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arts, J.</span><span> </span><span class="NLM_article-title">Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=294-298&author=P.+Angibaud.author=K.+Van+Emelenauthor=L.+Decraneauthor=S.+van+Brandtauthor=P.+Ten+Holteauthor=I.+Pilatteauthor=B.+Rouxauthor=V.+Ponceletauthor=D.+Speybrouckauthor=L.+Queguinerauthor=S.+Gaurrandauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=L.+Janssenauthor=M.+Verdonckauthor=J.+van+Dunauthor=J.+van+Gompelauthor=R.+Gilissenauthor=C.+Mackieauthor=M.+Du+Jardinauthor=J.+Peetersauthor=M.+Noppeauthor=L.+Van+Hijfteauthor=E.+Freyneauthor=M.+Pageauthor=M.+Janicotauthor=J.+Arts&title=Identification+of+a+series+of+substituted+2-piperazinyl-5-pyrimidylhydroxamic+acids+as+potent+histone+deacetylase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAngibaud.%26aufirst%3DP.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3Dvan%2BBrandt%26aufirst%3DS.%26aulast%3DTen%2BHolte%26aufirst%3DP.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DPoncelet%26aufirst%3DV.%26aulast%3DSpeybrouck%26aufirst%3DD.%26aulast%3DQueguiner%26aufirst%3DL.%26aulast%3DGaurrand%26aufirst%3DS.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DVerdonck%26aufirst%3DM.%26aulast%3Dvan%2BDun%26aufirst%3DJ.%26aulast%3Dvan%2BGompel%26aufirst%3DJ.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DPeeters%26aufirst%3DJ.%26aulast%3DNoppe%26aufirst%3DM.%26aulast%3DVan%2BHijfte%26aufirst%3DL.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DArts%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520a%2520series%2520of%2520substituted%25202-piperazinyl-5-pyrimidylhydroxamic%2520acids%2520as%2520potent%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D294%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Vannini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filocamo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavola, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brumetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzoni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, S.</span><span> </span><span class="NLM_article-title">Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">15064</span><span class="NLM_x">–</span> <span class="NLM_lpage">15069</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1073%2Fpnas.0404603101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=15477595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVShurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=15064-15069&author=A.+Vanniniauthor=C.+Volpariauthor=G.+Filocamoauthor=E.+C.+Casavolaauthor=M.+Brumettiauthor=D.+Renzoniauthor=P.+Chakravartyauthor=C.+Paoliniauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=S.+Di+Marco&title=Crystal+structure+of+a+eukaryotic+zinc-dependent+histone+deacetylase%2C+human+HDAC8%2C+complexed+with+a+hydroxamic+acid+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor</span></div><div class="casAuthors">Vannini, Alessandro; Volpari, Cinzia; Filocamo, Gessica; Casavola, Elena Caroli; Brunetti, Mirko; Renzoni, Debora; Chakravarty, Prasun; Paolini, Chantal; De Francesco, Raffaele; Gallinari, Paola; Steinkuehler, Christian; Di Marco, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">15064-15069</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of enzymes involved in the regulation of gene expression, DNA repair, and stress response.  These processes often are altered in tumors, and HDAC inhibitors have had pronounced antitumor activity with promising results in clin. trials.  Here, we report the crystal structure of human HDAC8 in complex with a hydroxamic acid inhibitor.  Such a structure of a eukaryotic zinc-dependent HDAC has not be described previously.  Similar to bacterial HDAC-like protein, HDAC8 folds in a single α/β domain.  The inhibitor and the zinc-binding sites are similar in both proteins.  However, significant differences are obsd. in the length and structure of the loops surrounding the active site, including the presence of two potassium ions in HDAC8 structure, one of which interacts with key catalytic residues.  CD data suggest a direct role of potassium in the fold stabilization of HDAC8.  Knockdown of HDAC8 by RNA interference inhibits growth of human lung, colon, and cervical cancer cell lines, highlighting the importance of this HDAC subtype for tumor cell proliferation.  Our findings open the way for the design and development of selective inhibitors of HDAC8 as possible antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs_auq2Wf8RLVg90H21EOLACvtfcHk0lj4fe_lfLuR4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVShurY%253D&md5=86bf33830743d2169514f686b7a30ed8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0404603101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0404603101%26sid%3Dliteratum%253Aachs%26aulast%3DVannini%26aufirst%3DA.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DFilocamo%26aufirst%3DG.%26aulast%3DCasavola%26aufirst%3DE.%2BC.%26aulast%3DBrumetti%26aufirst%3DM.%26aulast%3DRenzoni%26aufirst%3DD.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DPaolini%26aufirst%3DC.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520a%2520eukaryotic%2520zinc-dependent%2520histone%2520deacetylase%252C%2520human%2520HDAC8%252C%2520complexed%2520with%2520a%2520hydroxamic%2520acid%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D15064%26epage%3D15069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Donald, A. D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wibata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stimson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Needham, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, D. F.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6657</span><span class="NLM_x">–</span> <span class="NLM_lpage">6660</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6657-6660&author=A.+D.+G.+Donaldauthor=V.+L.+Clarkauthor=S.+Patelauthor=F.+A.+Dayauthor=M.+G.+Rowlandsauthor=J.+Wibataauthor=L.+Stimsonauthor=S.+A.+Ecclesauthor=L.+A.+Needhamauthor=F.+I.+Raynaudauthor=W.+Aherneauthor=D.+F.+Moffat&title=Design+and+synthesis+of+novel+pyrimidine+hydroxamic+acid+inhibitors+of+histone+deacetylases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDonald%26aufirst%3DA.%2BD.%2BG.%26aulast%3DClark%26aufirst%3DV.%2BL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DDay%26aufirst%3DF.%2BA.%26aulast%3DRowlands%26aufirst%3DM.%2BG.%26aulast%3DWibata%26aufirst%3DJ.%26aulast%3DStimson%26aufirst%3DL.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DNeedham%26aufirst%3DL.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DMoffat%26aufirst%3DD.%2BF.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520pyrimidine%2520hydroxamic%2520acid%2520inhibitors%2520of%2520histone%2520deacetylases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6657%26epage%3D6660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Norris, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braish, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vries, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massett, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santafianos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sklavounos, C.</span><span> </span><span class="NLM_article-title">Synthesis of trovafloxacin using various (1α,5α,6α)-3-azabicyclo[3,1,0]hexane derivatives</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_fpage">1615</span><span class="NLM_x">–</span> <span class="NLM_lpage">1622</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=1615-1622&author=T.+Norrisauthor=T.+F.+Braishauthor=M.+Buttersauthor=K.+M.+De+Vriesauthor=J.+M.+Hawkinsauthor=S.+S.+Massettauthor=P.+R.+Roseauthor=D.+Santafianosauthor=C.+Sklavounos&title=Synthesis+of+trovafloxacin+using+various+%281%CE%B1%2C5%CE%B1%2C6%CE%B1%29-3-azabicyclo%5B3%2C1%2C0%5Dhexane+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNorris%26aufirst%3DT.%26aulast%3DBraish%26aufirst%3DT.%2BF.%26aulast%3DButters%26aufirst%3DM.%26aulast%3DDe%2BVries%26aufirst%3DK.%2BM.%26aulast%3DHawkins%26aufirst%3DJ.%2BM.%26aulast%3DMassett%26aufirst%3DS.%2BS.%26aulast%3DRose%26aufirst%3DP.%2BR.%26aulast%3DSantafianos%26aufirst%3DD.%26aulast%3DSklavounos%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520trovafloxacin%2520using%2520various%2520%25281%25CE%25B1%252C5%25CE%25B1%252C6%25CE%25B1%2529-3-azabicyclo%255B3%252C1%252C0%255Dhexane%2520derivatives%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D2000%26spage%3D1615%26epage%3D1622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Brighty, K. E.</span><span> </span><span class="NLM_article-title">Azabicycloquinoline Carboxylic Acids</span>. WO 9102526,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=K.+E.+Brighty&title=Azabicycloquinoline+Carboxylic+Acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrighty%26aufirst%3DK.%2BE.%26atitle%3DAzabicycloquinoline%2520Carboxylic%2520Acids%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Pratt, L. M.; Keavey, K. N.; Pain, G. D.; Mounier, L. F.</span><span> </span><span class="NLM_article-title">Preparation of Hydroxamic and <i>N</i>-Formyl Hydroxylamine Derivatives as Antibacterial Agents</span>. WO 01010834,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=L.+M.+Pratt&author=K.+N.+Keavey&author=G.+D.+Pain&author=L.+F.+Mounier&title=Preparation+of+Hydroxamic+and+N-Formyl+Hydroxylamine+Derivatives+as+Antibacterial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPratt%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520Hydroxamic%2520and%2520N-Formyl%2520Hydroxylamine%2520Derivatives%2520as%2520Antibacterial%2520Agents%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Renslo, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaishankar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatachalam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackbarth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordeev, M. F.</span><span> </span><span class="NLM_article-title">Conformational constraint in oxazolidinone antibacterials. Synthesis and structure−activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5009</span><span class="NLM_x">–</span> <span class="NLM_lpage">5024</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058204j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5009-5024&author=A.+R.+Rensloauthor=P.+Jaishankarauthor=R.+Venkatachalamauthor=C.+Hackbarthauthor=S.+Lopezauthor=D.+V.+Patelauthor=M.+F.+Gordeev&title=Conformational+constraint+in+oxazolidinone+antibacterials.+Synthesis+and+structure%E2%88%92activity+studies+of+%28azabicyclo%5B3.1.0%5Dhexylphenyl%29oxazolidinones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm058204j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058204j%26sid%3Dliteratum%253Aachs%26aulast%3DRenslo%26aufirst%3DA.%2BR.%26aulast%3DJaishankar%26aufirst%3DP.%26aulast%3DVenkatachalam%26aufirst%3DR.%26aulast%3DHackbarth%26aufirst%3DC.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DD.%2BV.%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26atitle%3DConformational%2520constraint%2520in%2520oxazolidinone%2520antibacterials.%2520Synthesis%2520and%2520structure%25E2%2588%2592activity%2520studies%2520of%2520%2528azabicyclo%255B3.1.0%255Dhexylphenyl%2529oxazolidinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5009%26epage%3D5024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Kerns, E. H.; Di, L.</span><span> </span><span class="NLM_article-title">Drug-like Properties: Concepts, Structure Design and Methods</span>; <span class="NLM_publisher-name">Academic Press, Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">228</span>− <span class="NLM_lpage">241</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2FB978-012369520-8.50020-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kerns%2C+E.+H.%3B+Di%2C+L.+Drug-like+Properties%3A+Concepts%2C+Structure+Design+and+Methods%3B+Academic+Press%2C+Elsevier%3A+Amsterdam%2C+2008%3B+pp+228%E2%88%92241."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FB978-012369520-8.50020-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-012369520-8.50020-6%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DDrug-like%2520Properties%253A%2520Concepts%252C%2520Structure%2520Design%2520and%2520Methods%26pub%3DAcademic%2520Press%252C%2520Elsevier%26date%3D2008%26spage%3D228%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mol, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynands, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knuth, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tari, L. W.</span><span> </span><span class="NLM_article-title">Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1325</span><span class="NLM_x">–</span> <span class="NLM_lpage">1334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2Fj.str.2004.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=15242608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFyrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=1325-1334&author=J.+R.+Somozaauthor=R.+J.+Skeneauthor=B.+A.+Katzauthor=C.+Molauthor=J.+D.+Hoauthor=A.+J.+Jenningsauthor=C.+Luongauthor=A.+Arvaiauthor=J.+J.+Buggyauthor=E.+Chiauthor=J.+Tangauthor=B.+C.+Sangauthor=E.+Vernerauthor=R.+Wynandsauthor=E.+M.+Leahyauthor=D.+R.+Douganauthor=G.+Snellauthor=M.+Navreauthor=M.+W.+Knuthauthor=R.+V.+Swansonauthor=D.+E.+McReeauthor=L.+W.+Tari&title=Structural+snapshots+of+human+HDAC8+provide+insights+into+the+class+I+histone+deacetylases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases</span></div><div class="casAuthors">Somoza, John R.; Skene, Robert J.; Katz, Bradley A.; Mol, Clifford; Ho, Joseph D.; Jennings, Andy J.; Luong, Christine; Arvai, Andrew; Buggy, Joseph J.; Chi, Ellen; Tang, Jie; Sang, Bi-Ching; Verner, Erik; Wynands, Robert; Leahy, Ellen M.; Dougan, Douglas R.; Snell, Gyorgy; Navre, Marc; Knuth, Mark W.; Swanson, Ronald V.; McRee, Duncan E.; Tari, Leslie W.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1325-1334</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Modulation of the acetylation state of histones plays a pivotal role in the regulation of gene expression.  Histone deacetylases (HDACs) catalyze the removal of acetyl groups from lysines near the N termini of histones.  This reaction promotes the condensation of chromatin, leading to repression of transcription.  HDAC deregulation has been linked to several types of cancer, suggesting a potential use for HDAC inhibitors in oncol.  Here we describe the first crystal structures of a human HDAC: the structures of human HDAC8 complexed with four structurally diverse hydroxamate inhibitors.  This work sheds light on the catalytic mechanism of the HDACs, and on differences in substrate specificity across the HDAC family.  The structure also suggests how phosphorylation of Ser39 affects HDAC8 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPLrZup76hGLVg90H21EOLACvtfcHk0liedcf9MNdVWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFyrsLc%253D&md5=3f1842802bac2543509a25f5ddbea5f6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DMol%26aufirst%3DC.%26aulast%3DHo%26aufirst%3DJ.%2BD.%26aulast%3DJennings%26aufirst%3DA.%2BJ.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DArvai%26aufirst%3DA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChi%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DWynands%26aufirst%3DR.%26aulast%3DLeahy%26aufirst%3DE.%2BM.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DKnuth%26aufirst%3DM.%2BW.%26aulast%3DSwanson%26aufirst%3DR.%2BV.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26aulast%3DTari%26aufirst%3DL.%2BW.%26atitle%3DStructural%2520snapshots%2520of%2520human%2520HDAC8%2520provide%2520insights%2520into%2520the%2520class%2520I%2520histone%2520deacetylases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D1325%26epage%3D1334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">Equilibrium solubility was measured by resuspension of amorphous compound at 200 μg/mL in either 100% DMSO or 100% phosphate buffer at pH 5.5 and 7.4. Phosphate buffered samples were mixed for 24 h at room temperature using a PTFE magnetic stirrer bar. DMSO samples were mixed for 24 h at room temperature on an orbital shaker. Calibration lines were prepared using the 200 μg/mL DMSO stock which was diluted with DMSO to final concentrations of 100, 50, 25, 10, and 1 μg/mL. Two 250 μL aliquots of the phosphate buffered samples were removed and filtered using a Multiscreen HTS solubility filter plate (Millipore). Filtrate was analyzed in tandem with calibration samples by LC−UV and LC−MS/MS. Quantification of test compound solubility was by extrapolation from calibration lines.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_contrib-group">Shabason, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofilon, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camphausen, K.</span><span> </span><span class="NLM_article-title">HDAC inhibitors in cancer care</span> <span class="citation_source-journal">Oncology (Williston Park)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=20361469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A280%3ADC%252BC3c3jtlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=180-185&author=J.+E.+Shabasonauthor=P.+J.+Tofilonauthor=K.+Camphausen&title=HDAC+inhibitors+in+cancer+care"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors in cancer care</span></div><div class="casAuthors">Shabason Jacob E; Tofilon Philip J; Camphausen Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-5</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">The epigenetic control of gene expression has been shown to play an important role in cancer initiation, progression, and resistance.  Thus, agents that modify the epigenetic environment of tumors will likely be an important addition to the anticancer arsenal.  Specifically, there is much interest in modulating histone acetylation using a new class of drugs, histone deacetylase (HDAC) inhibitors.  Preclinical data have demonstrated the efficacy of various HDAC inhibitors as anticancer agents, with the greatest effects shown when HDAC inhibitors are used in combination with other therapies.  As a result of encouraging preclinical data, numerous HDAC inhibitors are being investigated in clinical trials either as monotherapies or in conjunction with other treatments such as chemotherapy, biologic therapy, or radiation therapy.  In fact, vorinostat and depsipeptide, two actively studied HDAC inhibitors, were recently approved for the treatment of refractory cutaneous T-cell lymphoma.  Although the use of HDAC inhibitors has generated great enthusiasm, a significant amount of work still needs to be done in order to understand their mechanisms of action, as well as to determine the appropriate patient characteristics and subsets of cancer for which HDAC inhibitors hold the most potential for effective treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnp5mHHevMSXELvajU9pjPfW6udTcc2eZPyOSpV_vB5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3jtlGkug%253D%253D&md5=d9b04c5ce177d55e9f2cea3a60640821</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShabason%26aufirst%3DJ.%2BE.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26aulast%3DCamphausen%26aufirst%3DK.%26atitle%3DHDAC%2520inhibitors%2520in%2520cancer%2520care%26jtitle%3DOncology%2520%2528Williston%2520Park%2529%26date%3D2010%26volume%3D24%26spage%3D180%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezzeldin, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diasio, R. B.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: current status and overview of recent clinical trials</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1911-1934&author=X.+Maauthor=H.+H.+Ezzeldinauthor=R.+B.+Diasio&title=Histone+deacetylase+inhibitors%3A+current+status+and+overview+of+recent+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DEzzeldin%26aufirst%3DH.%2BH.%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520current%2520status%2520and%2520overview%2520of%2520recent%2520clinical%2520trials%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1911%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_contrib-group">Bots, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">Rational combinations using HDAC inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3970</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1158%2F1078-0432.CCR-08-2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19509171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlOis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3970-3977&author=M.+Botsauthor=R.+W.+Johnstone&title=Rational+combinations+using+HDAC+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Combinations Using HDAC Inhibitors</span></div><div class="casAuthors">Bots, Michael; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3970-3977</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  In addn. to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis.  As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as anticancer drugs.  In numerous in vitro and preclin. settings, these compds. have shown their vast potential as single agent anticancer therapies, but unfortunately equiv. responses have not always been obsd. in patients.  Given the pleiotropic effects HDACi have on malignant cells, their true therapeutic potential most likely lies in combination with other anticancer drugs.  In this review we will focus on the anticancer effects of HDACi when combined with other cancer therapeutics with an emphasis on those combinations based on a strong mol. rationale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLnwCXjHtPbVg90H21EOLACvtfcHk0lj9ZHChSzeTjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlOis7w%253D&md5=117c52a204aa45615eb04c8600e51c10</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2786%26sid%3Dliteratum%253Aachs%26aulast%3DBots%26aufirst%3DM.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DRational%2520combinations%2520using%2520HDAC%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3970%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_contrib-group">Campbell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalitin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berenson, J. R.</span><span> </span><span class="NLM_article-title">Vorinostat enhances the antimyeloma effects of melphalan and bortezomib</span> <span class="citation_source-journal">Eur. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1111%2Fj.1600-0609.2009.01384.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19929977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlGmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=201-211&author=R.+A.+Campbellauthor=E.+Sanchezauthor=J.+Steinbergauthor=D.+Shalitinauthor=Z.+W.+Liauthor=H.+Chenauthor=J.+R.+Berenson&title=Vorinostat+enhances+the+antimyeloma+effects+of+melphalan+and+bortezomib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat enhances the antimyeloma effects of melphalan and bortezomib</span></div><div class="casAuthors">Campbell, Richard A.; Sanchez, Eric; Steinberg, Jeffrey; Shalitin, Dror; Li, Zhi-Wei; Chen, Haiming; Berenson, James R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-211</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives: Examine the antitumor activity of the histone deacetylase inhibitor vorinostat's antitumor activity against multiple myeloma (MM) using cell lines and a murine xenograft model.  Methods: RPMI8226, U266, and MM1S cells were cultured for 48 h in the presence of media, vorinostat, melphalan, or bortezomib alone, or combinations of vorinostat with melphalan or bortezomib.  Cell proliferation was measured using the MTS [3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfphophenyl)-2H-tetrazolium, inner salt] assay.  Severe combined immunodeficient mice bearing LAGκ-1B tumors were treated with vorinostat [30, 60, or 100 mg/kg daily for five consecutive days per wk (qd×5d), 100 or 300 mg/kg daily for 2 d/wk (qd×2d)], melphalan (1, 3, or 10 mg/kg qd×1d), bortezomib (0.25 or 0.5 mg/kg qd×2d), or combinations thereof for 35 d.  Tumor growth was detd. via measurement of human IgG (hIgG) levels and tumor vol.  Results and Conclusions: Vorinostat enhanced the anti-MM effects of melphalan and bortezomib in vitro.  Synergism was obsd. with vorinostat and melphalan in RPMI8226 and U266 cell lines.  Vorinostat 100 mg/kg in combination with melphalan 3 mg/kg resulted in significant inhibition of tumor growth in vivo, compared with control (tumor vol. P = 0.0001; hIgG P = 0.0001), single-agent vorinostat (tumor vol. P = 0.0025; hIgG P = 0.0137), and single-agent melphalan (tumor vol. P = 0.0043; hIgG P = 0.0426).  Vorinostat also enhanced the antimyeloma effects of bortezomib in vivo.  Vorinostat enhances the anti-MM activity of melphalan and bortezomib in vitro and in vivo.  This study provides rationale for further evaluation of vorinostat in combination with chemotherapeutic agents and bortezomib for the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoikDxI2DIkUrVg90H21EOLACvtfcHk0lhK3vgVVvKMtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlGmt7g%253D&md5=003b86234a2cb9d588d7f9d9aca08a4c</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0609.2009.01384.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0609.2009.01384.x%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DR.%2BA.%26aulast%3DSanchez%26aufirst%3DE.%26aulast%3DSteinberg%26aufirst%3DJ.%26aulast%3DShalitin%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBerenson%26aufirst%3DJ.%2BR.%26atitle%3DVorinostat%2520enhances%2520the%2520antimyeloma%2520effects%2520of%2520melphalan%2520and%2520bortezomib%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2010%26volume%3D84%26spage%3D201%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27c"><span><span class="NLM_contrib-group">Owonikoko, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanterewicz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balius, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belani, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hershberger, P. A.</span><span> </span><span class="NLM_article-title">Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">743</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1002%2Fijc.24759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=19621389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGjs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=743-755&author=T.+K.+Owonikokoauthor=S.+S.+Ramalingamauthor=B.+Kanterewiczauthor=T.+E.+Baliusauthor=C.+P.+Belaniauthor=P.+A.+Hershberger&title=Vorinostat+increases+carboplatin+and+paclitaxel+activity+in+non-small-cell+lung+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells</span></div><div class="casAuthors">Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Kanterewicz, Beatriz; Balius, Trent E.; Belani, Chandra P.; Hershberger, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">743-755</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We obsd. a 53% response rate in non-small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial.  Studies were undertaken to investigate the mechanism (s) underlying this activity.  Growth inhibition was assessed in NSCLC cells by MTT assay after 72 h of continuous drug exposure.  Vorinostat (1 μM) inhibited growth by: 17% ± 7% in A549, 28% ± 6% in 128-88T, 39% ± 8% in Calu1 and 41% ± 7% in 201T cells.  Vorinostat addn. to carboplatin or paclitaxel led to significantly greater growth inhibition than chemotherapy alone in all 4 cell lines.  Vorinostat (1 μM) synergistically increased the growth inhibitory effects of carboplatin/paclitaxel in 128-88T cells.  When colony formation was measured after drug withdrawal, vorinostat significantly increased the effects of carboplatin but not paclitaxel.  The % colony formation was control 100%; 1 μM vorinostat, 83% ± 10%; 5 μM carboplatin, 41% ± 11%; carboplatin/vorinostat, 8% ± 4%; 2 nM paclitaxel, 53% ± 11%; paclitaxel/vorinostat, 46% ± 21%.  In A549 and 128-88T, vorinostat potentiated carboplatin induction of gamma-H2AX (a DNA damage marker) and increased α-tubulin acetylation (a marker for stabilized mictrotubules).  In A549, combination of vorinostat with paclitaxel resulted in a synergistic increase in α-tubulin acetylation, which reversed upon drug washout.  We conclude that vorinostat interacts favorably with carboplatin and paclitaxel in NSCLC cells, which may explain the provocative response obsd. in our clin. trial.  This likely involves a vorinostat-mediated irreversible increase in DNA damage in the case of carboplatin and a reversible increase in microtubule stability in the case of paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZe4FtU9T3ILVg90H21EOLACvtfcHk0lhK3vgVVvKMtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGjs7bO&md5=2c84fdb0ba2c555073be96ad947c5048</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1002%2Fijc.24759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24759%26sid%3Dliteratum%253Aachs%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DKanterewicz%26aufirst%3DB.%26aulast%3DBalius%26aufirst%3DT.%2BE.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DHershberger%26aufirst%3DP.%2BA.%26atitle%3DVorinostat%2520increases%2520carboplatin%2520and%2520paclitaxel%2520activity%2520in%2520non-small-cell%2520lung%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D126%26spage%3D743%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27d"><span><span class="NLM_contrib-group">Venturelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armeanu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathil, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonthein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehrmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauer, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitzer, M.</span><span> </span><span class="NLM_article-title">Epigenetic combination therapy as a tumour-selective treatment approach for hepatocellular carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">2132</span><span class="NLM_x">–</span> <span class="NLM_lpage">2141</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=2132-2141&author=S.+Venturelliauthor=S.+Armeanuauthor=A.+Pathilauthor=C.+J.+Hsiehauthor=T.+S.+Weissauthor=R.+Vontheinauthor=M.+Wehrmannauthor=M.+Gregorauthor=U.+M.+Lauerauthor=M.+Bitzer&title=Epigenetic+combination+therapy+as+a+tumour-selective+treatment+approach+for+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenturelli%26aufirst%3DS.%26aulast%3DArmeanu%26aufirst%3DS.%26aulast%3DPathil%26aufirst%3DA.%26aulast%3DHsieh%26aufirst%3DC.%2BJ.%26aulast%3DWeiss%26aufirst%3DT.%2BS.%26aulast%3DVonthein%26aufirst%3DR.%26aulast%3DWehrmann%26aufirst%3DM.%26aulast%3DGregor%26aufirst%3DM.%26aulast%3DLauer%26aufirst%3DU.%2BM.%26aulast%3DBitzer%26aufirst%3DM.%26atitle%3DEpigenetic%2520combination%2520therapy%2520as%2520a%2520tumour-selective%2520treatment%2520approach%2520for%2520hepatocellular%2520carcinoma%26jtitle%3DCancer%26date%3D2007%26volume%3D109%26spage%3D2132%26epage%3D2141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Chou, T-C</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talalay, P.</span><span> </span><span class="NLM_article-title">Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors</span> <span class="citation_source-journal">Adv. Enzyme Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2F0065-2571%2884%2990007-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=6382953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADyaL2cXktlaksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1984&pages=27-55&author=T-C+Chouauthor=P.+Talalay&title=Quantitative+analysis+of+dose-effect+relationships%3A+the+combined+effects+of+multiple+drugs+or+enzyme+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of dose-effect relationships:  the combined effects of multiple drugs or enzyme inhibitors</span></div><div class="casAuthors">Chou, Ting Chao; Talalay, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Enzyme Regulation</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-55</span>CODEN:
                <span class="NLM_cas:coden">AEZRA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-2571</span>.
    </div><div class="casAbstract">A simplified exptl. design method for the anal. of multiple drug effects and for detg. summation, synergism, and antagonism is described.  The method is not limited by: whether the dose-effect relations are hyperbolic or sigmoidal, whether the effects are mutually exclusive or nonexclusive, whether the ligand interactions are competitive, noncompetitive, or uncompetitive, or whether the drugs are agonists or antagonists.  The method is independent of the no. of drugs involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX4wNupCqgpbVg90H21EOLACvtfcHk0liaV38d1uffeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktlaksLk%253D&md5=055a2711b52dde49389c3f526352333d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0065-2571%2884%2990007-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0065-2571%252884%252990007-4%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DT-C%26aulast%3DTalalay%26aufirst%3DP.%26atitle%3DQuantitative%2520analysis%2520of%2520dose-effect%2520relationships%253A%2520the%2520combined%2520effects%2520of%2520multiple%2520drugs%2520or%2520enzyme%2520inhibitors%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D1984%26volume%3D22%26spage%3D27%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Smith, J.</span><span> </span><span class="NLM_article-title">Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1513</span><span class="NLM_x">–</span> <span class="NLM_lpage">1534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1016%2Fj.clinthera.2005.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=16330289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWhu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2005&pages=1513-1534&author=J.+Smith&title=Erlotinib%3A+small-molecule+targeted+therapy+in+the+treatment+of+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer</span></div><div class="casAuthors">Smith, Janine</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1513-1534</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Erlotinib is an oral tyrosine kinase inhibitor, targeting the human epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) after the failure of more than 1 or 2 previous chemotherapeutic regimens.  The purpose of this article is to summarize the development, pharmacol., pharmacokinetics, efficacy, and adverse effects of erlotinib.  A literature search was conducted with the MEDLINE and EMBASE (1999-2005) databases using the search terms non-small-cell lung cancer, erlotinib, and epidermal growth factor receptor inhibitor.  Abstrs. from the American Society of Clin. Oncol. and documents submitted to the FDA also were reviewed.  BR.21, a randomized, placebo-controlled, multinational Phase III trial demonstrated clin. and statistically improved overall survival in patients with advanced or metastatic NSCLC treated with erlotinib vs. placebo as second-line therapy.  The erlotinib group had a median survival of 6.7 mo vs. a median survival of 4.7 mo in the placebo group (P < 0.001).  The toxicity profile of erlotinib was moderately benign, with the most commonly documented adverse events requiring dose redns. including skin rash (12%) and diarrhea (5%).  Interstitial lung disease and relative fatalities were reported infrequently (0.8%) in patients receiving erlotinib.  Two randomized, placebo-controlled, multicenter Phase III trials conducted in patients with locally advanced and metastatic NSCLC showed no clin. benefit with first-line administration of erlotinib plus concurrent platinum-based chemotherapy.  For patients with NSCLC in whom more than 1 or 2 previous chemotherapeutic regimens have failed, erlotinib is an effective therapy with significant overall survival benefits.  The use of erlotinib as first-line therapy in combination with platinum-based chemotherapeutic regimens, however, has failed to demonstrate efficacy in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ8XxLfuXqJbVg90H21EOLACvtfcHk0liaV38d1uffeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWhu7%252FK&md5=ccf04e1ffdfb147e172b5943a7f0d245</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2005.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2005.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DJ.%26atitle%3DErlotinib%253A%2520small-molecule%2520targeted%2520therapy%2520in%2520the%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DClin.%2520Ther.%26date%3D2005%26volume%3D27%26spage%3D1513%26epage%3D1534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Daskalakis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagitko-Dorfs, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackanson, B.</span><span> </span><span class="NLM_article-title">Decitabine</span> <span class="citation_source-journal">Recent Results Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1007%2F978-3-642-01222-8_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=20072836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=131-157&author=M.+Daskalakisauthor=N.+Blagitko-Dorfsauthor=B.+Hackanson&title=Decitabine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Decitabine</span></div><div class="casAuthors">Daskalakis, Michael; Blagitko-Dorfs, Nadja; Hackanson, Bjoern</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">131-157</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">0080-0015</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy deriv., 5-aza-2'-deoxycytidine (decitabine, Dacogen), are the most widely used inhibitors of DNA methylation which trigger demethylation leading to a consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.  Although the antileukemic capacity of decitabine has been known for almost 40 years, its therapeutic potential in hematol. malignancies is still under intensive investigation.  Multiple clin. trials have shown the promising activity of low-dose decitabine in AML, MDS, CML, and hemoglobinopathies, whereas its efficacy in solid tumors is rather limited.  Clin. responses appear to be induced by both epigenetic alterations and the induction of cell-cycle arrest and/or apoptosis.  Recent clin. trials have been investigating new dosing schedules, routes of administration, and combination of decitabine with other agents, including histone deacetylase (HDAC) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlEhCFh3GKLVg90H21EOLACvtfcHk0liaV38d1uffeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsLnF&md5=0e1fc9576bed410a64d778bb10fe0544</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-01222-8_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-01222-8_10%26sid%3Dliteratum%253Aachs%26aulast%3DDaskalakis%26aufirst%3DM.%26aulast%3DBlagitko-Dorfs%26aufirst%3DN.%26aulast%3DHackanson%26aufirst%3DB.%26atitle%3DDecitabine%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2010%26volume%3D184%26spage%3D131%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Krige, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Needham, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bawden, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirwin-Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legris, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laber, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odedra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bone, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayscough, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, A. H.</span><span> </span><span class="NLM_article-title">CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">6669</span><span class="NLM_x">–</span> <span class="NLM_lpage">6679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=6669-6679&author=D.+Krigeauthor=L.+A.+Needhamauthor=L.+J.+Bawdenauthor=N.+Floresauthor=H.+Farmerauthor=L.+E.+Milesauthor=E.+Stoneauthor=J.+Callaghanauthor=S.+Chandlerauthor=V.+L.+Clarkauthor=P.+Kirwin-Jonesauthor=V.+Legrisauthor=J.+Owenauthor=T.+Patelauthor=S.+Woodauthor=G.+Boxauthor=D.+Laberauthor=R.+Odedraauthor=A.+Wrightauthor=L.+M.+Woodauthor=S.+A.+Ecclesauthor=E.+A.+Boneauthor=A.+Ayscoughauthor=A.+H.+Drummond&title=CHR-2797%3A+an+antiproliferative+aminopeptidase+inhibitor+that+leads+to+amino+acid+deprivation+in+human+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrige%26aufirst%3DD.%26aulast%3DNeedham%26aufirst%3DL.%2BA.%26aulast%3DBawden%26aufirst%3DL.%2BJ.%26aulast%3DFlores%26aufirst%3DN.%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMiles%26aufirst%3DL.%2BE.%26aulast%3DStone%26aufirst%3DE.%26aulast%3DCallaghan%26aufirst%3DJ.%26aulast%3DChandler%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DV.%2BL.%26aulast%3DKirwin-Jones%26aufirst%3DP.%26aulast%3DLegris%26aufirst%3DV.%26aulast%3DOwen%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DLaber%26aufirst%3DD.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DWright%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DL.%2BM.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DBone%26aufirst%3DE.%2BA.%26aulast%3DAyscough%26aufirst%3DA.%26aulast%3DDrummond%26aufirst%3DA.%2BH.%26atitle%3DCHR-2797%253A%2520an%2520antiproliferative%2520aminopeptidase%2520inhibitor%2520that%2520leads%2520to%2520amino%2520acid%2520deprivation%2520in%2520human%2520leukemic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D6669%26epage%3D6679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Chou, T.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motzer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosl, G. J.</span><span> </span><span class="NLM_article-title">Computerized quantitation of synergism and antagonism of Taxol, topetecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">–</span> <span class="NLM_lpage">1524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm101177s&amp;key=10.1093%2Fjnci%2F86.20.1517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm101177s&amp;key=7932806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm101177s&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFWru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1994&pages=1517-1524&author=T.-C.+Chouauthor=R.+J.+Motzerauthor=Y.+Tongauthor=G.+J.+Bosl&title=Computerized+quantitation+of+synergism+and+antagonism+of+Taxol%2C+topetecan+and+cisplatin+against+human+teratocarcinoma+cell+growth%3A+a+rational+approach+to+clinical+protocol+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design</span></div><div class="casAuthors">Chou, Ting-Chao; Motzer, Robert J.; Tong, Youzhi; Bosl, George J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1517-24</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">Cisplatin-based induction chemotherapy may achieve a complete response (i.e., no sign of tumor following treatment) in 70%-80% of patients with germ cell tumors.  However, only a minority of patients in whom the firstline regimens fail are cured with the salvage regimens.  The aim of these studies was to identify new agents or new regimens for the treatment of germ cell tumors by carrying out quant. assessment in vitro of two promising new antitumor agents (paclitaxel [Taxol] and topotecan) and three more established agents (cisplatin, vincristine, and etoposide).  These agents were used singly or in two- and three-drug combinations and were selected because they represent five distinct categories of antineoplastic mechanisms.  The combination index-isobologram method, which is based on the median-effect principle developed by Chou and Talalay, was used for computerized data anal.  This method was selected because it takes into account both the potencies of each drug and combinations of these drugs and the shapes of their dose-effect curves.  Synergism against the growth of teratocarcinoma cells resistant to cisplatin (833K/64CP10 cells) was greater than against the growth of parent 833K cells.  The degrees of synergism were in the following order: cisplatin + topotecan ≥ paclitaxel + cisplatin + topotecan > paclitaxel + topotecan ≥ paclitaxel + etoposide > paclitaxel + cisplatin + etoposide > paclitaxel + cisplatin.  All other combinations showed nearly additive effects or moderate antagonism.  The degrees of antagonism were as follows: cisplatin + etoposide ≥ paclitaxel + vincristine > paclitaxel + cisplatin + vincristine > cisplatin + vincristine.  The combination of paclitaxel and cisplatin was synergistic against 833K/64CP10 cells and moderately antagonistic against 833K cells.  Since the combination of paclitaxel, cisplatin, and topotecan and the two-component combinations of these drugs (cisplatin + topotecan and paclitaxel + topotecan) showed synergism stronger than that of other combinations, these three drugs were selected for illustrating detailed data anal., using a computer software program developed in this institute.  The authors' findings suggest that, as a result of synergy, the doses of these agents needed to achieve an antitumor effect may be reduced by two-fold to eight-fold when these agents are given in combination.  The present quant. data analyses for synergism or antagonism provide a basis for a rational design of clin. protocols for combination chemotherapy in patients with advanced germ cell tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYyr-a9pkBELVg90H21EOLACvtfcHk0lh29tiqanf_8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFWru7w%253D&md5=faf1f3e4ba16b9869baac8c23716bf6f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F86.20.1517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F86.20.1517%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DT.-C.%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DBosl%26aufirst%3DG.%2BJ.%26atitle%3DComputerized%2520quantitation%2520of%2520synergism%2520and%2520antagonism%2520of%2520Taxol%252C%2520topetecan%2520and%2520cisplatin%2520against%2520human%2520teratocarcinoma%2520cell%2520growth%253A%2520a%2520rational%2520approach%2520to%2520clinical%2520protocol%2520design%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1994%26volume%3D86%26spage%3D1517%26epage%3D1524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1<i>H</i>-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Moreno-Farre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span> </span><span class="NLM_article-title">Analysis of potential drug−drug interactions for anticancer agents in human liver microsomes by high throughput liquid chromatography/mass spectrometry assay</span> <span class="citation_source-journal">Recent Adv. Res. Updates</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=207-224&author=J.+Moreno-Farreauthor=P.+Workmanauthor=F.+I.+Raynaud&title=Analysis+of+potential+drug%E2%88%92drug+interactions+for+anticancer+agents+in+human+liver+microsomes+by+high+throughput+liquid+chromatography%2Fmass+spectrometry+assay"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno-Farre%26aufirst%3DJ.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26atitle%3DAnalysis%2520of%2520potential%2520drug%25E2%2588%2592drug%2520interactions%2520for%2520anticancer%2520agents%2520in%2520human%2520liver%2520microsomes%2520by%2520high%2520throughput%2520liquid%2520chromatography%252Fmass%2520spectrometry%2520assay%26jtitle%3DRecent%2520Adv.%2520Res.%2520Updates%26date%3D2006%26volume%3D7%26spage%3D207%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T67" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T67','PDB','1T67'); return false;">PDB: 1T67</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i63"><a href="/doi/suppl/10.1021/jm101177s">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_51122"></div></div></div></div></div><hr /></hr><p class="last">Methods for fixed cell and electrochemiluminescent ELISA; results showing effects of <b>21f</b> and <b>21r</b> on proliferation of a P-glycoprotein isogenic cancer cell line pair; in vitro effects on histone and α-tubulin acetylation; in vivo PK of <b>21f</b> and effects on histone H3 and α-tubulin acetylation in samples from a HCT116 human tumor mouse xenograft efficacy study; synthesis and analytical data for <b>15b</b>, <b>18b</b>−<b>c</b>, <b>21b</b>−<b>e</b>, and <b>21g</b>−<b>21q</b>; single crystal X-ray structure of <b>21r</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm101177s/suppl_file/jm101177s_si_001.pdf">jm101177s_si_001.pdf (455.18 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm101177s&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm101177s%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-24" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm101177s" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a7fff82f1243","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
